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Abstract 
Background: With 2.7 million women living with HIV, the burden of HIV remains high in 
South Africa but adherence to antiretroviral therapy remains a concern among pregnant and 
postpartum women. Disclosure, or the process of gradually revealing one’s HIV status to 
individuals in one’s social network, is regarded as an important factor in HIV care, with 
potential benefits that include improved psychological well-being and adherence to 
antiretroviral therapy. This thesis sought to provide insights into the patterns, predictors and 
impact of HIV-status disclosure among pregnant and postpartum women in the context of 
lifelong antiretroviral therapy in South Africa, including considerations of stigma, social 
support, depression and unintended pregnancy. 
Methods: This research included women living with HIV in Gugulethu, Cape Town. A total 
of 1554 pregnant women were enrolled; those who were initiating antiretroviral therapy were 
followed up to 18 months postpartum, with one further visit at 36-60 months postpartum. 
Data were collected using questionnaires and blood specimens for HIV viral load testing.  
Findings: Across analyses, women’s social and economic circumstances emerged as central 
to understandings of disclosure, mental health and viral load. At entry into antenatal care, 
95% of women who were diagnosed HIV-positive before the pregnancy had disclosed to at 
least one person but disclosure events formed two separate dimensions: disclosure to (i) a 
male partner and (ii) family/community members. Among women diagnosed during the 
pregnancy and initiating antiretroviral therapy, 61% disclosed to a male partner and 71% to a 
family/community member by 12 months after diagnosis; relationship status modified the 
impact of each of pregnancy intentions and poverty on disclosure to a male partner.  
During pregnancy, 1 in 10 women reported elevated depressive symptoms and 60% of 
women who were subsequently followed during the postpartum period reported that their 
pregnancy was unintended. Stigma modified the association between social support and 
depression: when levels of stigma were high, higher levels of social support were not 
associated with decreased depressive symptoms. Pregnancy intention modified the impact of 
disclosure to a male partner on depression during pregnancy: disclosure was associated with 
higher depression scores among women who reported that their current pregnancy was 
unintended but was associated with lower depression scores among women who reported that 
the pregnancy was intended. Further, unintended pregnancy was a persistent predictor of 
elevated viral load up to 60 months postpartum.  
Finally, the effect of disclosure on elevated viral load at entry into antenatal care, delivery 
and 12 months postpartum was complex and modified by three factors: (i) timing of HIV 
diagnosis (before versus during the pregnancy); (ii) relationship to the person(s) to whom 
women disclose; and (iii) in the case of disclosure to a male partner, relationship status. 
Conclusions: These findings suggest that despite the widely-held view that disclosure has 
beneficial impacts on psychological well-being and adherence, the individual is central to our 
understanding of disclosure. In particular, both the prevalence of disclosure and its impact on 
depression and viral load are modified by women’s circumstances. Unintended pregnancy 
emerged as a critical factor that heightens women’s vulnerability. In this setting, HIV-status 
disclosure does not appear to be universally beneficial and counselling about disclosure may 
be most effective if tailored to individual women’s circumstances. 
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Chapter 1: Introduction 
 
1.1 Introduction and Background 
1.1.1 Background 
Globally, more than 18 million women aged 15 years and older were living with HIV in 
2017, including 2.7 million women in South Africa [1]. With the largest epidemic in the 
world, the burden of HIV in the country remains high, including among pregnant women. 
Surveillance data suggest that the maternal antenatal HIV prevalence in the country increased 
dramatically from 1990 (Figure 1.1), stabilising at around 30% [2]. Alongside global 
increases in the prevalence of HIV among general adult populations and among pregnant 
women, concerns arose regarding HIV-status disclosure, particularly to sexual partners, in 
order to reduce transmission and ensure support for HIV-infected individuals. Indeed, early 
guidelines for the management of HIV during pregnancy included the recommendation that 
all women be encouraged to disclose, or reveal their HIV status, to their partner [3]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Maternal antenatal HIV prevalence between 1990-2015 in South Africa [2] 
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In the absence of any preventive measures, the risk of mother-to-child transmission (MTCT) 
of HIV reaches 45% [4], but massive progress in prevention has been made globally. In 
South Africa, guidelines for the prevention of mother-to-child transmission (PMTCT) have 
evolved considerably since initial implementation during 2002. Table 1.1 presents an 
overview of changes in the maternal components of PMTCT guidelines in South Africa [5]. 
These have evolved from the provision of single-dose nevirapine (NVP) during labour, to all 
pregnant and breastfeeding women being eligible to initiate lifelong antiretroviral therapy 
(ART) under the World Health Organization’s ‘Option B+’ approach. This approach was 
piloted at several sites in South Africa from 2013-2014 and was rolled out nationally in 2015. 
Alongside immediate initiation of lifelong ART, PMTCT guidelines in the Western Cape 
province in South Africa recommend that all HIV-infected women receive support for 
disclosure [6]. Disclosure is promoted as having both population- and individual-level 
benefits, as discussed under Section 1.1.3, below. 
 
Table 1.1 Evolution of maternal components of prevention of mother-to-child transmission (PMTCT) 
guidelines in South Africa [5] 
Year Maternal PMTCT components1 
2002 Single-dose NVP given to mothers during labour 
2004 AZT given to mothers from 28 weeks gestation and single-dose NVP given during labour 
2010 AZT given to mothers from 14 weeks gestation 
2013 All pregnant women eligible for ART, but women with CD4 cell count >350 cells/mm3 and 
no other indication for ART to stop ART after the end of breastfeeding 
2015 All pregnant and breastfeeding women eligible for lifelong ART 
1 NVP: nevirapine; AZT: zidovudine; ART: antiretroviral therapy 
 
The provision of antiretroviral treatment is one aspect of the World Health Organization’s 
four-pronged approach to prevent MTCT, embedded in which is the promotion of disclosure 
[7]. These four components include: (i) among women of childbearing age, preventing new 
HIV infections; (ii) among HIV-infected women, preventing unintended pregnancies and (iii) 
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preventing HIV transmission to their infants; and (iv) providing treatment, care and support 
to HIV-infected women as well as their children and families [7]. Among both pregnant 
women and general adult populations, HIV care occurs across a cascade, from HIV testing 
and linkage to HIV care, to sustained engagement in care and adherence to ART. The final 
stage of the maternal treatment cascade is HIV viral suppression, or undetectable viral load, 
which is critical to promoting health, slowing disease progression, and reducing the risk of 
onward transmission of HIV. Although viral suppression can be compromised by factors such 
as drug resistance, the strongest predictor of viral suppression is adherence to ART [8]. 
Indeed, adherence is the behavioural mechanism of viral suppression, and the success of ART 
is primarily determined by adherence [9]. As such, HIV viral load is used in both research 
and practice as an objective marker of adherence [8].  
 
1.1.2 ART adherence during pregnancy and postpartum 
With preventive measures and sustained viral suppression, MTCT rates close to zero have 
been documented [10]. In South Africa, high coverage of PMTCT programmes has led to 
dramatic reductions in MTCT [11]. During 2010, the incidence of MTCT at 6 weeks 
postpartum was around 3.5% [12] and decreased to around 1.5% in 2015 [13]. However, 
women’s adherence to ART during the postpartum period is a major concern in South Africa 
and globally [14-16]. Further, in South Africa and many similar settings HIV care is 
integrated into antenatal care during pregnancy, but women must transfer to general adult 
ART clinics immediately post-delivery, and this transition may reflect a particularly risky 
period [17, 18], with implications for women’s retention in care during the postpartum 
period. A recent systematic review of studies reporting data on retention in Option B+ 
programmes in Africa reported that retention ranged from 47-88% in the 6 months after ART 
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initiation; pooled estimates suggest that only 76% of women were retained in care 12 months 
after ART initiation [19].  
 
Among general adult populations, psychosocial barriers to ART adherence may have 
profound effects on adherence [20]. Among pregnant and postpartum women, barriers may 
be even more pronounced as women must quickly adjust to a pregnancy and related demands 
and responsibilities; breastfeeding and infant care after delivery; as well as a new HIV 
diagnosis and starting lifelong ART for women diagnosed during the pregnancy or newly 
eligible to initiate ART [21]. At the same time, the timely initiation of ART and maintaining 
high levels of adherence is imperative for both maternal and child health outcomes. While 
improvements in ART availability and changing treatment guidelines have led to massive 
progress in reducing MTCT, pregnant and postpartum women represent a particularly 
vulnerable group for poor treatment outcomes, and there is an urgent need to understand how 
factors in these women’s lives affect their likelihood of being retained in care and remaining 
adherent to ART [21]. Chapter 2 presents a conceptual framework reflecting determinants of 
ART adherence in the context of PMTCT, including the major constructs of interest on which 
this thesis focusses.  
 
1.1.3 Potential benefits of HIV-status disclosure  
A widely-cited barrier to achieving optimal treatment outcomes is limited disclosure of one’s 
HIV status [21-24]. Indeed, major barriers to women’s retention in Option B+ programmes in 
Africa include women’s fears of inadvertent disclosure or reactions to HIV-status disclosure 
[19]. Disclosure has been defined as the gradual, sequential process of revealing one’s HIV 
status to an increasing number of individuals over time [25, 26]. The conceptual 
underpinning of this thesis is the Disclosure Processes Model, which has been posited as a 
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framework to understand when and why disclosure is beneficial [27, 28]. This framework is 
presented and discussed in Chapter 2.  
 
As alluded to above, disclosure is promoted as having both population- and individual-level 
benefits. At the population level, potential benefits include decreases in the incidence of HIV 
through behavioural change to reduce the risk of horizontal transmission. As such, there has 
been much focus historically on disclosure to sexual partners, and on promoting disclosure 
within sexual partnerships. Indeed, disclosure of an HIV-positive status is mandated in 
certain settings, with transmission criminalised [29]. Even in the absence of criminalisation, 
however, disclosure is seen as imperative to risk reduction and consequent reduction of the 
incidence of HIV [26]. Among pregnant and postpartum women, the prevention benefits may 
be two-fold: reduced transmission to HIV-uninfected sexual partners and reduced 
transmission to infants. At the individual level, disclosure is widely regarded as being an 
important factor in HIV care by potentially improving psychological well-being, ART 
adherence and treatment outcomes. Benefits to psychological well-being are thought to result 
from increased social support following disclosure [30]. Conversely, limited disclosure to 
individuals within the home or support network has been identified as a barrier to adherence 
in general HIV [20] and PMTCT programmes [31] through mechanisms which include not 
receiving support for adherence and secrecy around ART use.  
 
1.1.4 Disclosure as a public health issue  
Given these potential population- and individual-level benefits, HIV-status disclosure is 
strongly promoted in policy as well as counselling messaging [29, 32]. As stated above, early 
guidelines for the management of HIV in pregnant women stated that all women should be 
encouraged to disclose to their partner [3], and HIV treatment guidelines in the Western Cape 
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include support for disclosure to supportive family members or friends as a strategy to 
promote adherence [6]. Further, these guidelines state that patients experiencing issues with 
non-disclosure or stigma should receive on-going counselling [6]. In line with this, 
community health workers are described in the World Health Organization’s four-pronged 
approach to prevent MTCT as playing an important role in improving the uptake of PMTCT 
services, one aspect of which includes encouraging disclosure [7]. Along with other public 
health approaches, the above guidelines provide blanket recommendations that are not 
tailored to individual women’s experiences; rather, they take the position that disclosure is 
universally beneficial, and thus that all women should disclose. The majority of research to 
date has echoed this viewpoint by exploring associations between disclosure and improved 
outcomes in total samples, assuming that the potentially beneficial effects of disclosure do 
not differ across individuals [28].  
 
Alongside the viewpoint that disclosure is universally beneficial, there has been little 
consideration of the possibility that the benefits of disclosure may be dependent on women’s 
relationships with the person(s) to whom they disclose [28]. Indeed, the Western Cape 
guidelines referred to above recommend disclosure to ‘supportive family members or friends’ 
without distinguishing between these [6]. Most research has similarly neglected to distinguish 
between relationships when exploring the prevalence of disclosure or the benefits thereof: the 
majority focusses on disclosure to any versus no persons [33]. This approach treats disclosure 
as a unidimensional process in which there is no difference between disclosing to, for 
example, a partner, sister or friend. A further limitation is the reliance on cross-sectional 
research to explore patterns and benefits of disclosure, despite disclosure being inherently a 
process that occurs over time [25]. This approach assumes that the benefits of disclosure are 
consistent over time. Taken together, limitations of research and practice to date include the 
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assumptions that (i) disclosure is universally beneficial with (ii) effects that are consistent 
over time, and (iii) that these benefits are consistent across the person(s) to whom individuals 
disclose. This thesis aims to quantitatively explore each of these assumptions, as described 
under Section 1.2, below.  
 
1.1.5 Interrelated psychosocial factors  
A factor that is closely interrelated with disclosure is HIV-related stigma. Given improved 
availability of and access to ART, HIV is now a chronic, manageable disease. However, it 
remains highly stigmatised; is transmissible; and requires lifelong adherence to ART. As 
such, an HIV-positive diagnosis has major implications for psychological well-being. 
Worldwide, disclosure is strongly encouraged for the reasons discussed above, but stigma 
remains pervasive in many settings and has detrimental effects on health and well-being. In 
addition, stigma constitutes a major barrier to disclosure in both general adult populations 
[34] and in the context of PMTCT [35], and stigma and discrimination may compromise 
women’s retention in Option B+ programmes [19]. Chapter 2 includes a discussion of the 
conceptual framework related to stigma on which this thesis draws, and further elucidates the 
links between disclosure, stigma and HIV treatment outcomes. 
 
A second factor that is closely related to disclosure and to stigma is social support. Support is 
a critical facilitator of adherence and psychological well-being, and the potential for 
enhanced support is cited as a major reason to disclose. In addition, low levels of support are 
commonly reported as being associated with high levels of stigma [34]. Third, disclosure may 
lead to improved mental health [36]. Common mental disorders such as depression are major 
barriers to ART adherence and HIV treatment outcomes [20, 24], lending further support for 
the promotion of disclosure. Taken together, each of HIV-related stigma, social support and 
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mental health are important factors that are closely linked to HIV-status disclosure as well as 
health and well-being and should be considered in disclosure research and practice. 
 
1.1.6 Unintended pregnancy  
Among HIV-infected pregnant women, an important but understudied issue is that of 
unintended pregnancy. Preventing unintended pregnancies is the second prong in the World 
Health Organization’s approach to PMTCT [7], but the prevalence of unintended pregnancy 
remains high among women globally [37]. Ample qualitative research has described the 
profound implications of an unintended pregnancy for women’s psychological well-being 
[38, 39]. Indeed, an unintended pregnancy and new HIV diagnosis during pregnancy may 
have major implications for disclosure to a male partner [38]. In South Africa, levels of 
unintended pregnancy are high [40, 41] and around 50% of HIV-infected women initiating 
ART during pregnancy are newly-diagnosed when entering antenatal care [42]. However, 
there has been little quantitative consideration of the links between unintended pregnancy and 
disclosure and of the impact of an unintended pregnancy on HIV treatment outcomes. As 
discussed above, disclosure is promoted as a universally beneficial act, including among 
pregnant women, and the potential for an unintended pregnancy to confer additional 
vulnerability is absent from practice. In addition, despite policy objectives promoting the 
integration of contraceptive and fertility planning services into other health services in South 
Africa [43], family planning is not routinely integrated into HIV care in the country.  
 
1.2 Rationale 
Taken together, HIV-status disclosure, the closely related constructs of HIV-related stigma 
and social support, poor mental health and unintended pregnancy may be important factors in 
PMTCT care. However, existing quantitative research has important limitations, which are 
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alluded to above and are described further in the literature review presented in Chapter 2. 
Given these limitations, additional high-quality evidence for the impact of these factors in the 
context of PMTCT is needed. In particular, empirical evidence testing the assumptions that 
(i) disclosure is universally beneficial with (ii) effects that are consistent over time, and (iii) 
that these benefits are consistent across the person(s) to whom individuals disclose is needed 
to inform both research and practice. As argued above, factors such as stigma, social support, 
mental health and unintended pregnancy must be considered in explorations of disclosure and 
the potential benefits thereof. Given the relatively recent adoption of Option B+ guidelines 
and the consequent increasing numbers of women initiating lifelong ART during pregnancy, 
explorations of the factors which compromise high levels of adherence and viral suppression 
in this population are needed to reduce HIV transmission and promote maternal and child 
health within this vulnerable and growing population.  
 
As described above, HIV care exists along a continuum. This thesis focusses specifically on 
the final step in the maternal treatment cascade: HIV viral suppression. Although retention in 
care and adherence to ART are critical steps in this cascade, this thesis takes the viewpoint 
that these outcomes are behavioural mechanisms of viral load and focusses on viral 
suppression as the ultimate goal of ART use for prevention and treatment. Thus, when 
examining the effect of disclosure on viral load, retention in care and adherence to ART are 
assumed to be the behavioural mechanisms of any possible associations: the assumption is 
that disclosure facilitates engagement in care and optimal adherence to ART which result in 
sustained viral suppression. Further, measuring each of retention and adherence is difficult. 
Indeed, engagement in care is measured and operationalised variously throughout the 
literature [44], with implications for results [45]. Self-report is the most commonly used 
measure of ART adherence but suffers from social desirability and recall biases [46]; viral 
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load is thus viewed as a more objective marker of adherence. Taken together, this thesis 
focusses on viral load given methodological considerations and as a robust clinical outcome 
and the ultimate goal of ART use. In addition, this thesis focusses on a single mental health 
outcome, depression, as a particularly common mental disorder [47] with well-established 
detrimental effects on ART adherence [20, 24]. 
 
1.3 Aim and objectives 
The aim of this thesis is to provide insights into the patterns, predictors and impact of HIV-
status disclosure among pregnant and postpartum women in the context of lifelong ART in 
South Africa, including considerations of stigma, social support, depression and unintended 
pregnancy.  
 
Specific objectives are: 
1. To describe patterns and predictors of HIV-status disclosure over time. 
2. To examine the interplay between HIV-related stigma and perceived social support, 
and their impact on depressive symptoms.  
3. To examine the impact of HIV-status disclosure on depressive symptoms, and the role 
of unintended pregnancy in this association.  
4. To examine the impact of unintended pregnancy on HIV viral suppression, and the 
role of HIV-status disclosure in this association.  
5. To examine the impact of HIV-status disclosure on HIV viral suppression. 
 
This thesis focusses on three major outcomes: disclosure itself is examined as an outcome for 
Objective 1; depressive symptoms are investigated for Objectives 2 and 3; and viral load is 
the outcome of interest for Objectives 4 and 5. Throughout, this thesis aims to address the 
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limitations which are alluded to above and are discussed further in Chapter 2, while 
positioning these findings within the context of lifelong ART in South Africa.  
 
1.4 Data source 
1.4.1 Maternal and Child Health – Antiretroviral Therapy (MCH-ART) study 
Data for this thesis came from the Maternal and Child Health – Antiretroviral Therapy 
(MCH-ART) study [48, 49]. The MCH-ART study was a multi-phase implementation 
science study which sought to evaluate strategies for delivering HIV care and treatment 
services during the postpartum period. The study was conducted at a large primary care 
antenatal clinic in the former township of Gugulethu in Cape Town, South Africa. 
Participants were enrolled between March 2013 and June 2014, with follow-up visits 
conducted through May 2016. The study was conducted across three phases: Phase 1 was a 
cross-sectional evaluation of all HIV-infected women who were attending their first antenatal 
visit at the Midwife Obstetric Unit (MOU) at the Gugulethu Community Health Centre; 
Phase 2 was a longitudinal observational cohort study of Phase 1 women who were eligible to 
initiate ART, with participants attending up to three study visits during this phase; and Phase 
3 was a randomised controlled trial of women from Phase 2 who opted to breastfeed 
postpartum. For the randomised controlled trial, women were randomised to either (A) attend 
general ART services for ongoing care, or (B) continue receiving ART at the MOU for the 
duration of breastfeeding, with women in both trial arms attending up to six study visits 
during postpartum follow-up. Follow-up for the study was later extended to include one 
additional study visit. Figure 1.2 presents a schema of these phases as well as the sample size 
enrolled into each phase. Different sub-samples are included in different analyses of this 
thesis, as described in each chapter.  
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Figure 1.2. Schema of the Maternal and Child Health – Antiretroviral Therapy (MCH-ART) study  
 
 
For Phase 1, consecutive HIV-infected women who were entering antenatal care were 
approached and were eligible to participate if they were aged ≥18 years, were confirmed 
HIV-positive and pregnant, and were either established on ART or had not yet initiated ART 
or antiretroviral prophylaxis during the current pregnancy. For Phase 2, a subset of Phase 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase 1: 
HIV-infected women attending 1st antenatal visit at 
Gugulethu Midwife Obstetric Unit (MOU) enrolled 
(n=1554) 
Study measurements conducted at 1st antenatal visit 
Phase 2: 
Observational cohort of women from Phase 1 who were 
eligible to initiate antiretroviral therapy (ART) enrolled at 
2nd antenatal visit (n=628) 
Study measurements conducted at three study visits (2nd 
antenatal visit, late 3rd trimester, <7 days postpartum) 
Routine antenatal care and ART delivered at Gugulethu 
MOU; routine obstetric care delivered 
Women who initiated ART during pregnancy seen after 
delivery with live infant (n=587) 
Phase 3: 
Women on ART from Phase 2 who initiated breastfeeding 
randomised to two trial arms within 28 days postpartum 
(n=471) 
Trial arms: (A) women referred to general ART service for 
ongoing care; or (B) women continue to receive ART at 
Gugulethu MOU until cessation of breastfeeding, then 
referred to general ART service for ongoing care 
Study measurements conducted for both arms at 6 weeks 
and 3, 6, 9 12 and 18 months postpartum 
Not randomised by design (n=108) 
Refused (n=8) 
Additional follow-up visit: 
Women enrolled into Phase 3 eligible to attend an 
additional follow-up visit at 36-60 months postpartum 
(n=463 eligible; n=353 attended) 
Withdrew (n=5) 
Known maternal death (n=3) 
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participants who were ART-eligible according to local guidelines were enrolled into antenatal 
follow-up. At the time of the study, ART eligibility was determined based on CD4 cell count 
or clinical disease staging until June 2013, after which all women entering antenatal care 
were eligible to initiate ART under Option B+ guidelines, with the majority of participants 
enrolled under Option B+ guidelines. The potential implications of context and changes in 
treatment guidelines are discussed in Chapter 2. For Phase 3 of the MCH-ART study, a 
subset of Phase 2 participants who had initiated ART and were breastfeeding at the first 
postpartum study visit were eligible for further postpartum follow-up. Eligible participants 
were randomly allocated at this study visit. Data from Phases 1-3 are included in Chapters 3-
5 and in Chapter 7. 
  
Follow-up for the study was later extended to 36-60 months postpartum. All women who had 
been enrolled into Phase 3 and who were not known to have died or to have withdrawn from 
the study were eligible for further follow-up. A total of 353 women were successfully 
contacted and attended one additional study visit between 36-60 months postpartum. Data 
from Phases 1-3 and from this additional study visit are included in Chapter 6.  
 
The MCH-ART study was approved by the University of Cape Town’s Faculty of Health 
Sciences Human Research Ethics Committee and by Columbia University Medical Center’s 
Institutional Review Board in New York. The secondary data analyses undertaken for this 
thesis were approved by the University of Cape Town’s Faculty of Health Sciences Human 
Research Ethics Committee. All women provided written informed consent prior to 
enrolment. 
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1.4.2 Overview of data included 
Study measures collected as part of the MCH-ART study and the additional follow-up visit 
between 36-60 months postpartum are included in Appendix 1 and 2, respectively. Measures 
related to the primary focus of this thesis, HIV-status disclosure, were collected at all study 
measurement visits. Other major constructs of interest include unintended pregnancy 
(assessed at enrolment into the study) and HIV-related stigma and social support (data 
included from the 2nd antenatal study visit); demographic characteristics included were 
assessed at enrolment into the study. As stated above, the major outcomes of interest in this 
thesis are disclosure (Chapter 3), depressive symptoms (Chapters 4 and 5) and HIV viral load 
(Chapters 6 and 7). Depressive symptoms were measured at the 2nd antenatal study visit and 
at 6 weeks, 12 months, 18 months and 36-60 months postpartum. HIV viral load was 
measured at all study measurement visits. Additional information regarding the measures 
included is detailed in the results chapters (Chapters 3-7).  
 
An issue which may be related to each of these constructs is that of intimate partner violence. 
Violence within intimate partnerships is prevalent in South Africa [50], and a major reason 
for non-disclosure to sexual partners is the fear of violence [51, 52]. In addition, violence has 
been observed to be associated with stigma [53] and is a well-documented predictor of 
depression [54-56]. Although an in-depth exploration of intimate partner violence is beyond 
the scope of this thesis, it should be noted throughout that these data arose from a setting in 
which violence is common and may have far-reaching effects on women’s health and well-
being. 
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1.4.3 Overview of analytic methods 
The body of work contained in this thesis aims to provide an in-depth exploration of HIV-
status disclosure and related constructs. However, differences in the measures included in 
analyses and analytic methods used arose over time as this work progressed. An example is 
the measure of unintended pregnancy used: in some analyses, a single question was used to 
assess pregnancy intentions and in others a more sophisticated measure was used. These two 
measures have been compared within this cohort with high levels of concordance [41], thus 
the conclusions are likely robust despite the different measures used. For all analyses, 
potential confounders were defined a priori, and typically included measures of 
socioeconomic status, age and relationship status. When examining viral load outcomes, 
previous viral load results and duration on ART were controlled for as critical determinants 
of viral suppression. For postpartum viral load outcomes, allocation in the MCH-ART trial 
was included in multivariable models in order to control for design effect.   
 
1.5 Overview and structure of this thesis 
This introductory chapter introduces the topic of HIV-status disclosure. It includes a brief 
overview of the issues that this thesis will address and the rationale and aim and objectives. 
As this work includes only secondary analysis of data, this chapter includes a description of 
the broader study from which these data arise, and a brief overview of the measures included 
and analytic methods used. Following the introductory chapter, this thesis includes a 
literature review, five results chapters and a discussion chapter summarising the contributions 
of this work as well as recommendations for research and practice. 
 
Chapter 2 provides the background to this thesis in a review of the literature on each of the 
major constructs of interest which form the basis of this thesis: disclosure, stigma, social 
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support, mental health and unintended pregnancy. Details regarding the methodology and 
focus of this review are provided at the beginning of the chapter. Five results chapters, in the 
form of published papers or papers that have been submitted for publication, are presented in 
Chapters 3-7. These map to the objectives of this thesis. A summary of these results chapters, 
including the primary focus and methodologies used, is presented in Table 1.2, below.  
 
Table 1.2 Summary of thesis results chapters, including outcome variables and methodologies 
Chapter Objective Publication title Outcome Methodology 
3 1 Patterns and predictors of HIV-
status disclosure among pregnant 
women in South Africa: 
dimensions of disclosure and 
influence of social and economic 
circumstances 
Disclosure Cross-sectional analysis at one 
timepoint during pregnancy, 
and time-to-event analyses 
during pregnancy and 
postpartum 
4 2 Social support, stigma and 
antenatal depression among 
HIV-infected pregnant women in 
South Africa 
Depressive 
symptoms 
Cross-sectional analysis at one 
timepoint during pregnancy  
5 3 HIV-status disclosure and 
depression in the context of 
unintended pregnancy among 
South African women 
Depressive 
symptoms 
Analyses at three timepoints 
during pregnancy and 
postpartum, using cumulative 
reports of disclosure up to each 
timepoint 
6 4 Long-term effects of unintended 
pregnancy on antiretroviral 
therapy outcomes among South 
African women living with HIV 
HIV viral 
load 
Repeated measures analysis of 
HIV viral load results from 6 
weeks through 36-60 months 
postpartum 
7 5 Impact of HIV-status disclosure 
on viral load during pregnancy 
and postpartum in Cape Town, 
South Africa 
HIV viral 
load 
Analyses at three timepoints 
during pregnancy and 
postpartum, using cumulative 
reports of disclosure up to each 
timepoint 
 
 
Chapter 3 addresses the first objective of this thesis by describing patterns and predictors of 
disclosure during pregnancy and postpartum. This chapter includes a strong methodological 
focus in order to address limitations of research to date. First, these analyses use both cross-
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sectional and longitudinal data to examine patterns of disclosure, in contrast to the majority 
of research to date which has relied primarily on cross-sectional data. In addition, the chapter 
uses a novel analytic technique to examine patterns of disclosure in order to address a further 
limitation of research to date: the widespread focus on disclosure to any versus no persons, or 
the focus on disclosure to a sexual partner only. This chapter describes how disclosure forms 
two separate dimensions in this sample of women, specifically disclosure to a male partner, 
and disclosure to family/community members. Based on these findings, disclosure was 
analysed using these separate dimensions in subsequent chapters, thereby setting the scene 
for testing the assumption that the benefits of disclosure are consistent across the person(s) to 
whom individuals disclose. 
 
Chapter 3 additionally highlights that social and economic circumstances are central 
determinants of disclosure. Given this finding, factors such as relationship status and 
unintended pregnancy were explored as key determinants and potential effect modifiers of the 
major constructs of interest in this thesis in subsequent chapters. This chapter thus provides 
the basis for testing the assumption that the benefits of disclosure are universally beneficial 
rather than potentially differing across different sub-groups. The chapter concludes by 
arguing that further high-quality evidence of the impact of disclosure on HIV and health-
related outcomes is needed in order to inform counselling messaging and intervention efforts; 
the impact of disclosure on depression and viral load were thus explored in subsequent 
chapters. These subsequent chapters include investigations of the assumptions that (i) 
disclosure is universally beneficial with (ii) effects that are consistent over time, and (iii) that 
these benefits are consistent across the person(s) to whom individuals disclose.  
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Chapter 4 addresses the second objective of this thesis by exploring how social support and 
stigma are interrelated, and how they affect depression during pregnancy. As argued above, 
both social support and stigma are central to discussions of disclosure; indeed, non-disclosure 
has been described as a manifestation of stigma [57]. The impacts of social support and 
stigma on depression have been explored separately, but there are few considerations of how 
these constructs may be interrelated. This chapter thus describes the interrelationships among 
these factors, but also highlights stigma as an effect modifier in the association between 
social support and depressive symptoms, speaking to the profound impact of stigma in this 
context, and again speaking to the importance of considering sub-groups in exploring the 
effects of these factors. 
 
Chapter 5 addresses the third objective of this thesis by exploring the impact of disclosure on 
depressive symptoms during pregnancy and postpartum, as well as the role of pregnancy 
intention in this relationship. These analyses were restricted to women who had been newly-
diagnosed HIV-positive during the pregnancy. As described above, a new HIV diagnosis 
during pregnancy may heighten women’s vulnerability and may be further compounded by 
an unintended pregnancy, but there is limited quantitative evidence for the effects of 
unintended pregnancy on maternal health and well-being. Disclosure has been described as 
an important factor in the evolution of coming to terms with a new HIV diagnosis [58], thus 
the impact of disclosure was explored in this group of newly-diagnosed women. Chapter 5 
empirically tests each of the assumptions described above: (i) that disclosure is universally 
beneficial, by exploring unintended pregnancy as a potential modifier of the association 
between disclosure and depression; (ii) that the effects of disclosure are consistent over time, 
by assessing these associations at three different timepoints; and (iii) that the benefits of 
disclosure are consistent across the person(s) to whom individuals disclose, by exploring the 
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effects of disclosure to a male partner and to family/community members separately, based 
on the findings presented in Chapter 3. Chapter 5 describes how unintended pregnancy 
modifies the impact of disclosure to a male partner on depressive symptoms during 
pregnancy, providing strong evidence for the profound impact of an unintended pregnancy on 
women’s mental health.  
 
Chapter 6 addresses the fourth objective of this thesis. Given the impact of unintended 
pregnancy on mental health outcomes presented in Chapter 5, this chapter explores the long-
term effects of an unintended pregnancy on HIV treatment outcomes. Specifically, the 
chapter explores the impact of unintended pregnancy on viral load during the postpartum 
period to provide quantitative evidence for the profound effects of an unintended pregnancy 
on women’s health. This chapter also examines the role of disclosure to a male partner in this 
association, given the effect modification described in Chapter 5. This chapter provides 
strong and novel evidence for the long-term impact of an unintended pregnancy on HIV 
treatment outcomes in this population, speaking not only to the importance of preventing 
unintended pregnancies to prevent MTCT, but also to promote women’s health in the 
postpartum period.  
 
Chapter 7 addresses the fifth and final objective of this thesis by exploring the impact of 
disclosure on viral load. This chapter tests the three assumptions that this thesis aims to 
critique: (i) that disclosure is universally beneficial, by exploring the effect of disclosure in 
different sub-groups; (ii) that the effects of disclosure are consistent over time, by 
investigating these effects at three different timepoints; and (iii) that the benefits of disclosure 
are consistent across the person(s) to whom individuals disclose, by exploring each of 
disclosure to a male partner and disclosure to family/community members, again based on the 
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results presented in Chapter 3. Given the heightened vulnerability that results from a new 
HIV diagnosis during pregnancy, one of the sub-groups that was explored in testing the first 
assumption was the timing of HIV diagnosis (before versus during pregnancy), with 
important differences in results. Overall, this chapter provides strong evidence against the 
three assumptions presented above by describing a complex association between disclosure 
and viral load that is modified by three factors: (i) timing of HIV diagnosis (before versus 
during pregnancy); (ii) relationship to the person(s) to whom women disclose, and (iii) in the 
case of disclosure to a male partner, relationship status. Consistent with Chapters 3 and 5, 
these results speak to the critical role of women’s circumstances in considerations of these 
constructs. 
 
Finally, Chapter 8 summarises the empirical findings of this thesis and considers the public 
health implications of these results. This chapter concludes with recommendations for both 
research and practice, based on the evidence presented in this thesis against the three 
assumptions described above.  
 
1.6 Public health significance 
HIV-status disclosure has long been acknowledged as an important factor in HIV care, with 
potential benefits for both population and individual health. However, there are important 
limitations in research to date and current policy and practice. This thesis aims to critique 
three widely-held assumptions regarding the benefits of disclosure and to provide quantitative 
insights into other factors that are interrelated with disclosure and are similarly important in 
HIV care. Given the recent roll-out of Option B+ guidelines in South Africa and other 
settings, this research is timely. Public health approaches are centred on population-level 
interventions and are typically not tailored to the individual. However, this thesis will argue 
32 
 
that disclosure is ultimately an individual issue that occurs within social relationships, and 
that counselling messaging needs to be tailored to the individual. Second, stigma is widely 
acknowledged as a pervasive and harmful factor [47, 57]; this thesis will provide further 
quantitative evidence for this viewpoint. Finally, this thesis will highlight pregnancy as a 
critical window, both as a period during which disclosure may affect viral load and, if the 
pregnancy is unintended, as a profound determinant of adverse outcomes in the long term. 
Taken together, this thesis will argue that although much of the progress in preventing MTCT 
in South Africa and globally has been due to population-wide public health approaches, the 
individual cannot be ignored in our response to the HIV pandemic [59] and must be central in 
research, policy and practice.   
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Chapter 2: Literature review 
 
Overview 
The purpose of this literature review is to establish the conceptual background for this thesis 
by providing an orientation to and summary of existing knowledge related to HIV-status 
disclosure. In this thesis, disclosure is presented as both an exposure of interest and an 
outcome. This review summarises relevant knowledge related to four additional constructs of 
interest: stigma, social support, depression and unintended pregnancy. Stigma and social 
support are closely related to disclosure; indeed, each may be both a predictor and an 
outcome of disclosure. Mental health is a similarly related psychosocial factor that may be 
improved by disclosure, and depression is the second outcome of interest in this thesis. 
Finally, an important but understudied issue in the field of disclosure among pregnant women 
is that of unintended pregnancy. Each of these factors are discussed in this review as critical 
constructs related to disclosure and as important factors in prevention of mother-to-child 
transmission (PMTCT) care, and the review includes an overview of impacts on the third and 
final outcome of interest: HIV viral suppression. The review is structured according to the 
objectives of this thesis and addresses themes that are relevant to the results chapters which 
follow. Where appropriate, tables are used to summarise the results of selected primary 
quantitative studies to give an overview of findings. 
 
Section 2.1 presents a brief overview of the conceptual underpinnings of this thesis, including 
the theoretical understanding of disclosure on which this work is based as well as conceptual 
frameworks related to determinants of antiretroviral therapy (ART) adherence and to types of 
stigma. The purpose of this section is not to provide an exhaustive review of all theoretical 
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frameworks through which these constructs can be viewed but rather to briefly describe the 
conceptual frameworks on which this thesis draws to orientate readers to this thinking.  
Sections 2.2 to 2.4 review literature to provide context for the objectives of this thesis. 
Section 2.2 focusses on patterns and predictors of disclosure, providing background for 
Chapter 3. This section provides a summary of selected literature but also highlights the 
methodological limitations in the existing literature, providing a strong basis for the 
methodological approach taken in this thesis. To provide background for Chapters 4-6, 
stigma, social support, mental health and unintended pregnancy are reviewed in Section 2.3. 
As alluded to above and argued further in this section, stigma and social support may be both 
determinants and outcomes of disclosure and are themselves important determinants of HIV-
related outcomes. The literature on mental health provides background for Chapters 4 and 5 
and points to links with each of stigma, social support and disclosure while similarly 
highlighting the importance of mental health in HIV care. Literature on unintended 
pregnancy is summarised to provide additional background for Chapters 5 and 6.  
 
Section 2.4 reviews the potential impacts of disclosure along the HIV care cascade. Although 
not the focus of this thesis, this section provides a summary of literature pointing to 
associations between disclosure and outcomes such as entry into and engagement in HIV care 
before summarising and critiquing existing knowledge on associations with adherence and 
viral load. As argued in Chapter 1, viral load is arguably a more objective marker of 
adherence, and viral suppression is the ultimate goal of ART use for both prevention and 
treatment. This thesis focusses on viral load only but literature on adherence is summarised 
for two purposes: (i) as an important behavioural intermediate between disclosure and viral 
suppression; and (ii) as a means of contrasting this literature to findings regarding viral load.  
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Finally, Section 2.5 highlights limitations of the current evidence, points to the research needs 
that the subsequent results chapters aim to address and provides some context to this work. 
The data on which this thesis is based arise from a particular point in the HIV epidemic in 
South Africa, and it is critical to recognise the impact that this, along with changing treatment 
guidelines, has on the constructs on which this thesis focusses. More weight is given to 
relatively recent studies throughout this literature review, given these changes over time, but 
this section speaks to how context may have impacted on these constructs over time, and 
what impacts additional changes may have going forward.   
 
Methodology 
This review is not intended to be systematic or exhaustive but rather provides an overview of 
key points and gaps in our understanding of disclosure and critically interrelated constructs. 
The primary focus is on literature in the context of PMTCT, but the review also includes 
articles from general adult populations where these contribute important knowledge. 
Similarly, most literature reviewed is from low- and middle-income country (LMIC) settings, 
given that the data on which this thesis is based arise from South Africa, but literature from 
high-income countries is included where this contributes meaningfully. PubMed and 
PsycINFO were searched for relevant literature, and reference lists were checked for 
additional key publications.  
 
Many early papers focussed on the ethics of disclosure. These papers were excluded as they 
are beyond the scope of this thesis. Recently, there has been much research on disclosing to 
perinatally HIV-infected children. As the focus of this thesis is on women disclosing their 
own HIV-status to others within their social network, these papers were excluded, as were 
articles which focussed on disclosure to medical professionals. HIV-infected women may be 
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less likely to disclose their HIV-status compared to HIV-uninfected women [1, 2]; this thesis 
focusses only on HIV-infected women. The two potential benefits of disclosure on which this 
thesis focusses are improved mental health and viral suppression. Importantly, HIV-status 
disclosure may confer other benefits, including behaviours such as consistent condom use [3] 
and appropriate infant feeding [4]. These behaviours are beyond the scope of this thesis and 
will not be discussed in this review.  
 
2.1 Conceptual underpinnings 
2.1.1 The disclosure process 
Following an HIV-positive diagnosis, individuals must decide whether, how and to whom to 
disclose their HIV status [5]. Disclosure is inherently a sequential process that occurs over 
time [6, 7]. Indeed, much of the literature operationalises disclosure as any versus no 
disclosure [8]. Despite this, it has been argued that the disclosure process is neither singular 
nor uniform: rather, disclosure acts to different individuals may not be interchangeable 
indicators of a single underlying process [8, 9]. Disclosure may be either voluntary or 
involuntary, but few studies have differentiated between these [8, 9]. As the data on which 
this thesis is based include only voluntary acts of disclosure, this thesis focusses only on 
voluntary disclosure. 
 
The disclosure act has been described as fluid and dynamic [10]. Rather than being a discrete 
event, it may occur as a gradual process of slowly revealing an HIV-positive diagnosis to a 
particular individual over time. In addition, disclosure acts may occur in different ways [6]. 
Women in sub-Saharan Africa, for example, have described sometimes disclosing indirectly, 
for example by not hiding their antiretroviral drugs or by taking ART in front of others to 
whom they have not disclosed [11, 12]. A further strategy among women testing HIV-
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positive during antenatal care is to subsequently attend couples counselling and testing with a 
male partner. With this strategy, women are able to ‘discover’ their HIV-positive status in the 
presence of their partner and with a counsellor who acts as an intermediary [11]. The 
disproportionately high burden of disclosure which women face and the barriers that are 
specific to disclosing to a male partner are discussed under Section 2.2.6, below.  
 
The conceptual underpinning of this thesis is the Disclosure Processes Model [13, 14]. This 
model has been posited as a theoretical framework to understand when and why disclosure is 
beneficial. Given that this thesis aims to critique assumptions regarding disclosure as a 
universally and consistently beneficial act, a framework that focusses on when and why 
disclosure is beneficial is particularly relevant to this work. The model depicts the processes 
involved in one disclosure event that is situated within a lifelong series of disclosure events, 
and a feedback loop is included to depict the fact that one disclosure event can affect 
subsequent disclosure trajectories. Specifically, individuals who experience positive 
outcomes following disclosure may become more open about their HIV status, while negative 
outcomes may lead to greater concealment. Although neither aspects of the disclosure event 
itself nor responses to disclosure are addressed in this thesis, the framework is included as a 
useful overarching understanding of the disclosure process. Figure 2.1 presents the 
Disclosure Processes Model, adapted for this thesis.  
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The decision-making process begins with antecedent goals: individuals may disclose to 
pursue positive outcomes (approach goals, for example social support) or to prevent negative 
outcomes (avoidance goals, for example HIV-related stigma). After the decision to disclose is 
the disclosure event itself. Although not assessed in the study from which these data arise, the 
reaction of the person(s) to whom individuals disclose (‘confidants’ in the figure above) may 
be a critical determinant of whether the disclosure event leads to beneficial outcomes. Along 
with being antecedent goals, social support and stigma may be mediators of the associations 
between disclosure and individual outcomes. Specifically, disclosure may lead to increased 
social support, or to social rejection. A further mediating process is that of reduced secrecy 
around HIV care engagement and ART use. Limited disclosure may lead to poor treatment 
outcomes through secrecy, and reduced secrecy following disclosure may therefore be a 
mediator of improved outcomes. The outcomes that are the focus of this thesis are at the 
individual level: depression and viral suppression. Importantly, there may be other 
individual-level benefits of disclosure, as well as population-level benefits, but these are 
beyond the scope of this thesis.  
Figure 2.1 Disclosure Processes Model, adapted for this thesis [13, 14] 
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2.1.2 Determinants of ART adherence 
Figure 2.2 presents a conceptual framework reflecting determinants of ART adherence in the 
context of PMTCT, adapted for this thesis. This socio-ecological framework reflects the fact 
that determinants of adherence are multifaceted and occur at multiple levels [15]. This 
framework is a specific manifestation of the broader ecological framework which is widely 
posited in public health. The framework is included here as an overarching understanding of 
factors that may affect adherence among HIV-infected pregnant and postpartum women, with 
disclosure included as one of these factors. As will be argued in this thesis, disclosure is a 
complex act that occurs within social relationships. An overarching framework of other 
determinants of adherence is thus useful to situate disclosure within these broader socio-
ecological factors. Importantly, Figure 2.2 is not an exhaustive framework reflecting all 
determinants of adherence; instead, the framework is limited to factors included in this thesis.  
Figure 2.2 Socio-ecological framework of determinants of antiretroviral therapy (ART) adherence, 
adapted for this thesis [15] 
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Qualitative work from South Africa has described the disclosure process as embedded in a 
particular context and occurring against a backdrop of changing intrapersonal and 
interpersonal circumstances [10]. This thesis includes factors at the community; partner, 
family and peer; and individual levels, but all were assessed at the level of the individual. 
Specifically, although factors such as stigma and support operate at the community and 
interpersonal levels, these factors were measured using women’s reports of stigma and the 
availability of social support. Of note is that each of the factors in the above framework may 
be related to both disclosure and ART adherence. Further, all of these factors are situated 
within a broader social, cultural and political context which may affect the prevalence of 
disclosure [7], although these more distal factors were not assessed. The impact of these 
broader factors is discussed in Section 2.5, below. 
 
2.1.3 Types of stigma 
A final relevant framework is one describing different types of stigma [16]. Although the 
impact of stigma itself is beyond the scope of this thesis, non-disclosure is often treated as a 
proxy for stigma and is arguably a manifestation of stigma [16]. Indeed, the framework 
includes non-disclosure as a mediator between stigma and treatment outcomes. Many of the 
constructs that are central to this thesis are represented in this framework, including 
disclosure, different types of stigma, social support, mental health, unintended pregnancy and 
HIV treatment outcomes; as such, this framework is particularly relevant to this work. Figure 
2.3 presents this framework, adapted for this thesis.  
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The types of stigma reflected in this framework include enacted stigma (experiences of 
discrimination, referred to in Chapter 4 as ‘social rejection’), perceived stigma (perception of 
stigmatising attitudes), anticipated stigma (expectations that one will experience stigma) and 
internalised stigma (endorsement of negative beliefs about oneself, referred to in Chapter 4 as 
‘internalised shame’). Each of these may have an impact on disclosure, social support, mental 
health, and treatment outcomes. Indeed, enacted stigma following disclosure may deter future 
disclosure events [17], speaking to the relevance of the feedback loop included in the 
Disclosure Processes Model described above. Taken together, these frameworks provide an 
orientation to the conceptual underpinnings of this thesis and a useful point of departure for 
the remainder of this review.  
  
Figure 2.3 Framework of types of stigma and their impact on treatment outcomes, adapted for this 
thesis [16]. 
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2.2 Patterns and predictors of disclosure 
As described above, disclosure is a complex and fluid process that occurs within 
relationships. In research and practice, however, disclosure is typically assessed using self-
report. Although self-reported disclosure is not necessarily concordant with confirmation of 
the disclosure act by the person(s) to whom individuals report having disclosed [18], self-
report is the most feasible measure. However, the limitations of using self-report to assess 
disclosure, including limitations related to social desirability bias, should be noted 
throughout.   
 
2.2.1 Disclosure to at least one person 
HIV-infected individuals disclose to differing numbers of person(s). A range of disclosure 
strategies have been described, including no disclosure, selective disclosure, or disclosure to 
a wide range of people [19]. Overall, the most common strategy appears to be selective 
disclosure, with individuals revealing their HIV status to only a few persons [12, 20-23]. 
Despite the selective nature of disclosure, however, existing literature suggests that most 
individuals disclose to at least one person [22]. In 11 studies of general adult populations in 
sub-Saharan Africa, disclosure to at least one person was reported by ≥70% of participants 
[20, 24-33]. Of note is that only five of these studies included longitudinal data [20, 24, 28, 
30, 32] and only four explicitly described how disclosure was operationalised and assessed 
prior to presenting results [24, 27, 29, 33].  
 
In samples of women accessing PMTCT services, levels of disclosure to one or more persons 
are similarly high: in a four-country study of women testing HIV-positive in the context of 
PMTCT in sub-Saharan Africa, 79% of women reported that they generally kept their HIV 
status secret, although 83% had disclosed to at least one person [11]. Table 2.1 presents a 
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summary of selected publications reporting the prevalence of disclosure to at least one person 
in the context of PMTCT. Although most studies report that ≥70% of women disclosed to at 
least one person, markedly low levels were reported in Kenya [34] and in an early study in 
South Africa [35]. Overall, pooled estimates suggest that 67% of pregnant and postpartum 
women in sub-Saharan Africa disclose to at least one person [36]. 
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Table 2.1 Overview of select sub-Saharan African studies from the past decade reporting the prevalence of disclosure to at least one person in the context of 
prevention of mother-to-child transmission (PMTCT) 
First author; year of 
publication Study location Study population 
Used 
longitudinal 
data? 
Disclosure measure(s) 
explicitly described in 
Methods? 
Prevalence of 
disclosure (%) 
Ekama; 2012 [37] Nigeria Pregnant women attending a PMTCT clinic   87 
Ezegwui; 2009 [38] Nigeria Women accessing PMTCT services   97 
Geubbels; 2018 [39] Tanzania Women with a child <18 months old   95 
Kirsten; 2011 [40] Tanzania Pregnant women initiating combination antiretroviral prophylaxis   97 
Lawani; 2014 [41] Nigeria Women attending a clinic for infant HIV testing at 18 months postpartum   89 
Onono; 2014 [34] Kenya 
Women diagnosed HIV-positive at entry into 
antenatal care and followed through 4-8 weeks 
postpartum 
  31 
Ramlagan; 2018 [42] South Africa Pregnant women <6 months gestation and with a current partner   72 
Visser; 2008 [35] South Africa Women diagnosed HIV-positive during the pregnancy   59 
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Similar to studies among general adult populations, Table 2.1 suggests that most studies 
describing the prevalence of disclosure to one or more persons are cross-sectional and do not 
explicitly describe how disclosure was operationalised or assessed prior to presenting results.  
 
2.2.2 Disclosure to sexual partners 
Much research has focussed on disclosure to sexual partners, given that disclosure is 
promoted as a central strategy to reduce transmission of HIV. In general adult populations, 
the prevalence of disclosure to partner(s) ranges widely, from 49% of adults receiving HIV 
care in Uganda reporting that they have disclosed to their partner [43], to 85% in Cameroon 
[44]; other studies from sub-Saharan African report a prevalence between these estimates [31, 
45-51]. These differences may reflect underlying characteristics of these relationships, 
discussed further in Section 2.2.6, below. A recent nationally-representative survey of 
sexually active adults in South Africa reported that 77% of HIV-infected participants had 
disclosed to their current sexual partner(s) [52]. Levels of disclosure to partner(s) are 
significantly lower among women compared to men [3, 53]. In a sample of women in 
Nigeria, only 24% had disclosed to their partner [54]. An early review of disclosure to sexual 
partners in developing countries reported that the proportion of women who have disclosed 
ranges from 17% to 86% [55].  
 
Disclosure to male partners may be particularly difficult among women tested in the context 
of antenatal care [5]. Pooled estimates from studies among pregnant and postpartum women 
in sub-Saharan Africa suggest that 64% of women disclose to their male partner(s) [36]. 
Although some studies have reported that fewer than half of women in the context of PMTCT 
disclose to their partner [56, 57], higher levels of disclosure have been reported in other 
studies, summarised in Table 2.2.   
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Table 2.2 Overview of select sub-Saharan African studies from the past decade reporting the prevalence of disclosure to sexual partner(s) in the context of 
prevention of mother-to-child transmission (PMTCT) 
First author; year of 
publication Study location Study population
1 
Used 
longitudinal 
data? 
Disclosure measure(s) 
explicitly described in 
Methods? 
Prevalence of 
disclosure (%) 
Adeniyi; 2017 [58] South Africa Immediately postpartum women   74 
Brittain; 2015 [59] South Africa Pregnant women accessing PMTCT services and reporting a current male partner   74 
Bucagu; 2013 [60] Rwanda Pregnant women attending a PMTCT clinic   81 
Ebuy; 2015 [61] Ethiopia Pregnant women on ART >2 months; excluded women on ART before pregnancy   77 
Ezegwui; 2009 [38] Nigeria Women accessing PMTCT services   91 
Kinuthia; 2018 [1] Kenya 
Mothers bringing their infants for 6-week or 9-month 
immunisations, restricted to women reporting a 
current male partner 
  87 
Koss; 2017 [62] Uganda 
Previously ART-naïve women who had initiated ART 
at 12-28 weeks gestation, later contacted to attend one 
additional study visit (median: 4.2 years after ART 
initiation) 
  87 
Obai; 2017 [63] Uganda Women aged ≥15 years who had delivered at the study clinics   83 
Sendo; 2013 [64] Ethiopia Pregnant women   73 
1 ART: antiretroviral therapy 
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Consistent with studies reporting the prevalence of disclosure to at least one person, the 
majority of the studies included in Table 2.2 are cross-sectional, although more explicitly 
state that participants were asked to report whether or not they had disclosed their HIV status 
to their sexual partner(s) prior to reporting results [58, 60, 63, 64]. 
 
2.2.3 Disclosure to family members and/or friends 
Reported levels of disclosure to family members and/or friends are typically high among 
adults on ART [65-69]. Of note is that three of these five cited studies were cross-sectional 
[66-68] and only two explicitly described how disclosure was operationalised and assessed 
prior to reporting results [66, 68]. Pooled estimates from studies of disclosure among 
pregnant and postpartum women in sub-Saharan Africa suggest that 40% of women disclose 
to one or more family members and only 6% to one or more friends [36]. As discussed above, 
the most common disclosure strategy appears to be selective, rather than widespread, 
disclosure. Selective disclosure strategies also appear to extend to the targets of disclosure, 
with some individuals disclosed to more frequently than others. Indeed, the prevalence of 
disclosure to different individuals varies widely [11, 70-74]. Overall, female family members 
and friends appear to be the targets of disclosure more frequently compared to males [22, 39, 
58, 75-77].  
 
2.2.4 Time to disclosure 
Alongside individuals disclosing to different numbers and different categories of people, the 
timing of first disclosure events after diagnosis may differ widely. Among HIV-infected 
individuals in Kenya, for example, first reported disclosure events range from within a few 
hours of diagnosis to several years after diagnosis [78]. Despite this wide range, literature 
exists to suggest that the majority of first disclosure events occur rapidly after diagnosis. In a 
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study of adults in South Africa, for example, a high proportion of disclosure events to 
partners and family members reportedly occurred on the day of diagnosis [17], and the 
majority of postpartum women in Zimbabwe who disclose their HIV-positive status to their 
partner reportedly do so within a few days of diagnosis [2]. Other studies from sub-Saharan 
Africa similarly suggest that most disclosure events occur during the first week or month 
after diagnosis [50, 57, 79].  
 
2.2.5 Motivations for disclosure 
As is evident from the summary above, the prevalence of disclosure to different individuals 
differs markedly. In addition, the motivations for disclosing to particular individuals differ 
[80]. Early qualitative research among HIV-infected pregnant women in South Africa 
suggested that women disclose to their male partners primarily to encourage HIV testing and 
the reduction of risk behaviours, or out of a sense of obligation; but disclose to relatives and 
friends because they experience these relationships as supportive [35]. More recent work 
among postpartum women in South Africa has similarly suggested that women disclose to 
their male partners out of a sense of duty, and to family members and close friends to gain 
support [12], where support may include both emotional and practical assistance [81]. Similar 
findings have been reported among HIV-infected adults in Uganda [71]. Decisions regarding 
disclosure are additionally based on the individual’s perceived trustworthiness and ability to 
maintain confidentiality, as well as their anticipated reaction to disclosure [21, 82]; indeed, 
anticipated reactions are a critical consideration in deciding whether to disclose [83, 84]. 
 
2.2.6 Determinants of disclosure  
Along with differences in motivations, observed determinants of disclosure to different 
individuals may differ [8, 73], but examining predictors of disclosure to one or more persons 
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versus disclosure to none will blur these differences. Importantly, predictors of disclosure 
may vary according to the characteristics of both the HIV-infected individual and the person 
to whom they may disclose [17]. Among women, a very well-documented predictor of 
disclosure to a male partner is stable relationship status, for example being married or 
cohabiting. This association has been observed in multiple diverse contexts [17, 58, 76, 85, 
86]. Similarly, decisions to disclose to a sexual partner differ by whether the relationship is 
casual or committed [83], and the quality of women’s relationships with their male partner 
may be an important factor in deciding whether to disclose [5]. Indeed, non-disclosure may 
be a marker of an unhealthy relationship [87].  
 
Of concern is that stable relationships may not be the norm in many settings. In Malawi and 
Uganda, for example, women have described partnerships as being characterised by 
instability and a lack of trust and communication, with instability potentially heightened by 
disclosure [88]; similarly, women in South Africa are often in unstable relationships 
characterised by low expectations of partner commitment and low levels of communication 
[89, 90]. Women may experience additional difficulties in finding opportunities to disclose 
when their male partner lives or works far away [74]. Along with unstable relationships being 
prevalent in South Africa, migrant work is common, further heightening difficulties with 
disclosure to male partners.  
 
Because women test for HIV at much higher rates than men, for example in the context of 
antenatal care, women face a disproportionately higher obligation to disclose [90, 91], but 
there may be substantial gender differences in both the prevalence of and barriers to 
disclosure [92], with women significantly less likely to disclose to a partner compared to men 
[17, 27]. Women in many sub-Saharan African countries have described fearing disclosure to 
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their partners because of the possibilities of abandonment [92, 93] and violence [92, 94]. In 
some contexts, abandonment after disclosing to their husband would include women losing 
their social status as a wife [95]. Fears related to disclosing to male partners may be even 
further heightened in contexts where women are economically dependent on their partners 
[75, 88, 91, 92, 96]. Indeed, women’s fears of abandonment are closely tied to the fear of loss 
of economic support [55], with economic dependence decreasing the odds of disclosure to 
male partners among pregnant women [57].  
 
2.2.7 Synthesis 
Taken together, the findings summarised above lead to key insights into patterns and 
predictors of disclosure. Most HIV-infected individuals disclose to at least one person but 
levels of disclosure to different individuals differ markedly; indeed, selective disclosure 
appears to be the predominant strategy. The Disclosure Processes Model includes a feedback 
loop suggesting that one disclosure event can affect subsequent disclosure trajectories, but it 
has been noted that different disclosure events may not be interchangeable indicators of the 
same underlying process [8, 9]. The timing of first disclosure events may differ widely but 
research suggests that most first disclosure events occur rapidly. Disclosure acts may be 
motivated by approach or avoidance goals; indeed, the motivations for and determinants of 
disclosure to different people may differ. A well-documented determinant of disclosure to 
partners is stable relationship status, with major implications in countries such as South 
Africa where stable relationships may not be the norm. Further, non-disclosure to a partner 
may be a marker of an unhealthy relationship. Finally, women face a disproportionately high 
burden to disclose but disclosure to male partners may be particularly difficult for women 
tested in the context of antenatal care. Indeed, women may delay disclosure to ensure the 
continuation of social and economic security.  
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2.3 Interrelated psychosocial issues 
2.3.1 HIV-related stigma 
Disclosure is closely connected with HIV-related stigma, with stigma described as both 
affecting and being affected by disclosure [97]. Meta-analyses suggest an inverse relationship 
[98]: as stigma increases, the likelihood of disclosure decreases. Anticipated stigma, for 
example, limits levels of disclosure [99, 100] and higher levels of stigma reduce the odds of 
disclosure [51, 100-102]. Stigma adds to fears about disclosing: individuals fear gossip and 
blame following disclosure and, in the case of disclosure to a partner, rejection [11, 99]. 
These fears have led to women testing HIV-positive during pregnancy in Malawi 
experiencing what they describe as a ‘dilemma between silence and openness’ [81]. 
Decreases in stigma and improvements in community attitudes towards HIV have reportedly 
improved over recent years in some contexts [5, 102, 103], but stigma remains a pervasive 
issue and a major part of the lives of HIV-infected individuals [6, 22, 88, 104, 105]. Even 
where individuals have not personally experienced stigma, other forms of stigma may be 
pervasive, including perceived, anticipated and internalised stigma [21, 85, 99, 106-108].  
 
In addition to affecting disclosure, stigma may have profound negative effects on treatment 
outcomes. Stigma and discrimination are major challenges to accessing and remaining in care 
[4, 103, 109-111]. Further along the HIV care cascade, stigma may negatively affect both 
ART initiation and adherence [95, 112], including in the context of PMTCT [113-115], with 
a recent systematic review concluding that there is strong evidence for a link between stigma 
and adherence difficulties [116]. Qualitative research echoes these findings: women cite 
stigma and inadvertent disclosure as major barriers to participation in PMTCT programmes 
[117-119] and to adherence [37]. Even where fears of inadvertent disclosure have not 
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necessarily resulted in suboptimal adherence, these fears have been described as making it 
challenging to take antiretroviral drugs in the context of PMTCT in South Africa [120].  
 
2.3.2 Social support 
Each of disclosure and stigma are strongly interrelated with social support. Indeed, meta-
analyses suggest a positive correlation with disclosure and a negative correlation with stigma 
[98]. Concerns about stigma and the simultaneous need for support contribute to the 
complexity of decisions about disclosure [19]. As with the associations between disclosure 
and stigma, however, social support may both affect and be affected by disclosure: 
individuals are more likely to disclose to person(s) who they perceive as supportive [121] but 
disclosure may also result in increased support. Among pregnant women, for example, male 
partners and family members can play an important supportive role following disclosure 
[115]. Different types of support may stem from disclosure to different individuals, with 
pregnant and postpartum women in Kenya describing disclosure to a partner as important for 
emotional and day-to-day support for HIV care and disclosure to family members as a way to 
ensure future support in the event of their death [6].  
 
Social support is a critical determinant of treatment outcomes. Support from family members, 
for example, has been identified as improving ART adherence [122]. In the context of 
PMTCT, social support may be a facilitator of the uptake of antiretrovirals [114], adherence 
[112, 115], and engagement in care [118]. Improved outcomes may be facilitated through 
actions such as reminders to take antiretroviral drugs, material support such as food and 
money, or emotional encouragement and empathy [21, 88]. Receiving social support 
following disclosure is predicated on a positive response to the disclosure event. Conversely, 
negative responses to disclosure may lead to both higher levels of stigma and lower levels of 
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social support [123]. Indeed, initial responses to disclosure and subsequent actions in relation 
to an individual’s HIV status are critical markers of support or the lack thereof [124].  
 
2.3.3 Mental health 
Mental health problems are common among people living with HIV globally, including in 
Africa [125]. Depression is a particularly common mental health problem and is a key 
outcome in this thesis. In a global survey of HIV-infected adults, for example, 27% of 
participants reported symptoms of depression [102]. Further, depression may be associated 
with each of stigma and social support. Observed stigma, or stigma enacted on others in the 
community, is a major contributor to emotional turmoil [119], and levels of stigma are 
significantly higher among adults reporting depressive symptoms [102, 126-128]. 
Conversely, higher levels of depressive symptoms have been found to be associated with low 
levels of social support [70, 129]. However, there are few considerations of the 
interrelationships among stigma, social support and depression. 
 
The evidence for an association between depression and disclosure is mixed: some studies 
have reported that higher levels of depressive symptoms are associated with a lower [85, 129, 
130] or higher likelihood of disclosure [70, 102]; others have found no association [131, 
132]. One study from the United States demonstrated that the effect of disclosure on 
depressive symptoms differs depending on the person(s) to whom pregnant women disclose: 
in this study, disclosure to a male partner by delivery was not associated with postpartum 
depression, but disclosure to one or more family members was associated with a decreased 
prevalence of postpartum depression [86]. Depression itself has been highlighted as a major 
barrier to care and determinant of suboptimal adherence to ART [42, 111, 112, 133]. Further, 
pregnancy may be a particularly risky period for mental health problems. Pregnancy in the 
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context of HIV may lead to significant anxiety [134], and women who test HIV-positive 
during pregnancy may be less prepared to cope with their diagnosis [5].  
 
2.3.4 Unintended pregnancy 
An understudied issue in the context of PMTCT is that of unintended pregnancy. The burden 
of unintended pregnancies globally is massive: reviews report that up to 80 million 
unintended pregnancies may occur annually [135], with over half of pregnancies among HIV-
infected women in sub-Saharan Africa being unintended [136]. Table 2.3 presents data from 
a selection of cross-sectional studies from sub-Saharan Africa that reported the prevalence of 
unintended pregnancy among HIV-infected women, unless otherwise specified in the table. 
All studies report a high burden of unintended pregnancy, with a similar burden reported in 
the United States [137-139]. Other studies have included measures of ambivalence towards 
pregnancy: in a study from South Africa, for example, 46% of pregnant HIV-uninfected and 
HIV-infected women reported that their pregnancy was unintended, and 29% reported 
ambivalence [140]. Among HIV-uninfected and HIV-infected women in Uganda, mistimed 
pregnancy was reported by 30% of women, unwanted pregnancy by 13%, and ambivalence 
by 3% [141]. In a prospective cohort study in South Africa, 62% of pregnancies during one 
year of follow-up among women on ART were unplanned [142].  
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Table 2.3 Overview of select recent sub-Saharan African studies reporting the prevalence of unintended pregnancy 
First author; year of 
publication Study location Study population
1  Prevalence of unintended pregnancy (%) 
Adeniyi; 2018 [143] South Africa Recently postpartum women 71 
Feucht; 2014 [144] South Africa Mothers of infants born between 2002 and 2009 62 
Mayondi; 2016 [145] Botswana Pregnant and recently postpartum HIV-uninfected and HIV-infected women 44 
O’Shea; 2016 [146] Malawi Pregnant women who had initiated ART ≥6 months before the pregnancy 75 
Peltzer; 2013 [147] South Africa HIV-uninfected and HIV-infected pregnant women 55 
Peltzer; 2016 [148] South Africa Pregnant women 53 
Ramlagan; 2018 [42] South Africa Pregnant women accessing PMTCT services 53 
Warren; 2013 [149] Swaziland Recently postpartum HIV-uninfected and HIV-infected women 69 
Woldesenbet; 2015 [150] South Africa Nationally-representative survey of mothers attending 6-week immunisation visit 60 
1 All studies include only HIV-infected women unless otherwise specified; ART: antiretroviral therapy; PMTCT: prevention of mother-to-child transmission 
 
.  
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The psychosocial effects of an unintended pregnancy may be profound. Indeed, an 
unintended pregnancy causes significant disruption and heightens pre-existing social and 
economic vulnerabilities [151, 152]. Despite this, there is limited evidence for the impact of 
an unintended pregnancy on disclosure. Where an unintended pregnancy coincides with a 
new HIV diagnosis, women have limited time to adjust to both, and qualitative research 
suggests that some women delay disclosing to their male partner to ensure the continuation of 
the relationship [151]. Further, unintended pregnancy may be associated with higher levels of 
depressive symptoms [148], and it has even been suggested that unintended pregnancy may 
be a risk factor for mother-to-child transmission (MTCT) [153, 154]. However, despite 
several investigations of the impact of unintended pregnancy on maternal health behaviours 
and birth outcomes, data on longer-term maternal and child outcomes are lacking [135], 
particularly in the context of HIV. In addition, pregnancy intentions are nuanced, complex to 
measure, and change over time [135, 155]. Further, they are influenced by interrelated factors 
at multiple levels, including the individual, couple, family, and community [155], making 
causality difficult to determine.  
 
2.3.5 Synthesis 
Taken together, stigma, social support, depression and unintended pregnancy are critical 
constructs that may be related to disclosure and are themselves important factors in PMTCT 
care. Stigma and social support both affect and are affected by disclosure, and are strongly 
interrelated; further, each is related to depression. Although levels of stigma have decreased 
during recent years, it remains pervasive [102, 106, 107]. Depression is prevalent globally, 
and pregnancy may be a risky period. In particular, a new HIV diagnosis during pregnancy 
may heighten vulnerability, but the evidence for an association between disclosure and 
depression is mixed. Finally, unintended pregnancy is prevalent but understudied. Although 
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the psychosocial impacts are recognised, there is limited evidence for the effect of unintended 
pregnancy on disclosure and on long-term maternal outcomes in the context of HIV.  
 
2.4 Disclosure and HIV-related outcomes 
2.4.1 Impacts along the HIV care cascade 
There is widespread interest in the effects of disclosure along the HIV care cascade. In 
general adult populations and using various measures of disclosure, disclosure has been 
found to be associated with increased linkage to HIV care [53, 110, 156-158], presentation to 
care at earlier stages of disease [159], as well as increased likelihood of assessment for ART 
eligibility and initiation of ART [157]. Following ART initiation, disclosure may improve 
retention in HIV care [24, 160-162]; the fear of disclosure has been identified as a major 
barrier to accessing and remaining in care [110]. Disclosure has even been found to be 
associated with improved CD4 cell response after ART initiation [32, 163] and with reduced 
mortality [164]. Findings are similar in the context of PMTCT, with non-disclosure 
highlighted as a major barrier to care in resource-limited settings [111]. Disclosure has been 
found to be associated with CD4 cell count testing during pregnancy or receiving the result of 
this test [150], maternal receipt of ART or antiretroviral prophylaxis [165], increased linkage 
into ongoing HIV care during the postpartum period [166], and a reduced likelihood of 
disengagement from care [63, 167-169]. Disclosure may even reduce the risk of MTCT, as 
demonstrated in Kenya [170, 171] and in Rwanda [60], although this association was not 
observed in Zimbabwe [165].  
 
Alongside potential benefits to outcomes earlier in the care cascade, disclosure may be 
associated with improved adherence to antiretrovirals and consequent viral suppression. 
Indeed, non-disclosure has been highlighted as a key determinant of suboptimal adherence to 
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ART among adults in sub-Saharan Africa [112], and numerous quantitative studies have 
demonstrated associations between disclosure and improved adherence to ART among 
pregnant women [115]. The remainder of this section of the review provides a summary of 
papers reporting associations between disclosure and each of (i) adherence and (ii) viral 
suppression. As detailed above, literature on the association between disclosure and 
adherence is included given that this body of work underpins much of the belief that 
disclosure has beneficial effects on treatment outcomes. The literature on viral suppression 
then summarises findings using a more objective marker of adherence, and lays the basis for 
Chapter 7, which explores the effect of disclosure on viral load outcomes.  
 
2.4.2 Impacts on adherence  
In general adult populations and using various measures of disclosure, disclosure has been 
found to be significantly associated with improved adherence based on self-report [25, 67-69, 
133, 172], pill count or pharmacy refill [30, 65, 173], or a combination of measures [46, 174, 
175] in sub-Saharan African studies. Of note is that only four of these 12 studies included 
longitudinal data [30, 65, 69, 173] and only three explicitly described how disclosure was 
operationalised and assessed prior to reporting results [68, 174, 175]. A summary of select 
papers which report significant associations between disclosure and adherence in the context 
of PMTCT is presented in Table 2.4, including two studies from South Africa. Overall, the 
studies suffer from the same methodological limitations as studies reporting associations 
between disclosure and adherence in general adult populations: most rely on cross-sectional 
data and self-reported adherence, and few explicitly describe how disclosure was assessed. 
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Table 2.4 Overview of select sub-Saharan African studies reporting significant associations between disclosure and improved adherence in the context of 
prevention of mother-to-child transmission (PMTCT) 
First author; year of 
publication Study location Study population
1 
Used 
longitudinal 
data? 
Disclosure measure(s) 
explicitly described in 
Methods? 
Measure(s) of 
disclosure 
Measure of 
adherence 
Adeniyi; 2018 [176] South Africa 
HIV-infected women who had 
delivered in selected health 
centres 
  
Disclosure to (i) 
partner and (ii) 
family members 
Combination of 
self-report and 
pharmacy refill 
Ebuy; 2015 [61] Ethiopia 
Pregnant women on ART >2 
months; excluded women on 
ART before pregnancy 
  Disclosure to a partner Self-report 
Ekama; 2012 [37] Nigeria Pregnant women attending a PMTCT clinic   
Disclosure to at least 
one person Self-report 
Kirsten; 2011 [40] Tanzania 
Pregnant women initiating 
combination antiretroviral 
prophylaxis 
  
Disclosure to a 
partner, relative or 
friend 
Medication 
possession ratio  
Kinuthia; 2018 [1] Kenya Women bringing their infants for immunisations   
Disclosure to a 
partner Self-report 
Ramlagan; 2018 [42] South Africa 
Pregnant women <6 months 
gestation and reporting a current 
partner 
  Disclosure to at least one person Self-report 
1 ART: antiretroviral therapy  
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A notable exception is a study conducted among postpartum women in Zimbabwe: in this 
study, neither disclosure to a male partner nor disclosure to others was associated with self-
reported ingestion of nevirapine (NVP) at the correct time [177]. A further notable exception 
comes from Kenya, where women diagnosed HIV-positive when entering antenatal care were 
followed prospectively, with results suggesting that self-reported use of antiretroviral drugs 
during pregnancy was associated with each of disclosure to (i) anyone, (ii) a male partner and 
(iii) an immediate family member, but not with disclosure to others, including friends, more 
distant relatives and members of the community [100]. A study in the context of antenatal 
care in Malawi which assessed the impact of immediate disclosure, defined as disclosure to a 
male partner within one day of diagnosis, reported no association with adherence based on 
pill count [178]. Finally, a particularly notable study investigated the impact of living 
situations on the association between disclosure and adherence: in this early study of 
pregnant women offered single-dose NVP in Zambia, disclosure to a male partner was only 
associated with adherence among women who had delivered at home [179].   
 
2.4.3 Impacts on viral load outcomes  
Findings from studies investigating the impact of disclosure on viral load outcomes are more 
variable. In general adult populations in sub-Saharan Africa and using various measures of 
disclosure, disclosure has been observed to be associated with improved [28, 68] or poorer 
viral load outcomes [180]; several studies have found no association between disclosure and 
viral load outcomes [30, 69, 157]. Consistent with the limitations highlighted throughout this 
review, only two of these six studies explicitly described how disclosure was operationalised 
and assessed [68, 157], although most included longitudinal data [28, 30, 69, 157, 180]. In a 
recent case-control study from South Africa, the odds of virologic failure was higher among 
adults who had disclosed to their friends or colleagues, compared to their partner or close 
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relative(s) [181]. Finally, a large multi-country study of women reported no association 
between viral suppression and disclosure to one or more persons versus disclosure to none 
[182]. 
 
Few studies have explored the impact of disclosure on viral suppression in the context of 
PMTCT, making this an obvious gap in the literature. A cross-sectional study among recently 
postpartum women in South Africa reported that disclosure to a sexual partner was associated 
with a reduced odds of elevated viral load at delivery [58]. Although disclosure to family 
members was measured in this study, the association with viral load outcomes was not 
reported. Around four years after ART initiation during pregnancy in Uganda, disclosure to a 
male partner has been observed to be associated with viral suppression [62]. In this study, the 
way in which disclosure was operationalised and assessed was not explicitly described. 
Finally, in a large cohort study of pregnant women in France, non-disclosure to a male 
partner was found to be significantly associated with elevated viral load at delivery [183].   
 
2.4.4 Causality of associations 
The impact of disclosure on adherence and consequent viral suppression may occur in several 
ways. For example, patients report using a variety of strategies to avoid inadvertent 
disclosure. Hiding HIV medications is common [6, 21, 92, 184, 185], as is taking 
antiretrovirals under the guise of medications for other health issues or for pregnancy [21, 
186]. However, taking antiretrovirals without having disclosed to household members 
represents a logistical challenge [187] and may contribute to suboptimal adherence. In 
addition, individuals may travel to distant clinics to maintain anonymity and avoid 
inadvertent disclosure [6, 119, 184, 185, 188]. The logistical implications of this strategy may 
similarly present challenges to engagement in care and consequent challenges to adherence. 
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Other potential mechanisms of the associations between disclosure and improved outcomes 
include reduced stigma or increased support [100], or the reaction of the person(s) to whom 
an individual discloses [113]; each of these possibilities is in line with the conceptual 
frameworks presented at the beginning of this literature review.  
 
It is important to note the limitations in determining the causality of all associations 
summarised in this literature review. Disclosure may result directly in assistance with 
accessing care or may be a marker of more supportive relationships or decreased stigma, both 
of which may improve engagement in care [156]. Indeed, observed associations between 
social support and disclosure may be due to disclosure leading to increased support or to 
individuals disclosing to person(s) who are perceived to be supportive [189]. In line with this, 
it is plausible that women who disclose to their male partner may be in more supportive 
relationships compared to those who do not disclose, and that it is these supportive 
relationships themselves that improve ART adherence [190]. The causality of associations 
with unintended pregnancy is similarly difficult to determine, as discussed above, given that 
pregnancy intentions occur within complex individual and social circumstances. 
 
2.5 Discussion 
2.5.1 Limitations and research needs 
This review provided a summary of existing knowledge related to disclosure as well as four 
additional constructs of interest: stigma, social support, depression and unintended 
pregnancy. The limitations of existing knowledge are alluded to above but are expanded on in 
this section. In particular, limitations pertaining to the three assumptions that this thesis aims 
to test are summarised below: that (i) disclosure is universally beneficial with (ii) effects that 
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are consistent over time, and (iii) that these benefits are consistent across the person(s) to 
whom individuals disclose.  
 
First, there have been few considerations of how the impact of disclosure may differ across 
context. It has been noted that non-disclosure to a male partner may only negatively affect 
adherence under certain conditions [113] and that the effect of disclosure may be context- or 
culture-specific [114]. In line with the viewpoint that non-disclosure may be a marker of an 
unhealthy relationship, the outcomes of disclosing to male partners may be markers of 
relationship quality [191]. Without considerations of sub-groups, the assumption that 
disclosure is universally beneficial cannot be tested, but few studies have explored effects of 
disclosure within different groups, as is evident from the review above. In addition, it should 
be noted that exploring the effect of disclosure in contexts where levels of disclosure are 
extremely high may not be meaningful; indeed, there may not be enough variability in 
measures of disclosure in these contexts to warrant investigation.  
 
Second, it is clear from the review above that most studies include only cross-sectional data, 
thus precluding an investigation of the consistency of the effects of disclosure over time. It is 
notable that associations between disclosure and adherence are less frequently reported in 
longitudinal compared to cross-sectional studies [192]. Given that disclosure is inherently a 
dynamic phenomenon that occurs over time, longitudinal research is needed [193]. Alongside 
this limitation, it was noted in the review above that evidence for the impact of disclosure on 
viral load is more variable than that for the impact on adherence. As alluded to in Chapter 1, 
self-reported adherence suffers from social desirability and recall biases. It is plausible that 
this social desirability bias extends to the reporting of disclosure, such that individuals who 
report that they have disclosed are also more likely to report optimal adherence.  
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It has been suggested that the consequences of disclosure to different people may differ [8]. 
However, evidence for or against the third assumption, that the benefits of disclosure are 
consistent across the person(s) to whom individuals disclose, is limited given that most 
research operationalises disclosure as any versus none or focusses on disclosure to one person 
or category of persons. A recent systematic review of disclosure among pregnant and 
postpartum women in sub-Saharan Africa reported that 22 of 43 studies operationalised 
disclosure as any versus none [36]. Further, few authors explicitly describe how disclosure 
was operationalised and assessed prior to presenting results, as highlighted throughout the 
review above. It is thus impossible to determine whether the reported measure was the only 
measure of disclosure assessed, or if the reported measure was the only measure that was 
significantly associated with the outcome of interest.  
 
Finally, causality is difficult to determine, as alluded to in Section 2.4. First, most existing 
studies are cross-sectional, as detailed above, and temporality cannot be established. In 
addition, the potential for confounding cannot be ignored. As summarised above, it is likely 
that individuals who are in more supportive relationships are more likely to disclose, and that 
these supportive relationships themselves lead to improved outcomes. Limitations of existing 
research related to the other constructs of interest in this thesis have been alluded to 
throughout this review. In particular, there are few considerations of the interrelationships 
among stigma, social support and depression; mixed evidence for the effect of disclosure on 
depression; and few considerations of the long-term impacts of unintended pregnancy.  
 
The above limitations lead to several research needs. First, there is a critical need for 
improved measurement of disclosure. Two notable exceptions to the predominant approach 
have used psychometric analytic techniques to explore dimensions of disclosure [8, 9]. Given 
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that patterns of disclosure differ in different contexts, similar explorations in other settings 
are warranted, and research which explores the effects of disclosure to different individuals is 
needed. Second, longitudinal data are clearly needed to explore patterns of disclosure as well 
as the consistency of the effects of disclosure over time, and to ensure the temporality of 
findings. Third, the impact of disclosure in different sub-groups warrants exploration to 
provide evidence for or against the assumption that disclosure is universally beneficial. 
Further, additional research that explores the impact of disclosure on viral load, a robust 
biological measure and the ultimate goal of ART use, is needed. Finally, quantitative 
explorations of the interrelationships among stigma, social support and depression; the effect 
of disclosure on depression; and the long-term impacts of unintended pregnancy are needed. 
 
2.5.2. Context of this thesis  
The changing HIV epidemic and treatment guidelines in South Africa have implications for 
each of the major constructs described above. Indeed, it was noted in Section 2.1 that all of 
the factors within the socio-ecological framework of ART adherence are situated within a 
broader social, cultural and political context [7]. South Africa has a complicated history 
related to HIV and treatment and, despite hopes that increased access to testing and treatment 
would result in HIV becoming more normalised, levels of stigma remain high in the country 
[102, 106, 107]. Increased ART availability and uptake has led to HIV becoming a chronic 
disease, but this has not eliminated the psychological impacts of infection [194]. Indeed, the 
chronic nature of HIV necessitates a self-management model [195], where disclosure may be 
an important component of self-management. Disclosure was previously an entry criterion for 
ART initiation, given the viewpoint that treatment ‘buddies’ were critical to maintaining 
optimal adherence [7]. However, this acted as a barrier to treatment initiation, and disclosure 
is no longer required to initiate ART in the country.  
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Changes in PMTCT guidelines were summarised in Chapter 1. Early PMTCT regimens 
included only short-course prophylaxis, but all HIV-infected pregnant and postpartum 
women are now eligible to initiate lifelong ART under Option B+ guidelines in South Africa. 
The difficulties of concealing clinic attendance and ART use may be compounded by these 
guidelines: lifelong care results in many more opportunities for a woman’s HIV status to be 
inadvertently revealed [6]. For women who have not disclosed to individuals in their 
households, secrecy around ART use is now a lifelong concern. In addition, women now 
initiate lifelong ART on the day of diagnosis. For women who are newly-diagnosed during 
pregnancy, there is a need to accept the triple burden of pregnancy, diagnosis and ART 
eligibility within the very limited time that same-day initiation allows [93, 187]. This has 
major implications for disclosure, with women in South Africa often reporting that they are 
not yet ready to disclose but will do so with time [187].  
 
2.5.3 Conclusion  
In conclusion, this review has summarised existing knowledge related to HIV-status 
disclosure as well as four additional constructs of interest: stigma, social support, depression 
and unintended pregnancy. Overall, the importance of each of these factors in PMTCT care is 
clear, but existing insights have limitations. In particular, high-quality evidence is needed for 
the assumptions that (i) disclosure is universally beneficial with (ii) effects that are consistent 
over time, and (iii) that these benefits are consistent across the person(s) to whom individuals 
disclose. Using quantitative data, this thesis aims to contribute to the evidence base while 
addressing some of the limitations inherent in research to date. In particular, this thesis aims 
to provide insights into the patterns, predictors and impact of disclosure on depression and 
viral load among pregnant and postpartum women; including considerations of stigma, social 
support, depression and unintended pregnancy.   
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Abstract 
HIV-status disclosure may improve psychosocial health and adherence to antiretroviral 
therapy (ART), but existing insights suffer from methodological limitations. We explored 
disclosure over time during pregnancy and postpartum among 1347 HIV-positive women in 
Cape Town. Among 995 women diagnosed HIV-positive before the pregnancy and entering 
antenatal care (median age: 30 years), 95% had disclosed to ≥1 individual. In Mokken scale 
analysis, we observed two separate dimensions of disclosure: disclosure to a male partner, 
and disclosure to family/community members. Among 352 women diagnosed during the 
pregnancy and initiating ART (median age: 27 years), 61% disclosed to a male partner and 
71% to a family/community member by 12 months after diagnosis. Relationship status 
modified the impact of pregnancy intentions and poverty on disclosure to a male partner. 
These unique data provide important insights into dimensions of disclosure during pregnancy 
and postpartum, and suggest that women’s social and economic circumstances are central 
determinants of disclosure. 
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3.1 Introduction 
HIV-status disclosure may have beneficial effects on both psychosocial health and adherence 
to antiretroviral therapy (ART) among HIV-positive individuals. As a means of accessing 
social support from family and community networks, disclosure may improve psychological 
well-being [1] and facilitate the development of effective coping strategies [2]. Non-
disclosure has been identified as a barrier to antiretroviral adherence in studies of adults 
living with HIV [3] and specifically among women in prevention of mother-to-child 
transmission (PMTCT) programmes [4-6]. This association may be explained by attempts to 
hide antiretroviral usage so as not to inadvertently disclose, as well as individuals not 
receiving support for adherence. Given the potential benefits, disclosure is widely encouraged 
in counselling services for people living with HIV. Despite widespread fears around 
disclosing [7-9], documented reactions to disclosure are generally positive, with some 
evidence linking disclosure to sexual risk reduction in sexual partnerships and the ability to 
seek care openly, although some individuals do experience negative reactions such as anger 
or rejection [10, 11]. Most HIV-positive individuals typically report having disclosed to at 
least one person [7, 12-14], although selective disclosure appears to be the norm, with levels 
of disclosure to different individuals differing markedly [12]. 
 
Disclosure has been described as a process of revealing one’s HIV status to an increasing 
number of individuals over time [12]. This process includes a feedback loop where the 
individual’s positive or negative response to the disclosure event results in greater openness 
and additional future disclosure events or greater concealment, respectively [1]. Inherent in 
this model is the effect that one disclosure event can have on subsequent disclosure 
trajectories. A limitation of much disclosure research to date is the reliance on cross-sectional 
data to evaluate what is inherently a process that occurs over time [1]. A further limitation is 
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the commonly used approach of operationalising disclosure as any versus no disclosure, or 
using sum scores to indicate the total number of persons to whom an individual has disclosed 
[15]. These approaches treat disclosure to different individuals as interchangeable events. 
Rather, it has been argued that disclosure should be conceptualised as a multi-dimensional 
process consisting of clusters of disclosure events to different individuals, given that 
disclosure events are neither interchangeable nor independent [15, 16]. Based on this idea, 
two recent studies have sought to extend the methodology of disclosure research using 
psychometric data reduction techniques in general adult HIV-positive populations [15, 16].  
 
Less attention has been paid to the methodology of disclosure research among HIV-positive 
pregnant and postpartum women. In terms of disclosure, HIV-positive pregnant women differ 
from non-pregnant adults in important ways: in South Africa and other high-burden settings, 
women typically test HIV-positive in the context of antenatal care when they may feel 
healthy, rather than through voluntary counselling and testing or provider-initiated testing in 
other contexts. In many low- and middle-income country settings, women may be 
economically dependent on their male partner, with their economic vulnerability heightened 
by pregnancy and having implications for disclosure to their male partner [17]. Further, they 
may be at heightened risk of mental health problems such as depression, particularly in low- 
and middle-income country settings [18, 19], and may consequently require a greater degree 
of support. Among HIV-positive pregnant women, levels of disclosure to male partners may 
be particularly low [20-23], especially among women diagnosed in the context of antenatal 
care [12, 13, 24, 25]. A widely reported predictor of disclosure to a male partner is stable 
relationship status [7, 20, 23, 26], but there are few considerations of how factors such as 
relationship status may modify other determinants of disclosure.  
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Given methodological limitations in operationalising disclosure and the dearth of longitudinal 
data, high-quality evidence is lacking, and interventions and counselling messaging are based 
on data with substantial limitations. To address this gap, we explored patterns and predictors 
of HIV-status disclosure among HIV-positive pregnant women in Cape Town, South Africa. 
Our objectives were to explore patterns and predictors of disclosure among three analytic 
populations, each using different analyses: (i) women diagnosed HIV-positive before the 
pregnancy and entering antenatal care, using cross-sectional analyses and incorporating 
psychometric data reduction techniques previously used in a study of HIV-positive adults 
[15], with (ii) descriptive longitudinal analyses in a subset who were followed through 
pregnancy and postpartum; and (iii) women diagnosed HIV-positive during the pregnancy 
and followed through pregnancy and postpartum, using longitudinal analyses. 
 
3.2 Methods 
3.2.1 Study design 
These secondary analyses draw on the MCH-ART study, a multi-phase implementation 
science study evaluating strategies for providing HIV care and treatment services in Cape 
Town (ClinicalTrials.gov NCT01933477). The design and methods of the study have been 
previously described [27]. The study was conducted at one antenatal care clinic in the former 
township of Gugulethu, where an antenatal HIV prevalence of ~30% has been documented 
[28]. In this setting, ART eligibility was determined based on CD4 cell count or clinical 
disease staging until June 2013; from July 2013 onward, all HIV-positive pregnant women 
were eligible to initiate lifelong ART under Option B+ guidelines [29].  
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3.2.2 Participants 
For the broader MCH-ART study, consecutive HIV-positive women who were 18 years or 
older and were entering antenatal care were recruited and enrolled in a cross-sectional 
evaluation; women who were initiating ART were followed until their first postpartum clinic 
visit at up to three study visits, with follow-up at up to six additional study visits through 12 
months postpartum among women who chose to breastfeed [27]. For the purposes of the 
current analyses, we used different analytic methods across three analytic populations: (i) a 
cross-sectional analysis of disclosure reported at entry into antenatal care among all women 
who were known HIV-positive before the pregnancy; (ii) a descriptive analysis of 
longitudinal data through 12 months postpartum among women who were known HIV-
positive and who were initiating ART and followed as part of the broader study; and (iii) an 
analysis of longitudinal data through 12 months postpartum among women who were 
diagnosed HIV-positive during the pregnancy and who were initiating ART and followed as 
part of the broader study (see Figure 3.1 for an overview of the analytic populations and 
methods used). All women provided written informed consent prior to enrolment, and the 
study was approved by the University of Cape Town’s Faculty of Health Sciences Human 
Research Ethics Committee and by Columbia University Medical Center’s Institutional 
Review Board in New York. 
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3.2.3 Study measures 
Study measures were administered in isiXhosa, the predominant local language, by trained 
interviewers at study visits separate from routine HIV or antenatal/postpartum care. All 
measures were translated from English into isiXhosa and were back-translated to ensure 
accuracy using standard procedures for translation and back-translation [30]. Basic 
sociodemographic characteristics were assessed, and included age, educational attainment 
and relationship status. Pregnancy intentions were assessed by asking women whether or not 
they were trying to have a baby when they found out that they were pregnant. A composite 
poverty score was calculated based on current employment, housing type and access to 
household assets in order to categorise participants according to relative levels of 
disadvantage, as previously described [31]. Women self-reported their date of HIV diagnosis, 
and this was used to calculate the time between diagnosis and entry into antenatal care and to 
Figure 3.1 Analytic populations and methods used1 
 
1 ART: antiretroviral therapy. 
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categorise women according to the timing of diagnosis (before versus during the pregnancy). 
Gestation was assessed using ultrasound.  
 
Although HIV-status disclosure may be involuntary, for example if someone else reveals the 
individual’s HIV status without his/her permission, only voluntary disclosure was assessed in 
the broader study, thus we use the term ‘disclosure’ in the present article to refer only to 
voluntary disclosure. At entry into antenatal care, disclosure was assessed by asking women 
whether or not they had told anyone that they are HIV-positive, and then by asking whether 
or not they had disclosed to each of 18 possible categories: male partner; mother; father; 
sister; brother; daughter; son; uncle; aunt; male cousin; female cousin; other male family 
member; other female family member; other sexual partner; friend; spiritual leader; current or 
former employer; and the broader public/community. This list was developed for the 
purposes of this study, and disclosure to each category was assessed using response options 
of ‘Yes’, ‘No’, or ‘Not Applicable’. At each subsequent visit, women were asked whether 
they had disclosed to anyone new since their last visit, with disclosure to the same 18 
possible categories assessed. Given the exploratory nature of these analyses, we combined the 
response options ‘No’ and ‘Not Applicable’ in analyses, and excluded disclosure to certain 
categories given that disclosure to these categories was infrequently reported: daughter 
(reported by 9% of women who were diagnosed HIV-positive before the pregnancy), son 
(6%), employer (4%), other sexual partner (3%) and the public/community (1%).  
 
3.2.4 Data analysis 
Data were analysed using Stata 12 (StataCorp Inc, College Station, Texas, USA) and R (R 
Foundation for Statistical Computing, Austria). Baseline characteristics were summarised 
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using frequencies and percentages for categorical variables and medians and inter-quartile 
ranges (IQR) for non-normally distributed variables.  
 
3.2.4.1 Cross-sectional analyses 
Among women diagnosed before the pregnancy, we examined the dimensionality of 
disclosure using Mokken scale analysis, a form of non-parametric item response theory, 
based on the approach used by Dima et al [15]. The Mokken scale model implies an ordinal 
scale for observable scores (here, the number of categories of individuals disclosed to), 
allowing an ordering of HIV-positive individuals in terms of the number of categories to 
whom they report having disclosed [32, 33]. A special case of the model is the double 
monotonicity model which additionally allows for an ordering of items that have invariant 
item ordering [33]. Here, this would imply that the order in which individuals disclose to 
different categories does not differ across individuals [34].  
 
Using the mokken package in R and the approach recommended by Sijtsma & van der Ark 
[33], we ran an automated item selection procedure (aisp) algorithm 12 times consecutively 
at increasing values of c (c=0 to c=0.55), where c is a chosen positive coefficient representing 
the threshold of homogeneity above which an item is included in the scale. We calculated 
item (Hj, representing how well each item discriminates between individuals’ overall 
disclosure) and total scale (H, representing the accuracy with which items within the total 
scale are able to order individuals with respect to overall disclosure) scalability coefficients 
and standard errors; checked scale assumptions; and examined the possibility of invariant 
item ordering to assess whether or not women disclosed to different categories in the same 
order. Following this exploratory analysis and based on these results, we examined factors 
independently associated with disclosure to a male partner and to the sum of 
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family/community categories (which we refer to as the family/community subscale) in 
logistic and linear regression models, respectively. As we did not assess the exact number of 
family/community members to whom women have disclosed (as women may have disclosed 
to, for example, more than one friend), we used the sum of categories as a proxy for overall 
disclosure. Finally, we explored factors independently associated with report of any versus no 
disclosure in logistic regression models in order to serve as a comparison against these more 
nuanced disclosure analyses. Throughout, we adjusted for sociodemographic characteristics, 
ART use and time since HIV diagnosis. 
 
3.2.4.2 Longitudinal analyses 
Using longitudinal data, we explored the time to first report of disclosure to a male partner 
and to family/community categories. Where participants reported a new disclosure event at a 
study visit, we used the midpoint between that and the previous study visit as a proxy for the 
date of disclosure. Using these data, we then explored the time to first disclosure among 
previously-diagnosed women who had not disclosed at entry into antenatal care and who 
initiated ART and were followed prospectively. Similarly, we explored the time to first 
disclosure among women who were diagnosed during the pregnancy and who initiated ART 
and were followed prospectively, and used product-limit methods and Cox proportional 
hazards models to explore variables associated with disclosure to a male partner and to one or 
more family/community categories. We examined how relationship status may modify the 
predictors of disclosure to a male partner in stratified analyses by comparing (i) women who 
were married and/or cohabiting and (ii) women who were neither married nor cohabiting. 
This latter group included a small number of women who reported that they were not in a 
relationship. 
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3.3 Results 
3.3.1 Sociodemographic and clinical characteristics 
These analyses include data from 1347 HIV-positive pregnant women. A total of 995 
pregnant women who were known HIV-positive at entry into antenatal care (median age: 
30.5 years) were included in the cross-sectional component, with 276 women who initiated 
ART during pregnancy and who were followed prospectively included in longitudinal 
analyses. Longitudinal analyses were also conducted among 352 women who were diagnosed 
HIV-positive during the pregnancy and initiated ART (median age: 26.9 years). All 
participants were enrolled between March 2013 and June 2014, and characteristics measured 
at enrolment are described in Table 3.1. Low levels of educational attainment, employment, 
and married and/or cohabiting relationship status and high levels of unintended pregnancy 
were observed in both groups. Among women diagnosed before pregnancy, the median time 
since HIV diagnosis was 4.2 years. 
 
3.3.2 Reported disclosure at entry into antenatal care among women diagnosed before 
pregnancy 
Among women diagnosed before the pregnancy (n=995, with n=559 on ART at entry into 
antenatal care), 95% had disclosed to at least one individual, with disclosure to one or more 
individuals (versus disclosure to none) significantly associated with being on ART at entry 
into antenatal care (p<0.001) and longer time since HIV diagnosis (p=0.001). No other 
factors were associated with disclosure to one or more versus no individuals. Disclosure to 
different categories ranged from 77% of women having disclosed to their male partner, to 9% 
having disclosed to a spiritual leader; across all categories, disclosure was significantly more 
common among women who were already on ART when entering antenatal care (Table 3.2). 
  
97 
 
Table 3.1 Participant characteristics at entry into antenatal care by timing of HIV diagnosis 
 
Variable 
Diagnosed before pregnancy – 
total sample; n (%) 
Diagnosed before pregnancy – 
on ART; n (%)1 
Diagnosed before pregnancy – 
not on ART; n (%) 
Diagnosed during 
pregnancy – n (%) 
Number of women 995 559 436 352 
Median [IQR] maternal age 30.5 [26.9, 34.2] 31.5 [27.9, 34.9] 29.4 [26.0, 32.9] 26.9 [23.5, 31.6] 
Completed secondary/any 
tertiary education 233 (23) 125 (22) 108 (25) 109 (31) 
Currently employed 353 (35) 212 (38) 141 (32) 146 (41) 
Poverty categories 
   Least disadvantaged 
   Moderate disadvantage 
   Most disadvantaged  
299 (30) 
329 (33) 
367 (37) 
164 (29) 
191 (34) 
204 (36) 
135 (31) 
138 (32) 
163 (37) 
112 (32) 
116 (33) 
124 (35) 
Married and/or cohabiting 478 (48) 271 (48) 207 (47) 130 (37) 
First pregnancy 88 (9) 58 (10) 30 (7) 95 (27) 
Pregnancy unintended 603 (61) 313 (56) 290 (67) 245 (70) 
Median [IQR] gestation in 
weeks  20 [14, 27] 19 [14, 26] 20 [14, 26] 21 [16, 27] 
Median [IQR] years since 
diagnosis 4.2 [2.3, 6.8] 4.6 [2.9, 7.4] 3.7 [1.9, 5.9] - 
On ART 559 (56) 559 (100) 0 (0) 0 (0) 
1 ART: antiretroviral therapy 
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Table 3.2 Proportion of women reporting having disclosed to different individuals at entry into antenatal 
care and scalability coefficients (Hj) with standard errors (SE) for the family/community subscale from 
Mokken scale analysis among 995 women diagnosed HIV-positive before pregnancy 
 Proportion of women reporting having disclosed  
Hj (SE)  Total sample; n (%) On ART; n (%)1 Not on ART; n (%) 
Male partner 771 (77) 476 (85) 295 (68) - 
Sister 605 (61) 399 (71) 206 (47) 0.44 (0.03) 
Friend 518 (52) 359 (64) 159 (36) 0.39 (0.03) 
Mother 471 (47) 303 (54) 168 (39) 0.39 (0.03) 
Female cousin 373 (37) 256 (46) 117 (27) 0.54 (0.02) 
Brother 372 (37) 266 (48) 106 (24) 0.46 (0.02) 
Other female 
family member 271 (27) 199 (36) 72 (17) 0.57 (0.02) 
Male cousin 230 (23) 170 (30) 60 (14) 0.61 (0.02) 
Aunt 221 (22) 154 (28) 67 (15) 0.54 (0.02) 
Uncle 175 (18) 131 (23) 44 (10) 0.59 (0.02) 
Father 164 (16) 114 (20) 50 (11) 0.38 (0.03) 
Other male 
family member 159 (16) 125 (22) 34 (8) 0.62 (0.02) 
Spiritual leader 89 (9) 63 (11) 26 (6) 0.45 (0.04) 
1 ART: antiretroviral therapy 
 
Using Mokken scale analysis, we found that disclosure to a male partner formed a separate 
single-item dimension, while all 12 remaining categories formed one scale. This suggests that 
the decision to disclose to a male partner in this sample is independent of decisions to 
disclose to family/community members, with disclosure to family/community categories 
occurring as related events. Scalability coefficients and standard errors for the 12-item 
family/community subscale are presented in Table 3.2. For this subscale, H=0.5 (standard 
error: 0.02), suggesting that these items form a medium-strong scale [35]. The items father, 
female cousin and other female family member showed signs of violating invariant item 
ordering, suggesting that these categories are not disclosed to at the same point in the typical 
order of disclosure events by all women. After exclusion of these categories, the remaining 
nine items met criteria for invariant item ordering, suggesting that in this sample women 
tended to disclose to particular categories in the following order: a sister, friend, mother, 
brother, male cousin, aunt, uncle, other male family member and, lastly, a spiritual leader. 
This implies that women who had disclosed to, for example, their brother were likely to have 
also disclosed to their mother, friend and sister. This smaller scale showed medium accuracy 
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in terms of invariant item ordering (HT=0.42) and high reliability (Molenaar-Sijtsma 
coefficient=0.82) [35, 36]. 
 
3.3.3 Factors associated with disclosure at entry into antenatal care among women 
diagnosed before pregnancy 
Table 3.3 presents factors associated with disclosure to a male partner, as well as factors 
associated with the number of categories in the family/community subscale to whom women 
had disclosed at entry into antenatal care among women diagnosed before the pregnancy. 
After adjustment for age and time since diagnosis, disclosure to a male partner was strongly 
associated with being in a married and/or cohabiting relationship [adjusted odds ratio (aOR): 
2.51; 95% confidence interval (CI): 1.81, 3.48] and with being on ART at entry into antenatal 
care (aOR: 2.98; 95% CI: 2.15, 4.11), and was more common among women who had 
completed secondary or any tertiary education (aOR: 1.59; 95% CI: 1.08, 2.34); no 
association was observed between length of time since HIV diagnosis and disclosure to a 
male partner.  
 
As disclosure to family/community categories meets the criteria for a Mokken scale in this 
sample, sum scores represent a meaningful indicator of disclosure to family/community 
categories, and allow an ordering of individual women with regard to the number of 
family/community categories to whom they had disclosed. Women had disclosed to a median 
of 3 categories (IQR: 1-5) in this subscale. In a multivariable model adjusted for age, the 
number of categories to whom women had disclosed was lower among women who were in a 
married and/or cohabiting relationship [regression coefficient (β): -0.95; 95% CI: -1.31,  
-0.59]. This finding did not differ according to whether or not women had disclosed to their 
male partner. Other determinants of disclosure to a higher number of family/community 
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categories were being on ART at entry into antenatal care (β: 1.75; 95% CI: 1.38, 2.12) and a 
longer time since HIV diagnosis (β for a one-year increase in time since diagnosis: 0.24; 95% 
CI: 0.18, 0.30). Women who were employed or who reported one or more previous 
pregnancies had disclosed to fewer family/community categories (β: -0.65; 95% CI: -1.03,  
-0.27; and β: -0.76; 95% CI: -1.43, -0.09, respectively). 
 
3.3.4 Disclosure over time among women diagnosed before pregnancy 
In a subset of 276 women who were diagnosed before the pregnancy but initiated ART 
during the pregnancy and were followed prospectively, new disclosure events appeared 
uncommon. Of the 98 women who had not disclosed to their male partner at entry into 
antenatal care and were followed prospectively, only 25% had disclosed by 12 months after 
enrolment into the study. Similarly, new disclosure events to family/community categories 
ranged from 2% of women who had not disclosed at entry into antenatal care disclosing to 
their father by 12 months after enrolment, to 20% disclosing to a friend.  
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Table 3.3 Factors associated with disclosure to a male partner and with the number of family/community categories to whom women report having disclosed at entry 
into antenatal care among 995 women diagnosed HIV-positive before pregnancy 
Variable 
Disclosure to a male partner Number of family/community categories 
Unadjusted OR 
[95% CI]1 P-value 
Adjusted OR 
[95% CI]2 P-value 
Unadjusted β [95% 
CI]3 P-value 
Adjusted β  
[95% CI]2 P-value 
Maternal age 1.00 [0.97, 1.03] 0.791 0.97 [0.94, 1.00] 0.079 0.06 [0.02, 0.10] 0.003 0.01 [-0.04, 0.05] 0.793 
Education 
   Primary/some secondary 
   Secondary/tertiary 
Reference 
1.38 [0.95, 1.99] 0.091 
Reference 
1.59 [1.08, 2.34] 0.018 
Reference 
-0.28 [-0.75, 0.18] 0.236   
Employment 
   Unemployed 
   Employed 
Reference 
1.12 [0.82, 1.53] 0.478   
Reference 
-0.45 [-0.87, -0.03] 0.031 
Reference 
-0.65 [-1.03, -0.27] 0.001 
Poverty categories 
   Least disadvantaged 
   Moderate disadvantage 
   Most disadvantaged 
Reference 
0.83 [0.57, 1.21] 
0.99 [0.68, 1.44] 
0.340 
0.970   
Reference 
-0.21 [-0.71, 0.29] 
-0.14 [-0.63, 0.34] 
0.404 
0.562   
Relationship status 
   Neither married nor cohabiting 
   Married and/or cohabiting 
Reference 
2.29 [1.67, 3.13] <0.001 
Reference 
2.51 [1.81, 3.48] <0.001 
Reference 
-0.89 [-1.28, -0.50] <0.001 
Reference 
-0.95 [-1.31, -0.59] <0.001 
Previous pregnancies 
   First pregnancy 
   One or more previous pregnancies 
Reference 
0.81 [0.47, 1.41] 0.453   
Reference 
-0.74 [-1.43, -0.05] 0.037 
Reference 
-0.76 [-1.43, -0.09] 0.027 
Antiretroviral therapy (ART) use 
   Not on ART 
   On ART 
Reference 
2.74 [2.02, 3.73] <0.001 
Reference 
2.98 [2.15, 4.11] <0.001 
Reference 
2.00 [1.62, 3.48] <0.001 
Reference 
1.75 [1.38, 2.12] <0.001 
Years since diagnosis 1.03 [0.98, 1.07] 0.249 1.01 [0.96, 1.07] 0.585 0.27 [0.21, 0.32] <0.001 0.24 [0.18, 0.30] <0.001 
1 OR: odds ratio; 95% CI: 95% confidence interval; 2 Adjusted models are adjusted for covariates shown; 3 β: regression coefficient 
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3.3.5 Disclosure over time among women diagnosed during pregnancy 
The group of 352 women who were diagnosed during the pregnancy and initiated ART were 
followed for a median of 14.4 months (IQR: 6.1-16.5) from diagnosis. By 12 months after 
diagnosis, 86% had disclosed to at least one individual. During this time, 61% disclosed to a 
male partner, and 71% to one or more categories in the family/community subscale, with the 
frequency of disclosure to each family/community category similar to that observed among 
women diagnosed before pregnancy. Time to first disclosure events was short: 50% and 53% 
of women disclosed to their male partner and to a family/community member within 30 days 
of diagnosis, respectively; with women disclosing to a median of 1 (IQR: 0-2) 
family/community category over follow-up. 
 
3.3.6 Predictors of disclosure over time among women diagnosed during pregnancy 
In unadjusted analyses, disclosure to a male partner was strongly associated with married 
and/or cohabiting relationship status [hazard ratio (HR): 1.80; 95% CI: 1.37, 2.36] and was 
more common among women who reported that their pregnancy was intended (HR: 1.45; 
95% CI: 1.10, 1.93). In a multivariable Cox proportional hazards model adjusted for poverty, 
these associations persisted, and disclosing to a male partner was less likely with increasing 
age [adjusted hazard ratio (aHR): for a one-year increase in age 0.97; 95% CI: 0.95, 1.00]. 
Marked differences in the predictors of disclosure to a male partner were observed when 
stratified by relationship status: among women in married and/or cohabiting relationships, 
intended pregnancy remained significantly associated with disclosure (aHR: 1.61; 95% CI: 
1.07, 2.42) after adjustment for age, education, poverty and number of previous pregnancies, 
but this association was not observed among women who were neither married nor 
cohabiting (Figure 3.2.1; Figure 3.2.2; Table 3.4). Among this latter group, disclosure to a 
male partner was less common among those reporting higher levels of poverty (aHR for 
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moderate disadvantage and most disadvantaged, compared to least disadvantaged: 0.57; 95% 
CI: 0.37, 0.88; and 0.60; 95% CI: 0.38, 0.97, respectively), independent of age, educational 
attainment, pregnancy intention and number of previous pregnancies (Figure 3.3.1; Figure 
3.3.2; Table 3.4).  
 
 
 
 
 
 
  
Figure 3.2.1 Impact of pregnancy intention on occurrence of disclosure to 
a male partner among women diagnosed HIV-positive during pregnancy 
and married and/or cohabiting 
 
Figure 3.2.2 Impact of pregnancy intention on occurrence of disclosure to 
a male partner among women diagnosed HIV-positive during pregnancy 
and neither married nor cohabiting 
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Table 3.4 Impact of relationship status on the predictors of disclosure to a male partner among 352 women diagnosed HIV-positive during pregnancy 
Variable 
Married and/or cohabiting Neither married nor cohabiting 
Unadjusted HR 
[95% CI]1 P-value 
Adjusted HR 
[95% CI]2 P-value 
Unadjusted HR 
[95% CI] P-value 
Adjusted HR 
[95% CI]2 P-value 
Maternal age 0.99 [0.95, 1.03] 0.590 1.00 [0.96, 1.05] 0.835 0.97 [0.93, 1.00] 0.048 0.95 [0.91, 0.99] 0.024 
Education 
   Primary/some secondary 
   Secondary/tertiary 
Reference 
0.93 [0.59, 1.47] 0.766 
Reference 
0.94 [0.58, 1.52] 0.802 
Reference 
1.52 [1.05, 2.19] 0.028 
Reference 
1.44 [0.98, 2.12] 0.062 
Employment 
   Unemployed 
   Employed 
Reference 
0.71 [0.46, 1.09] 0.118   
Reference 
1.03 [0.71, 1.48] 0.886   
Poverty categories 
   Least disadvantaged  
   Moderate disadvantage 
   Most disadvantaged 
Reference 
1.36 [0.77, 2.42] 
1.41 [0.83, 2.37] 
0.290 
0.200 
Reference 
1.54 [0.85, 2.80] 
1.46 [0.83, 2.56] 
0.156 
0.189 
Reference 
0.55 [0.36, 0.84] 
0.57 [0.36, 0.90] 
0.006 
0.016 
Reference 
0.57 [0.37, 0.88] 
0.60 [0.38, 0.97] 
0.011 
0.035 
Pregnancy intention 
   Unintended 
   Intended  
Reference 
1.64 [1.10, 2.45] 0.016 
Reference 
1.61 [1.07, 2.42] 0.022 
Reference 
1.01 [0.65, 1.57] 0.970 
Reference 
1.02 [0.65, 1.60] 0.946 
Previous pregnancies 
   First pregnancy 
   One or more previous pregnancies 
Reference 
0.52 [0.31, 0.86] 0.012 
Reference 
0.51 [0.29, 0.90] 0.020 
Reference 
0.89 [0.61, 1.30] 0.531 
Reference 
1.29 [0.81, 2.05] 0.276 
1 HR: hazard ratio; 95% CI: 95% confidence interval; 2 Adjusted models are adjusted for covariates shown 
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Figure 3.3.1 Impact of poverty on occurrence of disclosure to a male 
partner among women diagnosed HIV-positive during pregnancy and 
married and/or cohabiting 
 
Figure 3.3.2 Impact of poverty on occurrence of disclosure to a male 
partner among women diagnosed HIV-positive during pregnancy and 
neither married nor cohabiting 
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Compared to women who were neither married nor cohabiting, women who were married 
and/or cohabiting were less likely to disclose to a family/community member over time (HR: 
0.62; 95% CI: 0.47, 0.82). This association persisted after adjustment for age and poverty 
(aHR: 0.62; 95% CI: 0.47, 0.83); no other predictors of disclosure to family/community 
categories were observed. 
 
3.4 Discussion 
This research explored patterns and predictors of disclosure among HIV-positive pregnant 
women in South Africa. In the group of women diagnosed before the pregnancy, which 
included both women on ART and women initiating ART during the pregnancy, disclosure 
appeared to consist of two separate dimensions: disclosure to a male partner, and disclosure 
to family/community members, with disclosure to family/community categories tending to 
occur in a particular order. Among women diagnosed during the pregnancy and initiating 
ART, initial disclosure occurred rapidly but women appeared to favour selective rather than 
widespread disclosure. Across both groups of women, relationship status was observed to be 
a central determinant of disclosure, with women who were married and/or cohabiting more 
likely to disclose to a male partner but less likely to disclose to family/community categories. 
In addition, relationship status modified the predictors of disclosure to a male partner among 
women diagnosed during the pregnancy.  
 
3.4.1 Extensions to the literature 
This study design and measurements allowed for both cross-sectional and longitudinal 
insights into a process that inherently occurs over time. Most disclosure research to date has 
relied solely on cross-sectional data [1], and our longitudinal work notably extends the 
existing literature. Among women diagnosed before the pregnancy, we showed that time 
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since diagnosis was associated with disclosure to more family/community categories, but not 
with disclosure to a male partner. This suggests that women who disclose to their male 
partner do so quickly, and is consistent with results among newly-diagnosed women: in this 
group, initial disclosure to male partners and to family/community categories occurred 
rapidly, as has been observed in a general adult population in South Africa [20].  
 
A further advance introduced by this study is that most research to date operationalises 
disclosure as any versus no disclosure. Here, we demonstrated in the group of women 
diagnosed before the pregnancy that operationalising disclosure in this way blurs the 
predictors of disclosure. Using a novel analytic technique, we showed that disclosure is not a 
unidimensional process in this sample. Consistent with Dima et al.’s findings [15], we 
observed that disclosure to a spouse/partner occurs as an independent event. In contrast to 
their finding of additional disclosure dimensions consisting separately of (i) close family 
members and (ii) other relatives and the larger community among HIV-positive adults in 
Tanzania [15], we observed that all family and community categories assessed formed one 
disclosure subscale. In the present study, we assessed disclosure to individual relatives rather 
than a single category of ‘other relatives’, which may have contributed to the differences 
observed. The single observed scale of disclosure events to family and community categories 
in the present study may also be due to isiXhosa culture, in which distant or extended family 
members are often seen to be as close as immediate family members, and nuclear families are 
relatively uncommon [37]. The order in which women tended to disclose to 
family/community categories in this sample may reflect the availability of different 
individuals to provide support, or may be reflective of social distance, again noting that the 
closeness of family members according to familial relationship may differ in this setting 
compared to Western settings.  
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3.4.2 Importance of social and economic circumstances 
The finding that married and/or cohabiting relationship status is a central determinant of 
disclosure to a male partner is well documented [7, 20, 23, 26]. Here, we additionally 
observed that married and/or cohabiting relationship status is associated with less disclosure 
to family/community members. We hypothesise that women in married and/or cohabiting 
relationships may receive a greater degree of support from their male partner, and 
consequently may experience less need to disclose to other individuals, or that partners may 
restrict a woman’s choice to disclose to family/community members. This finding has 
important implications for counselling: disclosure is highly dependent on women’s social 
circumstances, and these circumstances need to be taken into account in counselling 
messages. Conversations about disclosure need to consider the specific life experiences of 
individual women, as well as individual women’s experiences of disclosure.  
 
Further, we observed relationship status to be a modifier of the predictors of male partner 
disclosure among newly-diagnosed women, again highlighting the importance of context. 
Compared to women who were married and/or cohabiting, women who were neither married 
nor cohabiting were significantly less likely to disclose to their male partner, and the 
intendedness of the pregnancy did not change the likelihood of disclosure in this group. We 
hypothesise that an unintended pregnancy, which is typically associated with negative 
outcomes, may have no impact on disclosure when a relationship is already relatively 
unstable. Previous research in South Africa has suggested that pregnant women’s disclosure 
to their male partner may be subordinated to concerns over maintaining the relationship and 
receiving continued support [17]. Here, we found that higher levels of poverty were 
associated with a lower likelihood of disclosure to a male partner among women who were 
neither married nor cohabiting, suggesting that women who are in less stable relationships 
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and may be economically dependent on their male partner face heightened vulnerability and 
may be less likely to disclose. Along these lines, qualitative research in Uganda has 
highlighted the fear of loss of material and financial support as a key barrier to disclosure to 
male partners among women who test HIV-positive during antenatal care [38]. Among 
previously-diagnosed women, the finding that women who had attained higher levels of 
education were more likely to disclose to their male partner may similarly be explained by 
higher levels of dependence on their partner among women with lower educational 
attainment.  
 
3.4.3 Disclosure during pregnancy and postpartum 
These data are among the first to explore prospective reports of disclosure among pregnant 
and postpartum women, a highly vulnerable population. Among women diagnosed during 
pregnancy, we observed rapid disclosure to both male partners and family/community 
members, with levels of disclosure broadly similar by 12 months postpartum to levels among 
women diagnosed before the pregnancy. Although diagnosed during routine HIV testing in 
the context of antenatal care and clearly influenced by economic and social vulnerabilities, 
levels of disclosure among newly-diagnosed women were high. However, a better 
understanding of the differences in disclosure between pregnant and non-pregnant 
populations is needed, and these findings should be generalised to non-pregnant populations 
with caution. Further, these findings should be contextualised as arising during a particular 
period in the HIV epidemic: with dramatically increasing numbers of pregnant women 
initiating ART, it is possible that HIV and ART have become more normalized over time in 
this setting, with implications for disclosure. Finally, further study of the impact of disclosure 
during pregnancy and postpartum is warranted, and longitudinal data are needed to provide 
high-quality evidence.  
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3.4.4 Strengths and limitations 
A strength of the present study is the inclusion of both cross-sectional and longitudinal data, 
given the inherent nature of disclosure and the dearth of similar data in the literature, as well 
as the use of a novel analytic technique to advance understandings of disclosure. In addition, 
the inclusion of a large sample of HIV-positive women attending primary care increases the 
generalisability of these findings to other communities of pregnant and postpartum women in 
the region. A limitation of this analysis is the self-reported nature of these data, given 
concerns around recall and social desirability bias, although this is common to all disclosure 
research. Further, we used the first report of disclosure to family/community members in 
longitudinal analyses, and did not assess the exact number of individuals to whom women 
have disclosed within categories, thus sum scores in the family/community subscale are only 
proxies for the total number of disclosure events. Finally, we did not explore the impact of 
disclosure on HIV or health-related outcomes or on mental health in these analyses. 
 
3.4.5 Conclusion 
Despite some limitations, these results provide important insights into disclosure in this 
population. Our findings suggest that disclosure occurs rapidly after diagnosis but that levels 
of disclosure to different individuals differ widely, and that disclosure to male partners and 
family/community members form separate dimensions of disclosure events. Although we 
ultimately used sum scores as indicators of disclosure to family/community categories, we 
argue that researchers should first investigate the dimensionality of disclosure events in their 
data before proceeding with analyses rather than assuming that a rank ordering of individuals 
is meaningful [32]. Further high-quality evidence of the impact of disclosure on HIV and 
health-related outcomes is needed in order to inform counselling messaging and intervention 
efforts, and we argue that basing these on the current evidence base has limitations. Finally, 
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we note here that women’s social and economic circumstances are central determinants of 
disclosure to both male partners and to family/community members, reflecting women’s 
vulnerability in this context. This suggests that counselling about disclosure needs to consider 
and be tailored to the broader social and economic circumstances of women’s lives, 
particularly in the case of pregnancy, and that counselling messaging must take into account 
this vulnerability. 
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Abstract 
Depression, HIV-related stigma and low levels of social support may be particularly 
prevalent and adversely affect health and treatment outcomes among HIV-infected pregnant 
women. We examined factors associated with social support and stigma among pregnant 
women initiating antiretroviral therapy in the Western Cape, South Africa; and explored 
associations with depressive symptoms (Edinburgh Postnatal Depression Scale; EPDS) in 
linear regression models. Among 623 participants, 11 and 19% had elevated EPDS scores 
using thresholds described in the original development of the scale (scores ≥13 and ≥10, 
respectively). Social support and stigma were highly interrelated and were associated with 
depressive symptoms. Stigma was observed to moderate the association between social 
support and depression scores; when levels of stigma were high, no association between 
social support and depression scores was observed. Elevated depression scores are prevalent 
in this setting, and interventions to reduce stigma and to address risk factors for depressive 
symptoms are needed. 
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4.1 Background  
Antenatal depression is prevalent in low- and middle-income countries (LMICs) [1, 2], with 
documented adverse effects on both maternal and child health [3-5]. Many of the risk factors 
for antenatal depression are prevalent in LMIC settings where HIV is most common, 
including poverty, unplanned pregnancy, and traumatic life events [6]. HIV-infected pregnant 
women may be a particularly vulnerable group, with high rates of depressive symptoms and 
psychiatric morbidity reported globally [7]. Other prevalent risk factors in this population 
may include high levels of HIV-related stigma and low levels of social support, both of which 
have been shown to have negative effects on factors such as coping [8] and quality of life [9]. 
Of note is that depression has been shown to be associated with non-adherence to 
antiretroviral therapy (ART) [10] and with attrition from care [11] in general HIV 
populations in Africa. Each of depression, HIV-related stigma and a lack of social support 
have additionally been identified as barriers to accessing prevention of mother-to-child 
transmission (PMTCT) services [12] and to the uptake of antiretrovirals for PMTCT [13]; 
and HIV-related stigma is a widely reported barrier to ART initiation, adherence and 
retention in care among HIV-infected pregnant and postpartum women [14].  
 
There is thus strong evidence that depression and psychosocial factors play an important role 
in the treatment of HIV disease, and these factors are increasingly understood as constituting 
barriers to HIV care in the context of both general HIV and PMTCT programmes. In 
addition, recent evidence suggests that psychosocial factors and depression are interrelated. 
Studies conducted in sub-Saharan Africa have identified associations between depressive 
symptoms and both low levels of social support [15] and high levels of HIV-related stigma 
[16, 17], and recent research conducted among HIV-infected men and women in South Africa 
has reported that both HIV-related stigma and social support are independently associated 
118 
 
with depression [18]. However, the interrelationships among these constructs are poorly 
understood, and most previous research has not explored the potentially moderating effect of 
these factors on the relationships between other factors and depression. Research that 
simultaneously explores the independent effects of multiple psychosocial factors is needed in 
order to generate a more nuanced understanding of the complex interrelationships among 
these constructs, thereby guiding the development of much-needed interventions. Given the 
well-documented adverse effects of antenatal depression on both maternal and child health 
and development, and the fact that there are few effective treatment resources for antenatal 
depression in LMICs [4, 6], this understanding is urgently needed. 
 
Although risk factors for depression have been well described in many populations, including 
among HIV-infected pregnant women, research into psychosocial factors in the population of 
women who initiate lifelong ART during pregnancy is needed, as little research has focussed 
on this population specifically. Although ART eligibility in pregnant women was previously 
based on CD4 cell count and clinical disease staging, the World Health Organization now 
recommends that all pregnant women initiate lifelong ART, a recommendation known as 
‘Option B+’ [19]. This recommendation substantially increases the number of ART-eligible 
pregnant women, and a better understanding of the psychosocial factors that have been shown 
to impact on HIV care in other populations is needed in this context. We thus examined the 
factors associated with social support and stigma among HIV-infected pregnant women who 
were initiating ART in the Western Cape, South Africa; and explored the interrelationships 
among these constructs and antenatal depressive symptoms. Our aim was (i) to explore 
variables associated with the perceived availability of social support and HIV-related stigma; 
and (ii) to explore the relationships between the perceived availability of social support and 
HIV-related stigma, and antenatal depressive symptoms in this sample. 
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4.2 Methods 
This cross-sectional analysis draws on a multi-phase implementation science study evaluating 
strategies for delivering HIV care and treatment services during pregnancy and the 
postpartum period (https://clinicaltrials.gov/ct2/show/NCT01933477). The study is located at 
a large primary care antenatal clinic in the former township of Gugulethu in Cape Town, 
South Africa. This stable, low socioeconomic community is characterized by high levels of 
HIV and poverty, with an antenatal HIV prevalence of 29% [20] and an unemployment rate 
of 40% [21]. 
 
4.2.1 Participants 
HIV-infected pregnant women were eligible to participate if they were 18 years or older and 
were eligible to initiate ART based on current local guidelines during the study period. 
Between March and June 2013, ART eligibility was determined based on CD4 cell count or 
clinical staging; after June 2013, all HIV-infected pregnant women were eligible to initiate 
lifelong ART regardless of CD4 cell count or clinical staging. All women provided written 
informed consent prior to participation. The study was approved by the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee and by the 
Institutional Review Board of the Columbia University Medical Center. 
 
4.2.2 Measures 
All measures were translated into isiXhosa, the predominant local language, and were back-
translated to ensure accuracy. These measures were piloted prior to the study in order to 
ensure that items were understood by and applicable to a sample of women recruited from the 
same population. Given concerns around literacy levels, all measures were administered by 
trained isiXhosa-speaking interviewers. Study visits were conducted in an interview space 
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separate from the antenatal clinic at study visits which were scheduled to coincide with 
participants’ routine antenatal visits. Demographic characteristics, including age, marital 
status, gravidity, and timing of HIV diagnosis, were assessed at participants’ first study visit. 
For our purposes, a composite poverty score was developed in order to categorise participants 
into tertiles based on their relative level of disadvantage. This composite score was calculated 
based on current employment status and a standardised composite asset index score based on 
housing type and household access to a flush toilet, piped water inside the home, electricity, 
and a refrigerator, telephone and television. Participants were categorised from least to most 
disadvantaged based on this score. 
 
Participants completed a battery of psychosocial measures at their 2nd antenatal visit, 
including a 12-item measure to assess the perceived availability of social support. The 
original measure was constructed as part of the development of methods to identify members 
of individuals’ social support networks, with a view to developing procedures suitable for use 
in community surveys [22]. This measure was then modified and administered to a sample of 
HIV-infected injection drug users in the United States, and included domains of both 
instrumental and emotional support [23]. The measure used in the present study was based on 
this modified scale. Each item was assessed on a scale ranging from 1 to 5, with higher scores 
indicating higher levels of social support. The perceived availability of instrumental 
[Cronbach’s alpha (α): 0.88] and emotional support (α: 0.92) were assessed separately by 
calculating the mean response across items pertaining to these constructs, as widely used 
elsewhere [24]. 
 
HIV-related stigma was assessed using items adapted from the Social Impact Scale [25]. The 
original scale was developed in order to explore the differential impacts of stigma among 
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individuals diagnosed with HIV and with cancer, respectively, and was constructed through a 
process of consultation with clinical experts and HIV-infected individuals as well as factor 
analysis to group the items into sub-scales [25]. For our purposes, five items from the original 
scale were included, and two items were added assessing HIV-related stigma in the context of 
motherhood specifically. Items were assessed on a scale ranging from 1 to 5, with higher 
scores indicating higher levels of stigma. Mean scores were calculated for items assessing 
two dimensions of stigma, namely social rejection (α: 0.75) and internalised shame (α: 0.80), 
as described in the original development of the scale [25]. 
 
The Edinburgh Postnatal Depression Scale (EPDS; α: 0.78) [26] was used to measure self-
reported symptoms common to depressive disorders. This 10-item measure of recent 
depressive symptoms was originally developed for use in screening for possible depressive 
disorders among postnatal women, but has been validated for use in pregnancy [27]. In 
addition, the scale has been validated for use as a screening tool in South Africa in a sample 
of postnatal women [28]. Each item of the scale was assessed on a frequency scale ranging 
from 0 to 3, and a total score was obtained by summing individual item responses, with 
higher scores indicating more severe depressive symptoms. Threshold values of both ≥10 and 
≥13 were explored as suggestive of elevated depressive symptoms, as recommended in the 
original development of the scale [26]. For our purposes, the EPDS was used as a measure of 
self-reported depressive symptoms, rather than as a diagnostic tool. 
 
4.2.3 Data analysis  
Data were analysed using Stata 12 (StataCorp Inc, College Station, Texas, USA). Variables 
significantly associated with higher levels of instrumental and emotional support and with 
higher levels of social rejection and internalised shame were identified using Wilcoxon rank 
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sum (Mann-Whitney) and Kruskal-Wallis tests. Multivariable linear regression models were 
built to examine variables independently associated with these constructs. Variables 
significantly associated with higher depression scores were similarly identified in unadjusted 
analyses. The associations between social support, stigma, potential confounders, and 
depressive symptoms were then explored in linear regression models. In order to explore the 
effects of social support and stigma on depressive symptoms at different levels of the other 
variable, tertiles of social support and stigma scores were created corresponding to low, 
medium and high levels. The potentially moderating effect of each variable was then 
examined graphically at each level of the other variable. Continuous depression scores were 
used in all analyses, although the proportion of participants with elevated scores on the EPDS 
was calculated using the suggested threshold values described above. 
 
4.3 Results 
4.3.1 Demographic and clinical characteristics and antenatal depressive symptoms 
A total of 623 women [median age: 28 years; inter-quartile range (IQR): 24-32], enrolled 
between March 2013 and April 2014, completed psychosocial measures and were included in 
the analysis. Detailed demographic and clinical characteristics are presented in Table 4.1. 
Most participants had not completed secondary education and were currently unemployed, 
and less than half were married or cohabiting. Most participants reported a previous 
pregnancy, and most of the current pregnancies were unintended. Just over half of the 
participants were diagnosed with HIV during the current pregnancy. At the time of their 2nd 
antenatal visit, 84% of participants had initiated ART, with a median duration of ART use of 
16 days (IQR: 14-22). A total of 121 women (19%) had elevated EPDS scores using a 
threshold of ≥10, and 67 women (11%) had EPDS scores ≥13. 
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Table 4.1 Demographic and clinical characteristics and antenatal depressive symptoms 
Variable n (%) 
Number of mothers 623 
Age in years – median [IQR] 28 [24, 32] 
Ethnicity – Black/African 620 (99.5) 
Educational attainment 
   Primary/some secondary  
   Completed secondary/any tertiary 
457 (73) 
166 (27) 
Current employment 
   Unemployed 
   Employed 
386 (62) 
237 (38) 
Poverty level (assets + employment) 
   Most disadvantaged 
   Moderately disadvantaged  
   Least disadvantaged 
226 (36) 
205 (33) 
192 (31) 
Relationship status 
   Single 
   Married/cohabiting 
367 (59) 
256 (41) 
Primigravida 111 (18) 
Median gestation in weeks at enrolment [IQR] 20 [16, 26] 
Pregnancy intention 
   Unintended 
   Intended 
439 (70) 
184 (30) 
Time of HIV diagnosis 
   Before this pregnancy 
   During this pregnancy 
280 (45) 
343 (55) 
HIV viral load at start of antenatal care 
   Median [IQR; log10 copies/mL] 
   <50 copies/mL 
   50-1,000 copies/mL 
   1,001-10,000 copies/mL 
   10,001-100,000 copies/mL 
   >100,000 copies/mL 
4.0 [3.4, 4.6] 
23 (4) 
76 (12) 
216 (35) 
238 (38) 
70 (11) 
CD4 cell count at start of antenatal care (n=607) 
   Median [IQR; cells/µL] 
   ≤200 cells/µL 
   201-350 cells/µL 
   351-500 cells/µL 
   >500 cells/µL 
343 [235, 507] 
110 (18) 
206 (34) 
135 (22) 
156 (26) 
Taking antiretroviral therapy (ART) at time of 2nd antenatal visit 
   Median [IQR] time on ART in days 
524 (84) 
16 [14, 22] 
Antenatal depressive symptoms (EPDS) 
   Median score [IQR] 
   Above threshold ≥10 
   Above threshold ≥13 
4 [1, 8] 
121 (19) 
67 (11) 
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4.3.2 Perceived availability of social support 
Table 4.2 reports scale scores and item-specific responses from the measures of social 
support and HIV-related stigma. Although participants reported high levels of social support 
generally, the reported availability of instrumental support was significantly lower than that 
of emotional support (mean scores: 4.2 and 4.4, respectively; paired t test: t=-6.40; p<0.001). 
Of note, women reported a low availability of monetary support (mean score for item 
assessing monetary assistance to pay rent: 3.4). Variables associated with the subscales of 
social support were examined separately. Higher levels of both social rejection [β: -0.1; 95% 
confidence interval (CI): -0.2, -0.01; p=0.031] and internalised shame (β: -0.3; 95% CI: -0.4, 
-0.2; p<0.001) were significantly associated with lower perceived availability of instrumental 
support, after adjusting for age. In addition, after adjustment for age, participants 
experiencing higher levels of poverty reported significantly lower availability of instrumental 
support (β for most versus least disadvantaged: -0.3; 95% CI: -0.4, -0.1; p<0.001), while 
women who were diagnosed with HIV during the current pregnancy reported higher 
availability of instrumental support (β: 0.2; 95% CI: 0.03, 0.3; p=0.015). Higher levels of 
both social rejection (β: -0.2; 95% CI: -0.3, -0.1; p=0.003) and internalised shame (β: -0.2; 
95% CI: -0.3, -0.1; p<0.001) were similarly significantly associated with lower perceived 
availability of emotional support, independent of age and poverty. 
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Table 4.2 Social support and HIV-related stigma – total scale scores, item-specific responses, and Cronbach’s alpha (α) coefficients 
Variable Mean score (SD) α 
Perceived availability of support1 4.2 (0.8) 0.92 
Instrumental support 4.2 (0.9) 0.88 
   Is there someone who would help take care of you if you had to stay in bed for several weeks? 4.4 (1.0) 0.87 
   Is there someone you could turn to if you needed to borrow R10, get a ride to the doctor, or some other small immediate help? 4.2 (1.2) 0.87 
   Is there someone you could turn to if you needed to borrow some money to help pay your rent for one month? 3.4 (1.6) 0.91 
   Is there someone who could take care of your children if you got sick? 4.4 (1.0) 0.87 
   Is there someone who would help you or be with you when you are having the baby? 4.2 (1.2) 0.87 
   Is there someone who would help you take care of the baby, after the new baby is born? 4.2 (1.2) 0.87 
   Is there someone who would help take care of you if you had problems with your pregnancy? 4.4 (1.0) 0.86 
   Is there someone who would help when you get far along in your pregnancy? 4.4 (1.0) 0.86 
Emotional support 4.4 (0.9) 0.92 
   Would someone be available to talk to you if you were upset, nervous or depressed? 4.4 (1.0) 0.90 
   Is there someone you could contact if you wanted to talk about an important personal problem you were having? 4.4 (1.0) 0.89 
   Would the people in your personal life give you information, suggestions, or guidance if you needed it? 4.3 (1.1) 0.90 
   Is there someone you could turn to if you needed advice to help make a decision? 4.4 (1.1) 0.90 
   
HIV-related stigma2 2.2 (0.8) 0.84 
Social rejection 1.7 (0.8) 0.75 
   I feel others are concerned they could “catch” my HIV through contact like a handshake or eating food I make. 1.8 (0.9)  
   I feel others avoid me because of my HIV. 1.7 (0.8)  
Internalised shame 2.4 (0.9) 0.80 
   I do not feel I can be open with others about my HIV. 2.6 (1.4) 0.70 
   I feel I need to keep my HIV a secret. 2.6 (1.4) 0.71 
   Due to my HIV, I have a sense of being unequal in my relationships with others. 1.8 (1.0) 0.79 
   I feel like I am a bad mother because I am HIV-positive. 1.9 (1.0) 0.76 
   I worry about who will take care of my baby if I become sick. 2.8 (1.5) 0.82 
1 Items scored between 1 and 5, with higher scores indicating greater perceived availability of support; 2 Items scored between 1 and 5, with higher scores indicating 
greater stigma 
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4.3.3 HIV-related stigma 
In terms of HIV-related stigma, reported levels of internalised shame were higher than those 
of social rejection (mean score: 2.4 and 1.7 respectively; paired t test: t=-20.77; p<0.001). 
Women reported the highest levels of stigma on items assessing secrecy around their HIV-
infection (mean scores: 2.6 for both items) and on the item assessing concern around who 
will take care of their baby if they become sick (mean score: 2.8). Correlates of both 
dimensions of HIV-related stigma were explored separately. After adjustment for age and 
poverty, increased availability of both instrumental (β: -0.2; 95% CI: -0.3, -0.1; p<0.001) and 
emotional support (β: -0.1; 95% CI: -0.2, -0.02; p=0.013) were significantly associated with 
lower reported levels of social rejection. Higher levels of both dimensions of social support 
were similarly associated with lower levels of internalised shame in unadjusted analyses. In 
adjusted analyses, the relationship between higher levels of the perceived availability of 
instrumental support remained significantly associated with lower levels of internalised 
shame (β: -0.3; 95% CI: -0.5, -0.2; p<0.001), independent of age, poverty, and the perceived 
availability of emotional support. 
 
4.3.4 Variables associated with antenatal depressive symptoms 
The relationships between demographic and psychosocial constructs, and antenatal 
depressive symptoms were explored. In unadjusted analyses, significantly higher depression 
scores were observed among mothers who reported single marital status, an unintended 
pregnancy, and higher levels of social rejection and internalised shame. In addition, increases 
in age and in the perceived availability of instrumental and emotional support were 
significantly associated with lower depression scores (Table 4.3). When adjusted for age, 
marital status and pregnancy intention (adjusted model A), the associations between both 
dimensions of HIV-related stigma and depression scores persisted, as did the associations 
between both dimensions of social support and depression scores. In a multivariable model 
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adjusted for all other covariates (adjusted model B), maternal age, the report of an unintended 
pregnancy, and higher levels of social rejection and internalised shame remained significantly 
associated with depression scores, with a stronger effect observed for internalised shame 
compared to that observed for social rejection. A one-unit increase in social rejection was 
associated with a 0.7 unit increase (95% CI: 0.1, 1.3; p=0.025) in depression score; compared 
to a 1.8 unit increase in depression score (95% CI: 1.2, 2.3; p<0.001) associated with a one-
unit increase in internalised shame, independent of marital status, pregnancy intention and the 
perceived availability of both instrumental and emotional support. 
 
When stratified by tertiles of social support, a clear dose-response relationship was observed 
between tertiles of HIV-related stigma and increasing depression scores across all levels of 
social support (Figure 4.1.1). In contrast, a clear dose-response relationship was observed 
between higher levels of perceived social support and lower depression scores only when 
HIV-related stigma was low (Figure 4.1.2). At higher levels of stigma, the relationship 
between social support and depressive symptoms did not persist, suggesting that HIV-related 
stigma moderates the relationship between social support and depressive symptoms. This 
same moderating effect was observed when the subscales of social support and HIV-related 
stigma were examined. Specifically, social rejection and internalised shame were observed to 
moderate the effects of the perceived availability of instrumental and emotional support on 
depression scores. 
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Table 4.3 Association between perceived availability of social support, HIV-related stigma, and antenatal depressive symptoms  
 
 
Variable 
Mean EPDS 
score (SD) 
Unadjusted 
regression 
coefficient [95% CI] 
 
 
P-value 
(A) Regression 
coefficient 
[95% CI]1 
 
 
P-value 
(B) Regression 
coefficient 
[95% CI]2 
 
 
P-value 
Age  -0.1 [-0.2, -0.002] 0.044   -0.1 [-0.1, -0.01] 0.035 
Educational attainment 
   Completed secondary/any tertiary  
   Primary/some secondary 
5.2 (5.5) 
5.3 (5.2) 
Reference 
0.1 [-0.8, 1.1] 0.757     
Current employment 
   Employed 
   Unemployed 
4.8 (5.1) 
5.6 (5.3) 
Reference 
0.8 [-0.03, 1.7] 0.060     
Poverty level  
   Least disadvantaged 
   Moderately disadvantaged 
   Most disadvantaged 
4.8 (5.0) 
5.2 (5.3) 
5.7 (5.4) 
Reference 
0.4 [-0.6, 1.5] 
0.9 [-0.1, 2.0] 
0.405 
0.066     
Relationship status 
   Married/cohabiting 
   Single 
4.7 (4.8) 
5.7 (5.5) 
Reference 
1.0 [0.1, 1.8] 0.023   
Reference 
0.6 [-0.2, 1.4] 0.136 
Pregnancy intention 
   Intended 
   Unintended 
4.3 (4.6) 
5.7 (5.5) 
Reference 
1.4 [0.5, 2.3] 0.002   
Reference 
1.0 [0.2, 1.9] 0.018 
Time of HIV diagnosis 
   Before this pregnancy 
   During this pregnancy 
5.3 (5.2) 
5.3 (5.3) 
Reference 
0.03 [-0.8, 0.9] 0.949     
Perceived availability of support – 
instrumental   -1.1 [-1.6, -0.6] <0.001 -1.1 [-1.6, -0.7] <0.001 -0.2 [-0.8, 0.4] 0.561 
Perceived availability of support – 
emotional   -0.8 [-1.3, -0.4] <0.001 -0.9 [-1.3, -0.4] <0.001 -0.04 [-0.6, 0.5] 0.900 
HIV-related stigma – social rejection  2.2 [1.7, 2.7] <0.001 2.2 [1.7, 2.7] <0.001 0.7 [0.1, 1.3] 0.025 
HIV-related stigma – internalised shame  2.2 [1.8, 2.6] <0.001 2.2 [1.8, 2.6] <0.001 1.8 [1.2, 2.3] <0.001 
1 Regression coefficient [95% CI] adjusted for age, marital status and pregnancy intention; 3 Regression coefficient [95% CI] adjusted for all other covariates 
in model 
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Figure 4.1.1 Mean (SD) depression score across tertiles of HIV-related stigma, 
stratified by tertiles of social support 
 
 
Figure 4.1.2 Mean (SD) depression score across tertiles of social support, 
stratified by tertiles of HIV-related stigma 
 
 
0
5
10
15
D
ep
re
ss
io
n 
sc
or
e
Low support Mid support High support
Low stigma Mid stigma High stigma
0
5
10
15
D
ep
re
ss
io
n 
sc
or
e
Low stigma Mid stigma High stigma
Low support Mid support High support
130 
 
4.4 Discussion 
This research explored variables associated with the perceived availability of social support 
and HIV-related stigma in a sample of HIV-infected pregnant women in South Africa, and 
examined the interrelationships among these factors and antenatal depressive symptoms. 
Social support and HIV-related stigma were observed to be highly interrelated in this sample, 
with strong and persistent associations observed between these constructs, and between 
poverty and decreased levels of instrumental support. A high proportion of participants 
scored above suggested thresholds on the EPDS, with one in five women scoring ≥10, and 
one in ten scoring ≥13. Social rejection and internalised shame were found to be strongly 
associated with depression scores in this sample, with stronger effects observed for 
internalised shame. Although associations were observed between social support and 
depression scores in unadjusted analyses, stigma was observed to moderate this association, 
with social support only associated with depression scores when low levels of stigma were 
reported. In contrast, an association between stigma and depression scores was observed at all 
levels of social support, suggesting that social support does not act as a buffer against the 
detrimental effects of stigma in this sample. 
 
Although slightly lower than other recently reported estimates among pregnant women in the 
region [29-31], the proportion of participants with elevated depression scores observed here 
is concerning, given documented adverse effects on maternal and child health and on HIV-
related treatment outcomes. Although much progress has been made in improving maternal 
physical health, this persistently high prevalence of depressive symptoms suggests that more 
focus is needed on mental health in this population. The variables associated with depression 
scores observed here are well-documented risk factors for depression during pregnancy, 
although here they are described among a population of women among whom a dearth of 
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data exist. As this population grows, understanding and targeting these barriers to optimal 
mental health will become increasingly important to ensure long-term maternal and child 
health. 
 
The finding that stigma moderates the relationship between social support and depression 
scores is notable, and contrasts with previous research conducted among HIV-infected men 
and women in the Western Cape, South Africa, where both social support and stigma were 
found to be independently associated with depression [18]. This novel finding highlights the 
urgent need for interventions to reduce stigma in this context, particularly given its adverse 
effects in HIV-infected pregnant women who may already be at increased risk of depression. 
While much progress has been made in the stigma-reduction field, many gaps and challenges 
remain in developing effective interventions and incorporating them into national HIV 
programmes [32], and the need for evidence-based interventions has been widely described. 
Our findings highlight the need for an increased focus on preventive interventions to reduce 
stigma, particularly given the well-documented adverse effects of antenatal depression and 
the relative lack of effective treatment resources in LMICs [4, 6]. Although many 
interventions to increase social support for HIV-infected individuals have been posited, our 
findings suggest that increasing social support may not be sufficient in contexts where stigma 
is prevalent, and community- and structural-level approaches to alleviate stigma, which are 
currently rare [33], are urgently needed. 
 
In this low socioeconomic context, higher levels of poverty were identified as a risk factor for 
both higher levels of HIV-related stigma and lower levels of social support, and the 
relationship between poverty and instrumental support persisted in adjusted analyses. For 
women in adverse socioeconomic circumstances, instrumental support may be lacking if 
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friends and family are similarly living in poverty. Alternatively, women may require 
additional support to request assistance from friends and family, especially in contexts where 
stigma is prevalent. Interestingly, the perceived availability of instrumental support had 
stronger effects on depression scores in unadjusted analyses than did the perceived 
availability of emotional support. This is consistent with the findings of previous research in 
KwaZulu-Natal, South Africa [24], and may indicate that structural interventions to alleviate 
poverty may have a greater impact than interventions to increase emotional social support in 
these contexts. These interventions may be particularly beneficial among pregnant women, 
where financial constraints may be compounded by factors such as transport costs when 
accessing antenatal care, as well as increased household expenses after delivery. 
 
A particular strength of this study is the inclusion of a large sample recruited from a primary 
care clinic, as the results observed are likely to be generalisable to other communities in the 
region. In addition, the inclusion of multiple psychological constructs in one analysis and the 
exploration of the complex interrelationships between them is a novel aspect of the present 
study, given the dearth of similar data in this context. A limitation of the present analysis, 
however, is that all of the data included were based on self-report and may be subject to 
social desirability bias. Although the EPDS has been validated for use as a screening tool in a 
South African population [28], the use of self-reported depressive symptoms may not reflect 
the true prevalence of antenatal depression in this population. Since this measure is not a 
diagnostic assessment, it may additionally be picking up on generalised psychiatric distress, 
including symptoms of anxiety, even though it was developed specifically as a measure of 
depression. As this study was a cross-sectional analysis of baseline data, we cannot make 
inferences regarding causality among these variables. Recent research has demonstrated a 
dynamic relationship between social support and stigma [33], a finding which warrants 
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further exploration using other longitudinal datasets. In addition, it is possible that depression 
causes increases in reported stigma as well as decreases in the perceived availability of social 
support, a hypothesis that we were unable to explore in these cross-sectional data and that has 
major implications for the development of interventions in this context. 
 
Despite these limitations, the findings from the present study are notable, and add to the 
literature in several important ways. Few data examining psychosocial risk factors among 
women initiating ART in the context of Option B+ exist, and the present study is notable in 
that it explores these constructs in this important population. As increasing numbers of 
women initiate ART during pregnancy, understanding the psychosocial risk factors faced by 
these women will become increasingly important, given their possible impact on adherence 
and retention in care. The present analysis is notable in that it begins to explore these 
constructs, and highlights the importance of simultaneously considering the associations 
among multiple psychosocial risk factors and depressive symptoms in order to generate a 
more nuanced understanding of the complex interrelationships among these constructs. In 
particular, this analysis highlights the moderating role of HIV-related stigma in the 
relationship between social support and depressive symptoms in this population. These 
results suggest that research to identify ways of reducing stigma and increased efforts to 
alleviate stigma, particularly at the community and structural level, are urgently needed. 
Finally, these findings suggest that further study of the impact of psychosocial factors on 
HIV-related outcomes, including ART adherence and retention in care, is needed in this 
population. 
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Abstract 
Depressive symptoms are common among pregnant women living with HIV, and an 
unintended pregnancy may heighten vulnerability. HIV-status disclosure is thought to 
improve psychological well-being, but few quantitative studies have explored the 
relationships among disclosure, pregnancy intention and depression. Using multivariable 
linear regression models, we examined the impact of disclosure on depressive symptoms 
(Edinburgh Postnatal Depression Scale; EPDS) during pregnancy and postpartum among 
women who tested HIV-positive during the pregnancy in South Africa; and explored the role 
of pregnancy intention in this relationship. Among 350 women (median age: 27 years; 70% 
reporting that their current pregnancy was unintended), neither disclosure to a male partner 
nor disclosure to ≥1 family/community member had a consistent effect on depressive 
symptoms. However, pregnancy intention modified the association between disclosure to a 
male partner and depression during pregnancy: disclosure was associated with higher 
depression scores among women who reported that their current pregnancy was unintended 
but was associated with lower depression scores among women who reported that their 
pregnancy was intended. During the early postpartum period, disclosure to ≥1 
family/community member was associated with higher depression scores. Counselling around 
disclosure in pregnancy should consider the heightened vulnerability that women face when 
experiencing an unintended pregnancy. 
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5.1 Introduction 
Pregnant women living with HIV experience high rates of depressive symptoms globally [1]. 
In general populations of pregnant women, antenatal depression has well-documented 
negative effects on maternal health [2] and child health and development [3]; in the context 
of HIV, depression may have additional negative effects on the uptake of prevention of 
mother-to-child HIV transmission services [4, 5]. In South Africa, women undergo routine 
HIV testing when entering antenatal care, and a new HIV diagnosis during pregnancy may 
lead to heightened vulnerability. In this context, women face a ‘triple burden’ of transitioning 
into pregnancy, accepting their HIV diagnosis, and accepting the urgent need to start lifelong 
antiretroviral therapy (ART) [6]. This vulnerability may be further heightened by an 
unintended pregnancy. Unintended pregnancies are common among women living with HIV 
in South Africa [7, 8] and may lead to considerable disruption in women’s lives [9] as well as 
antenatal depression [10-12].  
 
Self-disclosure of HIV status to others within an individual’s social network is widely 
encouraged in counselling services for people living with HIV, and is thought to have 
beneficial effects on psychological well-being. However, the evidence for this association is 
mixed [13]. Among adults living with HIV, cross-sectional studies have reported that 
disclosure is associated with either higher [14, 15] or lower [16, 17] levels of depression; 
other studies have found no association [18-20]. In longitudinal studies, depression appears to 
be associated with lower levels of disclosure to sexual partners among men who have sex 
with men [21] as well as among women living with HIV [22], with higher levels of 
depression associated with a longer time to first disclosure among women living with HIV in 
the United States [23]. It has been suggested that the association between disclosure and 
lower levels of depression is mediated by social support [17], with disclosure being beneficial 
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only to the extent to which it alleviates psychological stress or provides a mechanism to 
obtain social support [13]. In contrast, negative responses to disclosure may be associated 
with lower levels of perceived social support and higher levels of psychological distress [24]. 
 
Qualitative work among pregnant and postpartum women living with HIV in Uganda has 
documented an evolution of coming to terms with an HIV diagnosis and developing coping 
strategies, with disclosing and receiving support described as integral to this process [25]. 
However, few quantitative studies have examined the role of pregnancy intention in the 
relationship between disclosure and psychological well-being among pregnant women living 
with HIV. In the context of an unintended pregnancy and an HIV diagnosis during 
pregnancy, women must negotiate a dual disclosure: disclosure of the unintended pregnancy 
as well as disclosure of their HIV status [9]. Given the well-documented negative effects of 
antenatal depression among pregnant women living with HIV, and heightened vulnerability 
due to an unintended pregnancy, studies are needed to examine the relationships among 
disclosure, pregnancy intention and depression. We thus examined the impact of HIV-status 
disclosure on depression during pregnancy and postpartum among women who tested HIV-
positive during the pregnancy; and explored the role of the intendedness of the current 
pregnancy in this relationship.  
 
5.2 Materials and methods 
5.2.1 Study design 
These analyses use data from a multi-phase implementation science study, the MCH-ART 
study, which evaluated strategies for delivering HIV care and treatment services during 
pregnancy and the postpartum period in Cape Town, South Africa (ClinicalTrials.gov 
NCT01933477). The design and primary results of the study have been previously described 
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[26, 27]. Briefly, the study was conducted at one antenatal care clinic in the former township 
of Gugulethu, where an antenatal HIV prevalence of ~30% has been documented [28]. The 
study included a cross-sectional evaluation of all pregnant women living with HIV who were 
entering antenatal care; an observational cohort following women who initiated ART during 
the pregnancy through their first postpartum clinic visit; and an intervention study evaluating 
strategies for delivering HIV care and treatment services to breastfeeding women through 12 
months postpartum. ART eligibility was determined based on local guidelines in this setting: 
until June 2013, eligibility was determined based on CD4 cell count or clinical disease 
staging; from July 2013 onward, all pregnant women living with HIV were eligible to initiate 
lifelong ART under the World Health Organization’s Option B+ guidelines [29]. 
 
5.2.2 Participants 
For the broader MCH-ART study, women who initiated ART during the pregnancy were 
followed through delivery, and women opting to breastfeed were followed through 12 months 
postpartum. For the current analyses, we included women who had tested HIV-positive 
during the pregnancy and who were initiating ART in analyses through 12 months 
postpartum. Participants were enrolled into the study between March 2013 and April 2014. 
All women provided written informed consent prior to enrolment, and the study was 
approved by the University of Cape Town’s Faculty of Health Sciences Human Research 
Ethics Committee and by Columbia University Medical Center’s Institutional Review Board 
in New York. 
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5.2.3 Measures 
Participants attended study measurement visits that were separate from routine HIV or 
antenatal/postpartum care. Study measures were administered by trained interviewers in 
isiXhosa, the predominant local language. Measures were translated from English into 
isiXhosa and were back-translated prior to the study using standard procedures to ensure 
accuracy [30]. Basic sociodemographic characteristics were assessed at enrolment into the 
study, which coincided with participants’ entry into antenatal care, and included age, 
educational attainment and relationship status. The intendedness of the current pregnancy was 
assessed by asking women whether or not they were trying to have a baby when they found 
out that they were pregnant. A composite poverty score was calculated in order to categorise 
participants according to relative levels of disadvantage, and was based on current 
employment, housing type and access to household assets [31]. At entry into antenatal care, 
women underwent phlebotomy for CD4 enumeration via flow cytometry (Beckman Coulter), 
and gestation was assessed using ultrasound.  
 
HIV-status disclosure was self-reported at all study visits using a tool previously described 
[32]. Briefly, disclosure was assessed by asking women whether they had told their male 
partner about their HIV status, as well as whether they had told family/community members, 
including their mother, father, sister, brother, uncle, aunt, male cousin, female cousin, other 
male family member, other female family member, friend, or spiritual leader. This list of 
individuals was developed for the purposes of this study, and disclosure to each category was 
assessed using response options of ‘Yes’, ‘No’, or ‘Not Applicable’; we combined the 
response options ‘No’ and ‘Not applicable’ in analyses.  
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Self-reported depressive symptoms were assessed at three timepoints (participants’ 2nd 
antenatal visit and at 6 weeks and 12 months postpartum) using the 10-item Edinburgh 
Postnatal Depression Scale (EPDS) [33]. The EPDS was originally developed as a screening 
tool for possible depressive disorders among postpartum women, but has been validated for 
use in pregnancy [34] and in a sample of postpartum women in South Africa [35]. Based on 
the original development of the scale, each item was assessed on a frequency scale ranging 
from 0 to 3, and a total score was obtained by summing individual item responses, with 
higher scores indicating more severe depressive symptoms. We used a threshold value of ≥13 
as suggestive of elevated depressive symptoms in descriptive analyses, as recommended in 
the original development of the scale [33]. 
 
5.2.4 Data analysis 
Data were analysed using Stata 14 (StataCorp Inc, College Station, Texas, USA). Baseline 
sociodemographic characteristics were summarised and were compared across pregnancy 
intention using Wilcoxon rank sum (Mann-Whitney) tests for non-normally distributed 
continuous variables, and chi-square and Fisher’s exact tests for categorical variables. For 
each timepoint at which depressive symptoms were assessed, we used multivariable linear 
regression models to explore the associations between cumulative reports of disclosure up to 
that study visit and depressive symptoms, adjusting for potential confounding by 
sociodemographic characteristics and, at postpartum timepoints, design effect. We explored 
the impact of the intendedness of the current pregnancy in stratified models and using 
interaction terms. Throughout, we explored disclosure using two separate constructs: (i) 
disclosure to a male partner and (ii) disclosure to ≥1 family/community member, based on 
previous analyses suggesting that these disclosure events form separate dimensions in this 
sample [32]. Continuous depressive symptom scores were used in all analyses, although the 
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proportion of participants with elevated scores on the EPDS was calculated at each timepoint 
using the suggested threshold value described above. Finally, we repeated our analysis 
restricted to women who had completed assessments at all three timepoints in order to assess 
potential changes in results (n=208). This restriction did not change results, thus we present 
results from the total sample below.  
 
5.3 Results 
5.3.1 Participant characteristics, disclosure and depressive symptoms 
A total of 350 women (median age: 26.9 years) who had tested HIV-positive during the 
pregnancy, were eligible to initiate ART, and completed assessments at the 2nd antenatal 
study visit were included in analyses. A total of 258 women (74%) completed assessments at 
the 6 week postpartum study visit, and 213 (61%) completed assessments at 12 months 
postpartum. Sociodemographic and clinical characteristics are presented in Table 5.1, 
stratified by pregnancy intention. Most participants reported a previous pregnancy, and 
reported low levels of educational attainment and employment; 70% of women reported that 
their current pregnancy was unintended. Women who reported an unintended pregnancy were 
significantly less likely to be married and/or cohabiting with their partner (p<0.001) and had 
entered antenatal care at a significantly later gestation (p=0.006). 
  
145 
 
Table 5.1 Participant characteristics, HIV-status disclosure and depressive symptoms (Edinburgh Postnatal 
Depression Scale; EPDS), by intendedness of the current pregnancy 
 
 
Variable 
Total sample 
– n (%) 
Pregnancy intention 
 
P-value 
Unintended  
– n (%) 
Intended  
– n (%) 
Number of women 350 244 106  
     
Participant sociodemographic and clinical characteristics at entry into antenatal care 
Median [IQR] age in years 26.9 [23.5, 31.5] 26.7 [23.1, 31.4] 27.5 [24.3, 31.6] 0.268 
Educational attainment 
   Primary/some secondary  
   Completed secondary/any tertiary 
241 (69) 
109 (31) 
167 (68) 
77 (32) 
74 (70) 
32 (30) 0.799 
Currently employed 146 (42) 103 (42) 43 (41) 0.774 
Poverty level (assets + employment) 
   Most disadvantaged 
   Moderately disadvantaged  
   Least disadvantaged 
123 (35) 
116 (33) 
111 (32) 
88 (36) 
80 (33) 
76 (31) 
35 (33) 
36 (34) 
35 (33) 0.857 
Married and/or cohabiting 130 (37) 72 (30) 58 (55) <0.001 
First pregnancy 95 (27) 65 (27) 30 (28) 0.748 
Median [IQR] gestation in weeks  21 [16, 26] 22 [17, 28] 20 [15, 24] 0.006 
Median [IQR] CD4 cell count (n=337) 352 [247, 504] 352 [248, 513] 351 [247, 504] 0.602 
     
HIV-status disclosure 
Disclosed to male partner by 2nd antenatal 
visit  188 (54) 120 (49) 68 (64) 0.010 
Disclosed to male partner by 6 weeks 
postpartum (n=258) 150 (58) 101 (54) 49 (68) 0.045 
Disclosed to male partner by 12 months 
postpartum (n=213) 127 (60) 85 (57) 42 (67) 0.175 
Disclosed to ≥1 family/community member 
by 2nd antenatal visit 202 (58) 141 (58) 61 (58) 0.967 
Disclosed to ≥1 family/community member 
by 6 weeks postpartum (n=258) 169 (66) 119 (64) 50 (69) 0.407 
Disclosed to ≥1 family/community member 
by 12 months postpartum (n=213) 155 (73) 107 (71) 48 (76) 0.467 
     
Depressive symptoms 
EPDS score ≥13 at 2nd antenatal visit 41 (12) 30 (12) 11 (10) 0.608 
EPDS score ≥13 at 6 weeks postpartum 
(n=258) 11 (4) 8 (4) 3 (4) 0.962 
EPDS score ≥13 at 12 months postpartum 
(n=213) 10 (5) 7 (5) 3 (5) 0.976 
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Reported disclosure to a male partner increased from 54% of participants at the 2nd antenatal 
study visit to 60% at 12 months postpartum; disclosure to ≥1 family/community member 
increased from 58% to 73% (Table 5.1). Few sociodemographic or clinical characteristics 
were associated with disclosure, but women who were married and/or cohabiting were more 
likely to report having disclosed to their male partner and less likely to report having 
disclosed to ≥1 family/community member (both p<0.001) at the 2nd antenatal study visit. 
Women who reported that their current pregnancy was intended were also more likely to 
report having disclosed to a male partner by their 2nd antenatal study visit compared to 
women who reported that their current pregnancy was unintended (p=0.010). The proportion 
of women scoring above threshold for depressive symptoms decreased from 12% at the 2nd 
antenatal study visit, to 4% and 5% at the 6 week and 12 month postpartum study visits, 
respectively; levels of depressive symptoms were similar when restricted to women with 
complete data across all three timepoints. No differences in depressive symptoms were 
observed across the intendedness of the current pregnancy. 
 
5.3.2 Impact of disclosure on antenatal depressive symptoms 
Overall, neither disclosure to a male partner nor disclosure to ≥1 family/community member 
was associated with depressive symptoms at the 2nd antenatal study visit (Table 5.2), with 
results unchanged when stratified by relationship status and by age categories. However, 
pregnancy intention appeared to modify the association between disclosure to a male partner 
and depressive symptoms. Among women who reported that their current pregnancy was 
unintended, disclosure to a male partner was associated with higher depression scores in both 
unadjusted models [regression coefficient (β): 1.53; 95% confidence interval (CI): 0.17, 2.89] 
and after adjustment for sociodemographic characteristics (β: 1.59; 95% CI: 0.21, 2.97). 
Conversely, disclosure to a male partner was associated with lower depression scores among 
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women who reported that their current pregnancy was intended after adjusting for 
sociodemographic characteristics (β: -2.27; 95% CI: -4.48, -0.07). Effect modification by 
pregnancy intention was clearly observed in a graphical portrayal of mean depressive 
symptom scores: on average, depressive symptom scores were highest among women who 
reported that the current pregnancy was unplanned and disclosed to their male partner, and 
among women who reported that the current pregnancy was planned but did not disclose to 
their male partner (Figure 5.1.1). Stratification by pregnancy intention did not change the null 
association between disclosure to ≥1 family/community member and depressive symptoms.  
 
5.3.3 Impact of disclosure on postpartum depressive symptoms 
At 6 weeks postpartum, no associations were observed between disclosure to a male partner 
and depressive symptoms in unadjusted models or after adjustment for age, poverty, 
relationship status and design effect; these null results persisted when stratified by pregnancy 
intention. However, disclosure to ≥1 family/community member was associated with higher 
depression scores at this timepoint (β: 1.10; 95% CI: 0.07, 2.12 in unadjusted model; and β: 
0.94; 95% CI: -0.11, 1.99 after adjustment for age, poverty, relationship status and design 
effect); this association was stronger among women who reported that the current pregnancy 
was intended (β: 1.92; 95% CI: 0.10, 3.74 in unadjusted model; and β: 1.94; 95% CI: -0.03, 
3.91 after adjustment for age, poverty, relationship status and design effect; Figure 5.1.2). In 
the total sample at 12 months postpartum, neither disclosure to a male partner nor disclosure 
to ≥1 family/community member was associated with depressive symptoms in unadjusted 
models or after adjustment for age, poverty, relationship status and design effect; these null 
results persisted when stratified by pregnancy intention (Figure 5.1.3). 
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Table 5.2 Impact of disclosure on depressive symptoms at 2nd antenatal visit, overall and by intendedness of the current pregnancy (n=350) 
Variable Mean (SD) EPDS score1  Unadjusted β [95% CI]2 P-value Adjusted β [95% CI]3 P-value 
All women      
Disclosure to a male partner  
   Has not disclosed 
   Has disclosed 
5.1 (5.3) 
5.5 (5.3) 
Reference 
0.44 [-0.68, 1.56] 0.443 
Reference 
0.51 [-0.65, 1.67] 0.388 
Disclosure to family/community members 
   Disclosed to none 
   Disclosed to ≥1 person 
5.1 (5.3) 
5.5 (5.3) 
Reference 
0.45 [-0.68, 1.58] 0.435 
Reference 
0.45 [-0.70, 1.60] 0.443 
 
Women reporting unintended pregnancy at 1st antenatal visit 
Disclosure to a male partner  
   Has not disclosed 
   Has disclosed 
4.8 (5.2) 
6.3 (5.6) 
Reference 
1.53 [0.17, 2.89] 0.027 
Reference 
1.59 [0.21, 2.97] 0.025 
Disclosure to family/community members 
   Disclosed to none 
   Disclosed to ≥1 person 
5.3 (5.4) 
5.7 (5.5) 
Reference 
0.44 [-0.95, 1.83] 0.532 
Reference 
0.53 [-0.89, 1.94] 0.463 
 
Women reporting intended pregnancy at 1st antenatal visit 
Disclosure to a male partner  
   Has not disclosed 
   Has disclosed 
6.1 (5.5) 
4.2 (4.6) 
Reference 
-1.97 [-3.96, 0.03] 0.053 
Reference 
-2.27 [-4.48, -0.07] 0.043 
Disclosure to family/community members 
   Disclosed to none 
   Disclosed to ≥1 person 
4.6 (5.0) 
5.1 (5.1) 
Reference 
0.47 [-1.50, 2.43] 0.640 
Reference 
0.25 [-1.81, 2.30] 0.813 
1 SD: standard deviation; EPDS: Edinburgh Postnatal Depression Scale; 2 β: regression coefficient; 3 adjusted for age, poverty and relationship status 
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 Figure 5.1.1 Mean (SD) depressive symptom scores at the 2nd antenatal study visit by 
disclosure to a male partner and to ≥1 family/community member, stratified by 
intendedness of the current pregnancy 
 
Figure 5.1.2 Mean (SD) depressive symptom scores at the 6 week postpartum study visit 
by disclosure to a male partner and to ≥1 family/community member, stratified by 
intendedness of the current pregnancy 
 
Figure 5.1.3 Mean (SD) depressive symptom scores at the 12 month postpartum study 
visit by disclosure to a male partner and to ≥1 family/community member, stratified by 
intendedness of the current pregnancy 
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5.4 Discussion 
This research examined the impact of HIV-status disclosure on depression during pregnancy 
and postpartum among women who had tested HIV-positive during the pregnancy; and 
explored the role of the intendedness of the current pregnancy in this relationship. The 
proportion of women with elevated depressive symptoms was high antenatally, but decreased 
during the postpartum period. Both unintended pregnancy and disclosure were common, and 
neither disclosure to a male partner nor disclosure to ≥1 family/community member was 
consistently associated with antenatal or postpartum depressive symptoms in the overall 
sample. However, the association between disclosure to a male partner and antenatal 
depressive symptoms was modified by the intendedness of the current pregnancy: disclosure 
was associated with higher depression scores among women who reported that their current 
pregnancy was unintended, but was associated with lower depression scores among women 
who reported that their current pregnancy was intended. During the early postpartum period, 
disclosure to ≥1 family/community member was associated with higher depression scores, 
but this association did not persist at 12 months postpartum.  
 
Several key findings warrant further discussion. First, women receiving a new HIV diagnosis 
in the context of an unintended pregnancy face additional vulnerability. Fears about 
disclosing are common among women living with HIV, with women fearing abandonment 
and intimate partner violence after disclosing to a partner, and gossip and discrimination after 
disclosing to community members [36]. In the context of an unintended pregnancy as well as 
a new HIV diagnosis, the dual disclosure that women must negotiate has been described as a 
‘double disclosure bind’ [9]. We have previously shown that disclosure to a male partner 
during pregnancy and postpartum is more common among women reporting an intended 
pregnancy [32]. Here, we have demonstrated that the intendedness of the pregnancy 
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additionally modifies the impact of disclosure to a male partner on depressive symptoms. In 
the context of an unintended pregnancy, women who disclosed their HIV status to their male 
partner reported higher levels of depressive symptoms during pregnancy compared to women 
who did not disclose. This effect did not persist during the postpartum period, and we 
hypothesise that this may indicate an evolution of coming to terms both with a new HIV 
diagnosis and with an unintended pregnancy. Further research is needed to explore this 
possibility, and to explore the causality of our findings. 
 
Second, these results highlight the importance of considering women’s relationships with the 
person(s) to whom they disclose. Most existing research operationalises disclosure as any 
versus no disclosure [37], or focusses only on disclosure to a partner. Our findings suggest 
that disclosure to different individuals may have different effects on depression; previous 
research has similarly shown that the impact of disclosure depends on women’s relationships 
with the person(s) to whom they have disclosed [38]. Further, our findings may explain the 
mixed evidence in the existing literature, where studies have mostly used simplified measures 
of disclosure as well as cross-sectional analyses. Finally, we observed a reduction in the 
proportion of women with elevated depressive symptoms in the postpartum compared to 
antenatal period, similar to findings from Malawi [39]. We included only women who had 
been diagnosed HIV-positive during the pregnancy in analyses, and thus hypothesise that a 
new HIV diagnosis may have led to a high prevalence of antenatal depressive symptoms, but 
that this prevalence decreased during the postpartum period as women came to terms with 
their diagnosis. Further research is needed to explore the evolution of depressive symptoms 
over time in this population.  
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A strength of the present study is the inclusion of longitudinal data as well as the use of 
disclosure measures that allowed for the consideration of women’s relationships to the 
person(s) to whom they had disclosed. In addition, we included a large sample of women 
who tested HIV-positive at a primary care facility, and our findings are likely to be 
generalisable to other communities of pregnant and postpartum women in the region. A 
limitation of this analysis is the use of self-report to measure disclosure. In addition, 
depressive symptoms were assessed using self-report and not a diagnostic interview. Self-
reported disclosure may be subject to recall and social desirability bias, although this is 
common to all disclosure research, and the EPDS has been validated in pregnancy and in 
postpartum women in South Africa. A further limitation of this analysis is that we did not 
assess responses to disclosure, which may be critical determinants of subsequent 
psychological well-being or distress. Finally, we did not examine associations between 
disclosure and other psychosocial variables, and our findings should be extrapolated to other 
markers of psychological well-being with caution.  
 
Despite some limitations, these results are novel and the findings notable. There is limited 
quantitative evidence for a beneficial effect of disclosure on depression among pregnant 
women living with HIV, and a dearth of research examining the role of the intendedness of 
the pregnancy in this relationship. Our findings suggest that disclosure does not have a 
consistent effect on depression; rather, disclosure to a male partner appears to have an 
adverse effect during the antenatal period among women experiencing an unintended 
pregnancy, and a beneficial effect among women experiencing an intended pregnancy. 
Although these findings did not persist during the postpartum period, we argue that they have 
important implications for counselling services during pregnancy, given the well-documented 
adverse effects of antenatal depression. Without consideration of pregnancy intention, as well 
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as women’s relationships to the person(s) to whom they disclose, counselling services may be 
encouraging women to disclose when this may have negative repercussions. Our findings 
suggest that counselling messaging around HIV-status disclosure in pregnancy should 
consider the heightened vulnerability that women face when experiencing an unintended 
pregnancy, and that disclosure may not be beneficial for all women.  
 
 
  
154 
 
References 
1. Kapetanovic S, Dass-Brailsford P, Nora D, Talisman N. Mental health of HIV-
seropositive women during pregnancy and postpartum period: a comprehensive 
literature review. AIDS Behav. 2014;18(6):1152-1173. 
2. World Health Organization, United Nations Population Fund. Mental health aspects 
of women's reproductive health: a global review of the literature. Geneva: World 
Health Organization; 2009. 
3. Stein A, Pearson RM, Goodman SH, Rapa E, Rahman A, McCallum M, et al. Effects 
of perinatal mental disorders on the fetus and child. The Lancet. 
2014;384(9956):1800-1819. 
4. Gourlay A, Birdthistle I, Mburu G, Iorpenda K, Wringe A. Barriers and facilitating 
factors to the uptake of antiretroviral drugs for prevention of mother-to-child 
transmission of HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 
2013;16:18588. 
5. O'Hiarlaithe M, Grede N, de Pee S, Bloem M. Economic and social factors are some 
of the most common barriers preventing women from accessing maternal and 
newborn child health (MNCH) and prevention of mother-to-child transmission 
(PMTCT) services: a literature review. AIDS Behav. 2014;18:S516-S530. 
6. Stinson K, Myer L. Barriers to initiating antiretroviral therapy during pregnancy: a 
qualitative study of women attending services in Cape Town, South Africa. Afr J 
AIDS Res. 2012;11(1):65-73. 
7. Adeniyi OV, Ajayi AI, Moyaki MG, Goon DT, Avramovic G, Lambert J. High rate of 
unplanned pregnancy in the context of integrated family planning and HIV care 
services in South Africa. BMC Health Serv Res. 2018;18(1):140. 
8. Iyun V, Brittain K, Phillips TK, le Roux S, Mcintyre JA, Zerbe A, et al. Prevalence 
and determinants of unplanned pregnancy in HIV-positive and HIV-negative pregnant 
women in Cape Town, South Africa: a cross-sectional study. BMJ Open. 
2018;8:e019979. 
9. Crankshaw TL, Voce A, King RL, Giddy J, Sheon NM, Butler LM. Double disclosure 
bind: complexities of communicating an HIV diagnosis in the context of unintended 
pregnancy in Durban, South Africa. AIDS Behav. 2014;18:S53-S59. 
10. Brittain K, Myer L, Koen N, Koopowitz S, Donald KA, Barnett W, et al. Risk factors 
for antenatal depression and associations with infant birth outcomes: results from a 
South African birth cohort study. Paediatr Perinat Epidemiol. 2015;29(6):505-514. 
11. Howard LM, Molyneaux E, Dennis C-L, Rochat T, Stein A, Milgrom J. Non-
psychotic mental disorders in the perinatal period. The Lancet. 2014;384(9956):1775-
1788. 
12. Peltzer K, Rodriguez VJ, Jones D. Prevalence of prenatal depression and associated 
factors among HIV-positive women in primary care in Mpumalanga province, South 
Africa. SAHARA J. 2016;13(1):60-67. 
13. Chaudoir SR, Fisher JD, Simoni JM. Understanding HIV disclosure: a review and 
application of the Disclosure Processes Model. Soc Sci Med. 2011;72(10):1618-1629. 
14. Seth P, Kidder D, Pals S, Parent J, Mbatia R, Chesang K, et al. Psychosocial 
functioning and depressive symptoms among HIV-positive persons receiving care and 
treatment in Kenya, Namibia, and Tanzania. Prev Sci. 2014;15:318-328. 
155 
 
15. Shacham E, Small E, Onen N, Stamm K, Overton ET. Serostatus disclosure among 
adults with HIV in the era of HIV therapy. AIDS Patient Care STDS. 2012;26(1):29-
35. 
16. Farley J, Miller E, Zamani A, Tepper V, Morris C, Oyegunle M, et al. Screening for 
hazardous alcohol use and depressive symptomatology among HIV-infected patients 
in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc 
Physicians AIDS Care. 2010;9(4):218-226. 
17. Vyavaharkar M, Moneyham L, Corwin S, Tavakoli A, Saunders R, Annang L. HIV-
disclosure, social support, and depression among HIV-infected African American 
women living in the rural southeastern United States. AIDS Educ Prev. 
2011;23(1):78-90. 
18. Daskalopoulou M, Lampe FC, Sherr L, Phillips AN, Johnson MA, Gilson R, et al. 
Non-disclosure of HIV status and associations with psychological factors, ART non-
adherence, and viral load non-suppression among people living with HIV in the UK. 
AIDS Behav. 2017;21:184-195. 
19. Mello VA, Segurado AA, Malbergier A. Depression in women living with HIV: 
clinical and psychosocial correlates. Arch Womens Ment Health. 2010;13:193-199. 
20. Patel R, Ratner J, Gore-Felton C, Kadzirange G, Woelk G, Katzenstein D. HIV 
disclosure patterns, predictors, and psychosocial correlates among HIV positive 
women in Zimbabwe. AIDS Care. 2012;24(3):358-368. 
21. Abler L, Sikkema KJ, Watt MH, Hansen NB, Wilson PA, Kochman A. Depression 
and HIV serostatus disclosure to sexual partners among newly HIV-diagnosed men 
who have sex with men. AIDS Patient Care STDS. 2015;29(10):550-558. 
22. Ojikutu BO, Pathak S, Srithanaviboonchai K, Limbada M, Friedman R, Li S, et al. 
Community cultrual norms, stigma and disclosure to sexual partners among women 
living with HIV in Thailand, Brazil and Zambia (HPTN 063). PLoS ONE. 
2016;11(5):e0153600. 
23. Liu C, Goparaju L, Barnett A, Wang C, Poppen P, Young M, et al. Change in patterns 
of HIV status disclosure in the HAART era and association of HIV status disclosure 
with depression level among women. AIDS Care. 2017;29(9):1112-1118. 
24. Cama E, Brener L, Slavin S, de Wit J. The relationship between negative responses to 
HIV status disclosure and psychosocial outcomes among people living with HIV. J 
Health Psychol. 2017: Epub ahead of print. 
25. Medley AM, Kennedy CE, Lunyolo S, Sweat MD. Disclosure outcomes, coping 
strategies, and life changes among women living with HIV in Uganda. Qual Health 
Res. 2009;19(12):1744-1754. 
26. Myer L, Phillips TK, Zerbe A, Ronan A, Hsiao N-Y, Mellins CA, et al. Optimizing 
antiretroviral therapy (ART) for maternal and child health (MCH): rationale and 
design of the MCH-ART study. J Acquir Immune Defic Syndr. 2016;72:S189-S196. 
27. Myer L, Phillips TK, Zerbe A, Brittain K, Lesosky M, Hsiao N-Y, et al. Integration of 
postpartum healthcare services for HIV-infected women and their infants in South 
Africa: a randomised controlled trial. PLoS Med. 2018;15(3):e1002547. 
28. Myer L, Phillips TK, Hsiao N-Y, Zerbe A, Petro G, Bekker L-G, et al. Plasma 
viraemia in HIV-positive pregnant women entering antenatal care in South Africa. J 
Int AIDS Soc. 2015;18:20045. 
29. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs 
for treating and preventing HIV infection. Geneva: World Health Organization; 2016. 
156 
 
30. Preciago J, Henry H. Linguistic barriers in health education and services. In: Garcia 
JG, Zea MC, editors. Psychological interventions and research with Latino 
populations. Boston: Allyn and Bacon; 1997. 
31. Brittain K, Mellins CA, Phillips T, Zerbe A, Abrams EJ, Myer L, et al. Social support, 
stigma and antenatal depression among HIV-infected pregnant women in South 
Africa. AIDS Behav. 2017;21(1):274-282. 
32. Brittain K, Mellins CA, Remien RH, Phillips T, Zerbe A, Abrams EJ, et al. Patterns 
and predictors of HIV-status disclosure among pregnant women in South Africa: 
dimensions of disclosure and influence of social and economic circumstances. AIDS 
Behav. 2018;22:3933-3944. 
33. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of 
the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-
786. 
34. Murray D, Cox JL. Screening for depression during pregnancy with the Edinburgh 
Depression Scale (EDDS). J Reprod Infant Psychol. 1990;8(2):99-107. 
35. Lawrie TA, Hofmeyr GJ, de Jager M, Berk M. Validation of the Edinburgh Postnatal 
Depression Scale on a cohort of South African women. S Afr Med J. 
1998;88(10):1340-1344. 
36. Ashaba S, Kaida A, Coleman JN, Burns BF, Dunkley E, O'Neil K, et al. Psychosocial 
challenges facing women living with HIV during the perinatal period in rural Uganda. 
PLoS ONE. 2017;12(5):e0176256. 
37. Dima AL, Stutterheim SE, Lyimo R, de Bruin M. Advancing methodology in the 
study of HIV status disclosure: the importance of considering disclosure target and 
intent. Soc Sci Med. 2014;108:166-174. 
38. Miller ES, Yee LM, Dorman RM, McGregor DV, Sutton SH, Garcia PM, et al. Is 
maternal disclosure of HIV serostatus associated with a reduced risk of postpartum 
depression? Am J Obstet Gynecol. 2016;215:521.e1-5. 
39. Harrington BJ, Hosseinipour MC, Maliwichi M, Phulusa J, Jumbe A, Wallie S, et al. 
Prevalence and incidence of probable perinatal depression among women enrolled in 
Option B+ antenatal HIV care in Malawi. J Affect Disord. 2018;239:115-122. 
 
  
157 
 
Chapter 6: Long-term effects of unintended pregnancy on 
antiretroviral therapy outcomes among South African 
women living with HIV 
 
 
 
 
Final published version:  
Brittain K, Phillips TK, Zerbe A, Abrams EJ, Myer L. Long-term effects of unintended 
pregnancy on antiretroviral therapy outcomes among South African women living with HIV. 
AIDS. 2019;33:885-893. 
 
 
 
 
 
Author contributions 
KB conceptualised and conducted the analysis, led data interpretation and drafted the 
manuscript. TKP and AZ directed data collection and assisted with data interpretation. EJA 
and LM conceptualised the study from which these data arise, were responsible for funding, 
implementation and overall leadership, and assisted with data interpretation. All authors read 
and approved the final manuscript. 
  
158 
 
Abstract 
Objective: Unintended pregnancies are common among women living with HIV, but there 
are no data on their long-term impact on treatment outcomes. In a cohort of women initiating 
antiretroviral therapy (ART) during pregnancy, we examined the association between the 
intendedness of the current pregnancy, measured antenatally, and elevated viral load (VL) up 
to five years postpartum.  
Design: Prospective study with enrolment at entry into antenatal care and follow-up at study 
visits separate from routine care.  
Methods: At enrolment women completed the London Measure of Unplanned Pregnancy. 
Mixed effects models examined the impact of the intendedness of the pregnancy (planned 
versus each of unplanned or ambivalent, respectively) on VL ≥50 copies/mL across 
postpartum study visits.  
Results: Overall, 459 women were followed for a median of 43 months postpartum, 
contributing 2535 VL measures (median per woman: 6). Ambivalent and unplanned 
pregnancy were commonly reported (20% and 60%, respectively), and the proportion of 
women with elevated VL increased over time (16% at 6 weeks to 43% by 36-60 months 
postpartum). Compared to those reporting a planned pregnancy, elevated VL was more 
common among women reporting an unplanned pregnancy [odds ratio (OR): 2.87; 95% 
confidence interval (CI): 1.46, 5.64], with a trend towards a higher odds among those 
reporting ambivalence (OR: 2.19; 95% CI: 0.97, 4.82); associations persisted after adjustment 
for a wide range of demographic, clinical and psychosocial factors. 
Conclusions: These novel data suggest that unplanned pregnancy may be a prevalent and 
persistent predictor of poor ART outcomes among women initiating ART during pregnancy.  
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6.1 Introduction  
Unintended pregnancies are a major public health concern, with global estimates suggesting 
that 44% of pregnancies were unintended in 2010-2014 [1]. In low- and middle-income 
country (LMIC) settings, unintended pregnancies are similarly prevalent: population-level 
surveys have reported that 65% of pregnancies during 2012 in South Africa [2] and 46% 
during 2001-2013 in Uganda were unplanned [3]; 69% of women in Swaziland have reported 
that their most recent pregnancy was unintended [4]. Outside the context of HIV, there are 
data to suggest that unintended pregnancy may be associated with a range of maternal health 
concerns [5] such as depression [6-9] or risk behaviours such as delayed initiation of 
antenatal care [5, 10, 11].  
 
Despite the frequency of unintended pregnancy there have been few considerations of long-
term effects among women living with HIV. In South Africa, fewer than 30% of pregnant 
women living with HIV report that their pregnancy was planned [12, 13], and experiencing 
an unintended pregnancy after being diagnosed HIV-positive is common in the United States 
[14, 15]. An unintended pregnancy may further heighten the psychosocial and economic 
vulnerabilities of pregnant women living with HIV [16, 17], and case-control studies have 
suggested that unintended pregnancies may be associated with mother-to-child HIV 
transmission [18, 19]. However, there are few data on the long-term effects on maternal and 
child outcomes.  
 
In particular there has been no consideration of the long-term impact of an unintended 
pregnancy on maternal HIV treatment outcomes, including adherence to antiretroviral 
therapy (ART). The World Health Organization’s policy of universal use of lifelong ART in 
all pregnant and breastfeeding women (‘Option B+’) [20] has contributed to major increases 
160 
 
in ART uptake but adherence to ART remains a major concern, particularly during the 
postpartum period [21-23]. Existing understandings of the drivers of suboptimal adherence in 
women living with HIV remain limited, including the potential role of unintended pregnancy. 
We have previously shown that unintended pregnancy is associated with elevated viral load 
(VL) at entry into antenatal care among women already on ART [24]. Here, we explored 
factors associated with the intendedness of the pregnancy among women who initiated ART 
during pregnancy; and examined the association between unintended pregnancy and elevated 
VL through 36-60 months postpartum. 
 
6.2 Methods 
6.2.1 Study design 
We recruited consecutive pregnant women living with HIV from a public sector antenatal 
clinic in Gugulethu, Cape Town, for the MCH-ART study (ClinicalTrials.gov 
NCT01933477). The design and primary results of the study have been previously described 
[25, 26]. In this setting, women receive integrated PMTCT services and antenatal care within 
the broader maternal and child health care platform during pregnancy. Women who were 
eligible to initiate ART were followed through delivery. Women who then opted to 
breastfeed were randomised immediately postpartum to different models for delivering HIV 
care and were followed at repeated study measurement visits up to 18 months postpartum. 
Women were randomised to either the local standard of care (referral out of the maternal and 
child health clinic to general adult ART services at their 1st postpartum visit), or to the MCH-
ART intervention of integrated concurrent and co-located maternal ART and paediatric care 
in the maternal and child health clinic through the end of breastfeeding. The trial found that 
there were significant improvements in the combined endpoint of viral suppression and 
retention in HIV care through 12 months postpartum among women randomised to the 
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intervention arm; retention in the MCH-ART trial did not differ across allocation [26]. We 
later extended follow-up to include one additional study visit between 36-60 months 
postpartum.  
 
6.2.2 Participants 
This secondary analysis includes all women who initiated ART during pregnancy and were 
followed as part of the randomised trial. ART eligibility was determined based on local 
guidelines: eligibility was based on CD4 cell count or clinical disease staging until June 
2013, after which all pregnant women were ART-eligible under Option B+ guidelines. All 
women provided written informed consent prior to enrolment, and the study was approved by 
the University of Cape Town’s Faculty of Health Sciences Human Research Ethics 
Committee and by Columbia University Medical Center’s Institutional Review Board. 
 
6.2.3 Measures 
Enrolment into the study coincided with women’s entry into antenatal care. Women attended 
a maximum of two additional antenatal and one early postpartum study visit. Further study 
visits were then completed at 6 weeks and at 3, 6, 9, 12, 18 and 36-60 months postpartum, for 
a maximum of seven postpartum study visits. All study visits were completed separately from 
any routine HIV or antenatal/postpartum care.  
 
Study measures based on self-report were administered in isiXhosa, the predominant local 
language, by trained study interviewers. Measures were translated from English into isiXhosa 
and were back-translated using standard procedures to ensure accuracy [27]. A composite 
poverty score was calculated based on employment, housing type and access to household 
resources [28]. At all study visits, women underwent phlebotomy for batched HIV VL testing 
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(Abbott RealTime HIV-1) conducted by the South African National Health Laboratory 
Services (NHLS). Infants underwent phlebotomy for HIV PCR testing at the 12 month study 
visit, conducted by the NHLS using the Roche Cobas AmpliPrep/Cobas TaqMan 
(CAP/CTM) HIV-1 assay (Roche diagnostics, New Jersey, USA).  
 
The intendedness of the current pregnancy was assessed at enrolment, coinciding with entry 
into antenatal care, using the 6-item London Measure of Unplanned Pregnancy (LMUP) tool 
[29]. Each item was scored 0, 1 or 2, and all items were summed to create a score between 0 
and 12, with higher scores indicating higher levels of intendedness; total scores were then 
categorised into unplanned (a score of 0-3), ambivalent (4-9) or planned pregnancy (10-12) 
[29]. The performance of the LMUP has been evaluated in both high-income and LMIC 
settings [30]. We have previously shown that the LMUP is a valid and reliable tool 
(Cronbach’s alpha, 0.84) in pregnant women living with and without HIV in South Africa 
[13].  
 
The Edinburgh Postnatal Depression Scale (EPDS) [31] was administered at participants’ 
second antenatal study visit and at 6 weeks and 12, 18 and 36-60 months postpartum. A score 
of ≥13 was used to indicate elevated depressive symptoms [31]. The Alcohol Use Disorders 
Identification Test (AUDIT) [32] was administered at participants’ 2nd antenatal study visit to 
assess alcohol use in the year prior to pregnancy recognition, and at 6, 12 and 36-60 months 
postpartum to assess postpartum alcohol use. In analysis, the AUDIT-C (AUDIT-
Consumption) scoring system was used, where a score ≥3 on the first 3 items of the tool was 
used to indicate risky alcohol use [33, 34]. The World Health Organization Violence Against 
Women tool was used to assess intimate partner violence [35]. Violence in the year prior to 
pregnancy recognition was assessed at participants’ 2nd antenatal study visit, and postpartum 
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violence was assessed at 12 and 36-60 months postpartum. In analysis, we categorised 
women as reporting any versus no violence.  
 
6.2.4 Data analysis 
Data were analysed using Stata 14 (StataCorp Inc, College Station, Texas, USA). We used 
mixed effects models to examine the impact of the intendedness of the pregnancy on elevated 
VL ≥50 copies/mL during the postpartum period. Throughout, we compared women 
reporting each of ambivalence or an unplanned pregnancy, respectively, to those reporting a 
planned pregnancy; and also examined the effect of increasing intendedness of the pregnancy 
using continuous LMUP scores. We conducted sensitivity analyses using (i) VL ≥1000 
copies/mL and (ii) restricted to women who were virally suppressed <50 copies/mL at 
delivery. We explored the impact of missing data by assuming that women who did not 
attend a study visit had (i) suppressed and then (ii) elevated VL at that visit.  
 
Given the potential for confounding of the putative association between the intendedness of 
the pregnancy and elevated VL we present results from unadjusted models and then: (A) 
adjusting for demographic and clinical characteristics only; (B) additionally adjusting for 
psychosocial factors measured at participants’ second antenatal study visit; and (C) 
additionally adjusting for postpartum psychosocial factors. To account for differences in viral 
suppression at 12 months postpartum observed in the primary trial analysis, all adjusted 
models were adjusted for women’s allocation in the MCH-ART trial. For postpartum 
psychosocial factors, we categorised women as scoring above the threshold value at any 
study visit at which these were assessed versus scoring below threshold at all visits. Possible 
modifiers of the association between the intendedness of the pregnancy and postpartum VL 
were examined in stratified analyses. Using standard formulae and assuming that unplanned 
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pregnancy is an independent cause of elevated VL for these purposes, we calculated the 
population attributable fraction for the proportion of elevated VL that may be due to 
unplanned pregnancy. Finally, we used product-limit methods and the log-rank test to 
compare vertical transmission across LMUP categories. 
 
6.3 Results 
6.3.1 Intendedness of the pregnancy 
A total of 471 women who had initiated ART during pregnancy and opted to breastfeed were 
followed postpartum. Seven women had not completed the LMUP and were excluded from 
analysis; a further five women attended no follow-up visits and were excluded. The 
remaining 459 women were enrolled while pregnant between March 2013-April 2014. 
Approximately two-thirds of women reported that they were not using contraception during 
the month prior to the pregnancy; had not discussed getting pregnant with their partner; and 
did not want a baby or intend to get pregnant (Table 6.1). However, 49% of women who 
reported not wanting a baby and not intending to get pregnant, respectively, reported that the 
timing of the pregnancy was okay, although not quite right. Using the LMUP tool, 20%, 20% 
and 60% of women reported that their current pregnancy was intended, ambivalent and 
unplanned, respectively. 
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Table 6.1 Responses to London Measure of Unplanned Pregnancy tool 
Variable n (%) 
Number of women 459 
In the month that I became pregnant… 
   I/we were not using contraception 
   I/we were using contraception, but not on every occasion 
   I/we always used contraception, but knew that the method had failed at least once 
   I/we always used contraception 
315 (69) 
88 (19) 
49 (11) 
7 (2) 
In terms of becoming a mother, I feel that my pregnancy happened at the… 
   Right time 
   Okay, but not quite right time 
   Wrong time 
146 (32) 
173 (38) 
140 (31) 
Just before I became pregnant… 
   I intended to get pregnant 
   My intentions kept changing 
   I did not intend to get pregnant 
129 (28) 
34 (7) 
296 (64) 
Just before I became pregnant… 
   I wanted to have a baby 
   I had mixed feelings about having a baby 
   I did not want to have a baby 
131 (29) 
36 (8) 
292 (64) 
Before I became pregnant… 
   My partner and I had agreed that we would like me to be pregnant 
   My partner and I had discussed having children together, but hadn’t agreed for me to 
   get pregnant 
   We never discussed having children together 
124 (27) 
 
29 (6) 
306 (67) 
Actions to improve health in preparation for pregnancy1 
   None 
   One 
   Two or more 
 
414 (90) 
8 (9) 
4 (0.9) 
LMUP score – median [IQR] 
   Unplanned 
   Ambivalent 
   Planned 
3 [2, 9] 
275 (60) 
91 (20) 
93 (20) 
1 Actions could include taking folic acid; stopping/cutting down on smoking or drinking alcohol; eating 
more healthily; seeking medical advice; or other actions 
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6.3.2 Demographic, clinical and psychosocial characteristics 
Overall the median age was 27.9 years, and women had entered antenatal care at a median 
gestation of 21 weeks (Table 6.2). Women reported low levels of educational attainment and 
employment; 83% reported one or more previous pregnancies; and 58% were diagnosed 
HIV-positive during their current pregnancy. Psychosocial risk factors were commonly 
reported; 61% had disclosed their HIV status to their male partner by delivery; and 75% were 
virally suppressed <50 copies/mL at delivery. Women reporting lower levels of intendedness 
related to their current pregnancy were significantly less likely to be married and/or 
cohabiting; had entered antenatal care at a later gestation with consequent ART initiation at a 
later gestation; and were somewhat less likely to have VL <50 copies/mL at delivery. In 
addition, women reporting lower levels of intendedness were more likely to report risky 
alcohol use prior to pregnancy and during the postpartum period and were less likely to 
disclose to their male partner by delivery. No differences in intendedness of the pregnancy 
were observed by age; timing of HIV diagnosis (before versus during the pregnancy); or 
allocation in the MCH-ART trial. 
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Table 6.2 Demographic, clinical and psychosocial characteristics by the intendedness of the pregnancy 
Variable1 Total – n (%) Unplanned – n (%) Ambivalent – n (%) Planned – n (%) P-value 
Number of women 459 275 91 93  
Median [IQR] age 27.9 [24.5, 32.6] 27.7 [24.3, 32.3] 27.8 [24.9, 31.9] 28.9 [24.6, 33.0] 0.600 
Completed secondary/any tertiary education 113 (25) 66 (24) 19 (21) 28 (30) 0.324 
Employed 175 (38) 99 (36) 41 (45) 35 (38) 0.303 
Married and/or cohabiting 189 (41) 87 (32) 35 (38) 67 (72) <0.001 
Timing of HIV diagnosis 
   Before this pregnancy 
   During this pregnancy 
194 (42) 
265 (58) 
117 (43) 
158 (57) 
39 (43) 
52 (57) 
38 (41) 
55 (59) 0.953 
Previous antiretroviral use 125 (27) 80 (29) 26 (29) 19 (20) 0.255 
First pregnancy 78 (17) 48 (17) 11 (12) 19 (20) 0.305 
Median [IQR] gestation in weeks at entry into antenatal care 21 [16, 26] 22 [17, 28] 20 [14, 24] 19 [15, 24] 0.003 
Median [IQR] CD4 cell count at entry into antenatal care 353 [247, 527] 346 [245, 534] 400 [273, 565] 345 [223, 493] 0.135 
Median [IQR] HIV viral load at entry into antenatal care 
(log10 copies/mL) 4.0 [3.4, 4.6] 4.0 [3.4, 4.5] 4.0 [3.3, 4.6] 4.1 [3.3, 4.7] 0.847 
Gestation at ART initiation 
   <14 weeks 
   14-27 weeks 
   ≥28 weeks 
 
67 (15) 
279 (61) 
113 (25) 
 
32 (12) 
162 (59) 
81 (29) 
 
19 (21) 
52 (57) 
20 (22) 
 
16 (17) 
65 (70) 
12 (13) 
 
 
 
0.007 
Antenatal depression: EPDS score ≥13 45 (10) 31 (11) 8 (9) 6 (6) 0.374 
Risky alcohol use prior to pregnancy: AUDIT-C score ≥3 115 (25) 78 (28) 23 (26) 14 (15) 0.036 
Any intimate partner violence prior to pregnancy 102 (22) 66 (24) 18 (20) 18 (19) 0.512 
HIV viral load at delivery 
   <50 copies/mL 
   50-999 copies/mL 
   ≥1,000 copies/mL 
346 (75) 
83 (18) 
30 (7) 
198 (72) 
52 (19) 
25 (9) 
73 (80) 
15 (16) 
3 (3) 
75 (81) 
16 (17) 
2 (2) 0.090 
Disclosed to male partner by delivery 282 (61) 164 (60) 50 (55) 68 (73) 0.025 
Postpartum depression: EPDS score ≥13 at any timepoint 59 (13) 33 (12) 17 (19) 9 (10) 0.151 
Risky postpartum alcohol use: AUDIT-C score ≥3 at any 
timepoint (n=439) 99 (23) 66 (25) 22 (24) 11 (13) 0.047 
Any postpartum intimate partner violence reported at any 
timepoint (n=424) 49 (12) 31 (12) 8 (9) 10 (12) 0.764 
1 EPDS: Edinburgh Postnatal Depression Scale; AUDIT-C: Alcohol Use Disorders Identification Test – Consumption 
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6.3.3 Impact of the intendedness of the pregnancy on postpartum VL 
Women were followed for a median of 42.6 months postpartum, contributing a total of 2535 
VL measures [median per woman: 6; inter-quartile range (IQR): 5-7]. The proportion of 
women with VL ≥50 copies/mL increased from 16% at 6 weeks postpartum to 43% by 36-60 
months postpartum. Overall, 56% of women had VL ≥50 copies/mL at one or more 
postpartum study visit. At most visits, a dose-response association was observed: elevated VL 
was more common among women who had reported ambivalence compared to a planned 
pregnancy, with the prevalence of elevated VL even higher among those who had reported 
that their pregnancy was unplanned (Figure 6.1). VL ≥50 copies/mL at one or more 
postpartum study visit was observed among 60% of women who reported that their 
pregnancy was unplanned, 62% of women who reported ambivalence, and 41% of women 
who reported that their pregnancy was planned.  
 
 
 
 
  
Figure 6.1 Proportion with elevated viral load (VL) ≥50 copies/mL at 
postpartum timepoints1 by intendedness of the pregnancy 
 
 
1 Postpartum timepoints: 6 weeks and 3, 6, 9, 12, 18 and 36-60 months 
postpartum. 
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In unadjusted analyses, lower levels of intendedness were associated with elevated VL at 
postpartum study visits: compared to women who had reported a planned pregnancy, those 
who had reported an unintended pregnancy had almost 3 times the odds [odds ratio (OR): 
2.87; 95% confidence interval (CI): 1.46, 5.64] of elevated VL across study visits, with a 
trend towards a higher odds among those reporting ambivalence (OR: 2.19; 95% CI: 0.97, 
4.92; Table 6.3). Elevated VL was also more common among women who were younger; 
were neither married nor cohabiting; had entered antenatal care at a later gestation and with 
higher VL; and reported risky pre-conception alcohol use or intimate partner violence. In 
addition, the odds of elevated VL increased with increasing duration on ART, and elevated 
VL was more common among women reporting risky alcohol use or intimate partner 
violence during the postpartum period.    
 
The effect of the intendedness of the pregnancy on elevated VL persisted after adjustment for 
demographic and clinical characteristics (adjusted model A); additional adjustment for pre-
conception and antenatal psychosocial factors (B); and after additional adjustment for 
postpartum psychosocial factors (C), although the associations did not reach statistical 
significance in all instances. Results were similar when elevated VL was defined as ≥1000 
copies/mL and when models were restricted to women who were virally suppressed <50 
copies/mL at delivery (data not shown) but were slightly attenuated when assuming that 
missing VL measures were (i) suppressed or (ii) elevated (Table S6.1).   
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Table 6.3 Associations between the intendedness of the pregnancy and elevated viral load (VL) ≥50 copies/mL postpartum from unadjusted models, and after 
adjustment for (A) demographic and clinical factors; and additional adjustment for (B) baseline and (C) postpartum psychosocial factors 
 
Variable1 
Unadjusted models Adjusted model A Adjusted model B Adjusted model C 
OR [95% CI]2 P-value aOR [95% CI]3 P-value aOR [95% CI] P-value aOR [95% CI] P-value 
LMUP category (versus Planned) 
   Ambivalent 
   Unplanned 
2.19 [0.97, 4.92] 
2.87 [1.46, 5.64] 
0.058 
0.002 
1.72 [0.73, 4.05] 
1.97 [0.94, 4.14] 
0.217 
0.074 
1.72 [0.73, 4.05] 
1.86 [0.89, 3.89] 
0.214 
0.099 
1.56 [0.65, 3.76] 
1.73 [0.81, 3.69] 
0.322 
0.156 
Age 0.91 [0.87, 0.95] <0.001 0.91 [0.86, 0.95] <0.001 0.90 [0.86, 0.95] <0.001 0.90 [0.85, 0.94] <0.001 
Poverty score 1.02 [0.81, 1.27] 0.893 1.09 [0.86, 1.37] 0.484 1.08 [0.86, 1.37] 0.506 1.08 [0.84, 1.38] 0.534 
Married and/or cohabiting (versus 
neither married nor cohabiting) 0.45 [0.27, 0.75] 0.002 0.69 [0.39, 1.24] 0.216 0.71 [0.39, 1.28] 0.259 0.78 [0.42, 1.44] 0.431 
Diagnosed HIV-positive during this 
pregnancy (versus before)  0.82 [0.49, 1.36] 0.444       
Previous antiretroviral use (versus no 
previous use) 1.68 [0.96, 2.94] 0.068 2.03 [1.12, 3.66] 0.019 2.02 [1.12, 3.64] 0.020 2.00 [1.10, 3.64] 0.023 
Reports one or more previous 
pregnancies (versus first pregnancy) 0.70 [0.36, 1.37] 0.297       
Log10 VL at entry into antenatal care 1.63 [1.24, 2.14] <0.001 1.76 [1.32, 2.35] <0.001 1.78 [1.33, 2.38] <0.001 1.73 [1.28, 2.33] <0.001 
Gestation at ART initiation in weeks 1.06 [1.03, 1.10] <0.001 1.08 [1.04, 1.12] <0.001 1.07 [1.03, 1.11] <0.001 1.07 [1.03, 1.11] 0.001 
Months on ART at VL assessment 1.06 [1.05, 1.07] <0.001 1.06 [1.05, 1.07] <0.001 1.06 [1.05, 1.07] <0.001 1.06 [1.05, 1.07] <0.001 
Disclosed to male partner by delivery 
(versus did not disclose) 0.72 [0.43, 1.21] 0.216       
Antenatal depression 1.37 [0.58, 3.22] 0.472   0.64 [0.26, 1.57] 0.329 0.65 [0.26, 1.64] 0.363 
Risky pre-conception alcohol use 1.80 [1.02, 3.20] 0.043   1.06 [0.57, 1.98] 0.846 0.95 [0.49, 1.87] 0.891 
Any pre-conception intimate partner 
violence 2.93 [1.63, 5.28] <0.001   2.81 [1.49, 5.31] 0.001 2.17 [1.12, 4.20] 0.022 
Postpartum depression 1.98 [0.96, 4.11] 0.065     1.37 [0.61, 3.09] 0.446 
Risky postpartum alcohol use 2.66 [1.48, 4.81] 0.001     1.73 [0.86, 3.47] 0.124 
Any postpartum intimate partner 
violence  2.66 [1.23, 5.78] 0.013     2.23 [0.95, 5.19] 0.064 
1 LMUP: London Measure of Unplanned Pregnancy; depression defined as Edinburgh Postnatal Depression Scale (EPDS) score ≥13; risky alcohol use defined as 
Alcohol Use Disorders Identification Test – Consumption (AUDIT-C) score ≥3; 2 OR: odds ratio; 95% CI: 95% confidence interval; 3 aOR: adjusted odds ratio; All 
adjusted models adjusted for all covariates shown and for design effect 
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Results were consistent when examining the effect of continuous LMUP scores: increasing 
intendedness of the pregnancy was strongly associated with a reduced odds of elevated VL in 
unadjusted models, with associations only slightly attenuated in adjusted models (Table 
S6.2). In a graphical portrayal of LMUP scores and the predicted probability of experiencing 
elevated VL at each score (Figure 6.2), the magnitude of these results is clearly seen. First, 
the distribution of LMUP scores is bimodal, but the majority of women fall within the range 
of an unplanned pregnancy. Second, the highest probability of elevated VL falls in the large 
group of women who reported that their pregnancy was unintended, and the probability 
decreases in a dose-response relationship as the intendedness of the pregnancy increases. 
 
 
 
 
  
Figure 6.2 Distribution of London Measure of Unplanned Pregnancy 
(LMUP) scores1, with predicted probability of elevated viral load (VL) ≥50 
copies/mL at postpartum study visits 
 
1 Higher score represents increasing intendedness of the pregnancy 
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6.3.4 Impact of the intendedness of the pregnancy across subgroups 
The association between continuous LMUP scores and elevated VL ≥50 copies/mL was 
examined across subgroups (Figure S6.1). Overall, increasing intendedness of the pregnancy 
reduced the relative odds of elevated VL in most subgroups explored. However, this effect 
appeared to be stronger among women who had completed less than secondary education and 
who reported more disadvantage. In addition, the effect was stronger among women who 
were married and/or cohabiting and who reported no previous pregnancies. Although HIV-
status disclosure to a male partner was not associated with elevated VL in the total sample 
(Table 6.3), the effect of the intendedness of the pregnancy on elevated VL appeared to be 
stronger among women who had disclosed to their male partner by delivery.  
 
The role of HIV-status disclosure to a male partner was further explored in stratified analyses 
(Table S6.2). Among women who had not disclosed to their male partner by delivery, the 
intendedness of the pregnancy was not associated with elevated VL in either unadjusted or 
adjusted models. Among women who had disclosed by delivery, increasing intendedness of 
the pregnancy was strongly associated with a reduced odds of elevated VL (OR: 0.85; 95% 
CI: 0.77, 0.94); this effect persisted after adjustment for demographic and clinical factors but 
was slightly attenuated after additional adjustment for antenatal and postpartum psychosocial 
factors.  
 
6.3.5 Impact of the intendedness of the pregnancy on vertical transmission 
A total of 466 infants were born to the 459 women included in analysis, with 5 infants testing 
HIV-positive in the first 12 months postpartum. The rate of transmission at 12 months 
postpartum was 1.2% overall, with no difference across LMUP categories (p=0.999). 
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6.4 Discussion  
This analysis presents novel data suggesting that unplanned pregnancy may be a common and 
persistent risk factor for poor ART outcomes among women initiating ART during 
pregnancy. We observed a dose-response association between lower levels of pregnancy 
intendedness and elevated VL, with elevated VL most common among women who had 
reported an unplanned pregnancy. This association persisted up to 36-60 months postpartum 
and was observed independent of demographic, clinical and psychosocial factors. To our 
knowledge, these data are the first to demonstrate a long-term effect of the intendedness of a 
pregnancy on VL and, given the high frequency of unintended pregnancy in women living 
with HIV in many LMIC settings, make an important new contribution to our understanding 
of the drivers of suboptimal adherence during the postpartum period. 
 
Unintended pregnancies have been previously linked to other adverse health behaviours 
including delays in seeking antenatal care [5, 11, 36-38], substance use during pregnancy [36, 
37], and lower levels of breastfeeding [5]. Further, the psychosocial consequences may be 
profound: an unintended pregnancy can cause severe disruption to pre-existing life plans [36] 
and may lead to common mental disorders such as depression [5, 7, 36, 38] as well as 
relationship dissolution or intimate partner violence [5, 36]. Our finding that unintended 
pregnancy affects maternal ART outcomes extends these findings to the biomedical outcomes 
of HIV treatment, viral suppression. Preventing unintended pregnancies is a central aspect of 
the approach to reduce vertical HIV transmission [39]; further, our data suggest that an 
unintended pregnancy may compromise the benefits of ART for maternal health in the long 
term.  
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Although the impact of pregnancy intention persisted despite adjustment for multiple other 
risk factors, direct causality is difficult to determine [5]. Unintended pregnancies occur in 
complex social contexts and relationships [37], including being more common among 
unmarried women [36], and may heighten existing vulnerabilities [16, 17]. It is likely that an 
unintended pregnancy is one of several risk factors that contribute to women’s vulnerability, 
rather than a standalone factor that independently predicts elevated VL. Indeed, both the 
intendedness of a pregnancy and subsequent health outcomes may be determined by the same 
underlying factors [5]. In this study, several factors were associated with both lower levels of 
pregnancy intendedness and elevated VL: each was more common among women who were 
neither married nor cohabiting; had entered antenatal care at a later gestation; and who 
reported risky alcohol use. Here we posit that an unintended pregnancy heightens women’s 
vulnerability as part of a constellation of risk factors. In addition, we posit that unintended 
pregnancy may be a marker of some degree of ambivalence both towards pregnancy and 
towards one’s own health, with these ambivalences reflected in women’s adherence to ART. 
Additional socio-behavioural research is needed to explore these possibilities and the 
mechanisms of these novel findings.  
 
If unplanned pregnancy can be viewed as an independent cause of elevated VL for the 
purpose of considering population-level impacts, then it is possible to calculate a population 
attributable fraction for the proportion of elevated VL in the cohort that may be due to 
unplanned pregnancy. Using standard formulae, we estimate that approximately 16% of 
elevated VL may be associated with unplanned pregnancy in this population, compared to 
either ambivalence or a planned pregnancy; if we include ambivalence to pregnancy in the 
calculations this estimate increases to 28%. Given that unintended pregnancies are 
preventable (for example through effective contraception), an alternate way to conceptualise 
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this is to consider the possibility that only women with planned pregnancies entered the 
cohort. In this case, we estimate that 64% and 85% of all episodes of elevated VL would be 
prevented by the prevention of unplanned, or unplanned and ambivalent, pregnancies, 
respectively. Regardless of the formula used, these estimates speak to the population-level 
implications of the associations observed here.  
 
A strength of this study is the inclusion of longitudinal data with long-term follow-up and the 
use of a robust biological endpoint. However, our results must be interpreted in light of 
several limitations. Unintended pregnancy is a complex construct to measure [37, 38] but the 
LMUP has been validated widely, including in this population [13], and is robust enough to 
be recommended as an outcome measure for preconception care [40]. We assessed the 
intendedness of the pregnancy at entry into antenatal care, but the desirability of the 
pregnancy may change during the course of pregnancy [5]. Indeed, we did not assess how 
quickly women adapted in psychosocial terms to the pregnancy but note that 49% of women 
who reported not wanting a baby and not intending to get pregnant, respectively, reported that 
the timing of the pregnancy was okay. Preconception measurement of pregnancy intentions 
would be ideal but is challenging. As these data arise from a peri-urban setting in South 
Africa in the context of a research study, our findings should be generalised to other settings 
with caution, but we note that high levels of both unplanned pregnancy and elevated VL have 
been observed in many high-burden settings [3, 4, 21-23]. Finally, this research focussed on 
women initiating ART in pregnancy, and the question of how unplanned pregnancy effects 
outcomes among women who initiated ART before conception needs further investigation.   
 
Despite these limitations, these results clearly warrant further attention. Given the high levels 
of unintended pregnancy and elevated postpartum VL observed here and in other settings, we 
176 
 
argue that unintended pregnancy needs to be escalated as a global public health concern for 
maternal and child health in the context of HIV. Moreover, these data shed light on a unique 
factor in this patient population that may shape adherence behaviours and suggest that 
postpartum women who report antenatally that they did not intend their pregnancy may 
require specific attention from counselling and support interventions. Further, we argue that 
pregnancy planning needs to be incorporated into routine care for all women living with HIV: 
preventing unintended pregnancies may reduce the prevalence of elevated VL in this 
population and maximise maternal health. 
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Table S6.1 Associations between the intendedness of the pregnancy and elevated viral load (VL) ≥50 copies/mL postpartum from unadjusted models, and after 
adjustment for (A) demographic and clinical factors; and additional adjustment for (B) baseline and (C) postpartum psychosocial factors; stratified by assumptions 
regarding missing viral load measures 
 
Variable1 
Unadjusted models Adjusted model A Adjusted model B Adjusted model C 
OR [95% CI]2 P-value aOR [95% CI]3 P-value aOR [95% CI]4 P-value aOR [95% CI]5 P-value 
Total sample 
LMUP category (versus Planned) 
   Ambivalent 
   Unplanned 
2.19 [0.97, 4.92] 
2.87 [1.46, 5.64] 
0.058 
0.002 
1.72 [0.73, 4.05] 
1.97 [0.94, 4.14] 
0.217 
0.074 
1.72 [0.73, 4.05] 
1.86 [0.89, 3.89] 
0.214 
0.099 
1.56 [0.65, 3.76] 
1.73 [0.81, 3.69] 
0.322 
0.156 
         
Assuming that all missing viral load measures were <50 copies/mL 
LMUP category (versus Planned) 
   Ambivalent 
   Unplanned 
2.12 [1.06, 4.21] 
2.35 [1.32, 4.16] 
0.033 
0.003 
1.80 [0.92, 3.51] 
1.78 [1.00, 3.17] 
0.085 
0.049 
1.76 [0.91, 3.41] 
1.69 [0.96, 2.98] 
0.093 
0.070 
1.47 [0.75, 2.88] 
1.52 [0.85, 2.70] 
0.261 
0.157 
         
Assuming that all missing viral load measures were ≥50 copies/mL 
LMUP category (versus Planned) 
   Ambivalent 
   Unplanned 
 
1.17 [0.69, 1.98] 
1.58 [1.03, 2.44] 
 
0.570 
0.037 
 
1.17 [0.62, 2.22] 
1.50 [0.87, 2.58] 
 
0.628 
0.143 
 
1.19 [0.63, 2.26] 
1.47 [0.85, 2.53] 
 
0.593 
0.163 
 
1.30 [0.68, 2.46] 
1.49 [0.87, 2.58] 
 
0.430 
0.150 
1 LMUP: London Measure of Unplanned Pregnancy; 2 OR: odds ratio; 95% CI: 95% confidence interval; 3 aOR: adjusted odds ratio; model adjusted for age, 
socioeconomic status, marital status, previous antiretroviral use, log10 VL at entry into antenatal care, gestation at ART initiation, months on ART at VL assessment 
and design effect; 4 Model additionally adjusted for antenatal depression, risky pre-conception alcohol use and any pre-conception intimate partner violence; 5 
Model additionally adjusted for postpartum depression, risky postpartum alcohol use and any postpartum intimate partner violence. 
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Table S6.2 Associations between the intendedness of the pregnancy and elevated viral load (VL) ≥50 copies/mL postpartum from unadjusted models, and after 
adjustment for (A) demographic and clinical factors; and additional adjustment for (B) baseline and (C) postpartum psychosocial factors; stratified by HIV-status 
disclosure to a male partner by delivery 
 
Variable1 
Unadjusted models Adjusted model A Adjusted model B Adjusted model C 
OR [95% CI]2 P-value aOR [95% CI]3 P-value aOR [95% CI]4 P-value aOR [95% CI]5 P-value 
Total sample 
LMUP score 0.88 [0.82, 0.95] 0.001 0.92 [0.85, 1.00] 0.054 0.93 [0.85, 1.00] 0.058 0.93 [0.85, 1.01] 0.074 
         
Did not disclose to male partner by delivery 
LMUP score 0.95 [0.84, 1.06] 0.352 1.00 [0.88, 1.14] 0.990 1.00 [0.87, 1.14] 0.949 0.99 [0.86, 1.14] 0.909 
         
Disclosed to male partner by delivery 
LMUP score 0.85 [0.77, 0.94] 0.001 0.89 [0.80, 0.99] 0.026 0.91 [0.82, 1.00] 0.061 0.92 [0.83, 1.02] 0.098 
1 LMUP: London Measure of Unplanned Pregnancy, with higher scores indicating greater intendedness of the pregnancy; 2 OR: odds ratio; 95% CI: 95% 
confidence interval; 3 aOR: adjusted odds ratio; model adjusted for age, socioeconomic status, marital status, previous antiretroviral use, log10 VL at entry into 
antenatal care, gestation at ART initiation, months on ART at VL assessment and design effect; 4 Model additionally adjusted for antenatal depression, risky pre-
conception alcohol use and any pre-conception intimate partner violence; 5 Model additionally adjusted for postpartum depression, risky postpartum alcohol use and 
any postpartum intimate partner violence. 
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Figure S6.1 Odds ratios with 95% confidence intervals for the association between increasing 
intendedness of the pregnancy (one-unit increase in London Measure of Unplanned Pregnancy 
score) and elevated viral load ≥50 copies/mL postpartum, by subgroups 
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Abstract 
Background: HIV-status disclosure is widely encouraged by counselling services, in part 
because it is thought to improve antiretroviral therapy (ART) adherence and thus HIV viral 
suppression. However, few longitudinal studies have examined the impact of disclosure on 
HIV viral load (VL) during pregnancy and postpartum. 
Methods: We explored these associations among 1187 women living with HIV, enrolled 
between March 2013 and June 2014 in Cape Town, South Africa. 
Results: Among women who tested HIV-positive before pregnancy, we observed no 
association between disclosure and VL at entry into antenatal care among those already on 
ART, nor at delivery and 12 months postpartum among those initiating ART. Among women 
who tested HIV-positive during pregnancy and initiated ART subsequently, disclosure to a 
male partner was associated with a reduced risk of VL ≥50 copies/mL at delivery [adjusted 
risk ratio (aRR): 0.56; 95% confidence interval (CI): 0.31, 1.01]. After stratification by 
relationship status, this association was only observed among women who were married 
and/or cohabiting. In addition, disclosure to ≥1 family/community member was associated 
with a reduced risk of VL ≥50 copies/mL at 12 months postpartum (aRR: 0.69; 95% CI: 0.48, 
0.97) among newly-diagnosed women. 
Conclusion: These findings suggest that the impact of disclosure on VL is modified by three 
factors: (i) timing of HIV diagnosis (before versus during the pregnancy); (ii) relationship to 
the person(s) to whom women disclose; and (iii) in the case of disclosure to a male partner, 
relationship status. Counselling about disclosure may be most effective if tailored to 
individual women’s circumstances. 
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7.1 Introduction 
Rapidly expanding access to antiretroviral therapy (ART) and universal initiation of lifelong 
ART for all pregnant and postpartum women (the World Health Organization’s Option B+ 
approach) [1] have contributed to major increases in ART uptake and prevention of mother-
to-child HIV transmission (PMTCT) [2-4]. Pregnancy represents a time-limited opportunity 
for the timely initiation of ART and promotion of optimal adherence which is imperative for 
both maternal and child health outcomes, including preventing vertical transmission. 
However, pregnant and postpartum women’s adherence to ART remains a concern in many 
settings [5-7], thus limiting the benefits of ART for prevention and treatment.  
 
HIV-status disclosure is widely believed to have beneficial impacts on ART adherence, as 
well as on factors such as social support and psychological well-being, and limited disclosure 
is a commonly cited barrier to adherence in the context of PMTCT [8-10]. Thus, disclosure to 
at least one person is routinely encouraged in counselling services. However, fears around 
disclosing among women living with HIV are widespread and include abandonment in the 
case of disclosing to a partner, and anticipated stigma in the case of disclosing to community 
members [11]. Further, some individuals experience negative reactions after disclosing [12, 
13]. If disclosure does not improve adherence, then counselling services may be encouraging 
individuals to disclose when this may have negative repercussions. However, the current 
evidence for a beneficial effect of disclosure on adherence has limitations.  
 
A major concern is that most studies to date have relied on cross-sectional data, making 
causality difficult to determine. Further, disclosure is a process that occurs over time, and it is 
plausible that the impact of disclosure may change over time. Notably, cross-sectional studies 
in numerous countries in Africa have found significant associations between disclosure and 
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adherence in the context of PMTCT [14-18], but significant associations are less frequently 
reported in longitudinal studies [19]. Prospective investigations are needed to provide high-
quality evidence for the association between disclosure and adherence, as well as to explore 
the possibility of changes in this association over time.  
 
Further limitations in this literature include a widespread reliance on self-reported adherence 
and few considerations of subgroups or differences in the effects of disclosure to different 
individuals. Self-reported adherence measures suffer from recall and social desirability biases 
[20], but few studies in the context of PMTCT have explored the impact of disclosure on HIV 
viral suppression, a more robust biological measure, a strong indication of ART adherence, 
and the ultimate goal of ART use. The few existing studies suggest that non-disclosure to a 
male partner is associated with elevated viral load (VL) at delivery in South Africa [21] and 
in France [22], and at approximately 4 years postpartum in Uganda [23]. However, only one 
of these studies assessed the impact of disclosure to family members on VL. We have 
previously shown that disclosure to male partners and to family/community members form 
separate dimensions, and that factors such as relationship status modify the associations 
between women’s characteristics and disclosure [24]. It is plausible that disclosure to 
different individuals may have different effects on medication taking behaviours, and thus on 
VL, and that the effect of disclosure may differ in different subgroups, but these possibilities 
require further consideration.  
 
There is an urgent need to help women maintain optimal adherence in order to achieve and 
maintain viral suppression during pregnancy and while breastfeeding, thereby minimising the 
risk of vertical transmission, and HIV-status disclosure may confer these benefits. Further 
investigations that use longitudinal data to explore the association between disclosure and VL 
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are clearly needed, as well as investigations of how disclosure in different subgroups and to 
different individuals may change this association. To address this gap, we explored the 
impact of disclosure on HIV VL among two groups of women in Cape Town, South Africa: 
(i) women already on ART when entering antenatal care, using cross-sectional analyses; and 
(ii) women initiating ART during pregnancy and followed through pregnancy and 
postpartum, using longitudinal data. 
 
7.2 Methods 
7.2.1 Study design 
These analyses draw on a multi-phase implementation science study (the MCH-ART study) 
which evaluated strategies for delivering HIV care and treatment services during pregnancy 
and postpartum (ClinicalTrials.gov NCT01933477). The design, methods and primary 
findings of the study have been previously described [25, 26]. Briefly, the study was 
conducted at one antenatal care clinic in the former township of Gugulethu, and included a 
cross-sectional evaluation of pregnant women living with HIV who were entering antenatal 
care; an observational cohort study following women who initiated ART during the 
pregnancy through their first postpartum clinic visit (for up to three additional study visits); 
and an intervention study evaluating strategies for delivering HIV care to breastfeeding 
women during the postpartum period (for up to six additional study visits). ART eligibility 
was determined based on local guidelines: until June 2013, eligibility was determined based 
on CD4 cell count or clinical disease staging; from July 2013 onward, all pregnant women 
living with HIV were eligible to initiate lifelong ART under Option B+ guidelines. 
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7.2.2 Participants 
For the broader MCH-ART study, consecutive pregnant women living with HIV who were 
entering antenatal care were recruited and enrolled; for the current analyses, women who had 
tested HIV-positive before the pregnancy and were already on ART were included in cross-
sectional analyses. Women who initiated ART during the pregnancy were followed through 
delivery in the broader study, and women opting to breastfeed were followed through the 
postpartum period. For the current analyses, all women initiating ART and followed as part 
of the broader study were included in longitudinal analyses through 12 months (m) 
postpartum. All women provided written informed consent prior to enrolment, and the study 
was approved by the University of Cape Town Faculty of Health Sciences Human Research 
Ethics Committee and by Columbia University Medical Center Institutional Review Board. 
 
7.2.3 Measures 
Study measures were administered by trained interviewers at study visits separate from 
routine HIV or antenatal/postpartum care. All measures were translated into and administered 
in isiXhosa, the predominant local language. Measures were back-translated prior to the study 
using standard procedures to ensure accuracy [27]. Basic sociodemographic characteristics 
were assessed at enrolment, and included age, educational attainment, relationship status and 
pregnancy intention. A composite poverty score was calculated based on current 
employment, housing type and access to household assets, as previously described [28]. 
Gestation was assessed using ultrasound. Women self-reported their date of HIV diagnosis 
and their date of ART initiation. Disclosure to male partners and to family/community 
members was assessed at all study visits. Family/community members included: mother; 
father; sister; brother; uncle; aunt; male cousin; female cousin; other male family member; 
other female family member; friend; and spiritual leader. This list was developed for the 
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purposes of this study. At each study visit, disclosure to each category was assessed using 
response options of ‘Yes’, ‘No’, or ‘Not Applicable’. Given that our intention was to 
compare women who had disclosed to those who had not disclosed, either through deciding 
not to disclose to a specific individual or because this individual is not present in their life, we 
combined the response options ‘No’ and ‘Not applicable’ in analyses. CD4 enumeration via 
flow cytometry (Beckman Coulter) was conducted as part of routine care at entry into 
antenatal care, and women underwent phlebotomy at every study visit for batched HIV VL 
testing (Abbott RealTime HIV-1) conducted by the South African National Health 
Laboratory Services. 
 
7.2.4 Data analysis 
Data were analysed using Stata 12 (StataCorp Inc, College Station, Texas, USA). 
Throughout, we explored disclosure using two separate constructs: (i) disclosure to a male 
partner and (ii) disclosure to ≥1 family/community member, given that these disclosure 
events form separate dimensions in this sample [24]. We defined elevated VL as ≥50 
copies/mL, and ≥1000 copies/mL in sensitivity analyses. Results were similar in sensitivity 
analyses, thus we present only results using ≥50 copies/mL.  
 
Among women who had tested HIV-positive before the pregnancy and were established on 
ART, we examined the impact of disclosure on elevated VL at entry into antenatal care in 
logistic regression models. Among women initiating ART during pregnancy (including those 
who had tested HIV-positive before the pregnancy as well as those who tested HIV-positive 
during the pregnancy), we examined the impact of disclosure on elevated VL at (i) delivery 
and (ii) 12m postpartum in Poisson regression models with robust error variance [29]. For 
these analyses, we used cumulative reports of disclosure through delivery and 12m 
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postpartum, and stratified analyses by the timing of HIV diagnosis (before versus during the 
pregnancy). For the analyses of VL at delivery, we excluded women who had not been on 
ART >12 weeks (and >16 weeks in sensitivity analyses) in order to exclude women who may 
not have had a sufficient duration of ART use to reach viral suppression. Finally, we explored 
the impact of missing data by assuming that women who were lost from the study prior to 
delivery or 12m postpartum had (i) suppressed and (ii) elevated VL; these assumptions did 
not appreciably change the results.  
 
7.3 Results 
7.3.1 Sociodemographic and clinical characteristics 
We included 1187 pregnant women living with HIV, enrolled between March 2013 and June 
2014. A total of 559 women who had tested HIV-positive before the pregnancy and were 
already on ART at entry into antenatal care (median age: 31.5 years; median time since 
diagnosis: 4.6 years) were included in cross-sectional analyses. Data from 628 women who 
were initiating ART during the pregnancy (median age overall: 28.0 years; 56% diagnosed 
HIV-positive during the pregnancy) were included in longitudinal analyses. 
Sociodemographic and clinical characteristics are described in Table 7.1. Low levels of 
married and/or cohabiting relationship status and intended pregnancy were observed in both 
groups. Overall, women had entered antenatal care at a median gestation of 20 weeks (inter-
quartile range: 15-26 weeks). 
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Table 7.1 Demographic and clinical characteristics at entry into antenatal care, stratified by timing of HIV diagnosis and antiretroviral therapy (ART) use 
Variable Total sample – n (%) 
Tested HIV-positive before 
pregnancy and on ART at entry 
into antenatal care – n (%) 
Initiating ART during pregnancy – n (%) 
Tested HIV-positive 
before pregnancy 
Tested HIV-positive 
during pregnancy 
Number of women 1187 559 276 352 
Median [IQR] age 29.9 [26.0, 33.9] 31.5 [27.9, 34.9] 29.6 [26.3, 32.9] 26.9 [23.5, 31.6] 
Educational attainment 
   Less than secondary 
   Completed secondary/any tertiary 
896 (75) 
291 (25) 
434 (78) 
125 (22) 
219 (79) 
57 (21) 
243 (69) 
109 (31) 
Currently employed 450 (38) 212 (38) 92 (33) 146 (41) 
Poverty categories 
   Most disadvantaged 
   Moderate disadvantage 
   Least disadvantaged 
431 (36) 
399 (34) 
357 (30) 
204 (36) 
191 (34) 
164 (29) 
103 (37) 
92 (33) 
81 (29) 
124 (35) 
116 (33) 
112 (32) 
Married/cohabiting 530 (45) 271 (48) 129 (47) 130 (37) 
First pregnancy 169 (14) 58 (10) 16 (6) 95 (27) 
Pregnancy intentions 
   Unintended 
   Intended 
755 (64) 
432 (36) 
313 (56) 
246 (44) 
197 (71) 
79 (29) 
245 (70) 
107 (30) 
Median [IQR] gestation in weeks 20 [15, 26] 19 [14, 26] 20 [15, 25] 21 [16, 27] 
Median [IQR] CD4 cell count 371 [259, 530] 403 [286, 541] 338 [228, 528] 352 [247, 504] 
Median [IQR] years since diagnosis, among 
women who tested HIV-positive before pregnancy 4.3 [2.5, 7.0] 4.6 [2.9, 7.4] 3.8 [2.1, 6.1] - 
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7.3.2 Women established on ART: impact of disclosure on VL 
Among women already on ART at entry into antenatal care, 21% had an elevated VL ≥50 
copies/mL (Table 7.2). Disclosure to a male partner was reported by 85% of women, and 
95% had disclosed to ≥1 family/community member. Neither disclosure to a male partner nor 
disclosure to ≥1 family/community member was associated with VL in unadjusted or 
adjusted models. This lack of association persisted when models were stratified by 
relationship status and by age categories. 
 
7.3.3 Women initiating ART: impact of disclosure on VL at delivery  
Of 628 women who were initiating ART during the pregnancy, only 30 (5%) were lost from 
the study prior to delivery. Of the women retained at study measurement visits, 147 (25%) 
had not been on ART >12 weeks at delivery and were excluded from analysis, as they may 
not have had a sufficient duration of ART use to reach viral suppression. No differences in 
disclosure to a male partner were observed between those excluded versus those included 
(64% versus 65%; p=0.899; Table S7.1), but women who were excluded from analysis were 
less likely to have disclosed to ≥1 family/community member by delivery (64% versus 75%; 
p=0.013; Table S7.1). 
 
Among women who tested HIV-positive before the pregnancy and who were included in 
analysis (20% with elevated VL ≥50 copies/mL at delivery), neither disclosure to a male 
partner nor disclosure to ≥1 family/community member was associated with elevated VL at 
delivery (Table 7.3). By delivery, 73% of this group had disclosed to their male partner, and 
84% had disclosed to ≥1 family/community member. Among the women who tested HIV-
positive during the pregnancy and who were included in analyses (21% with elevated VL ≥50 
copies/mL at delivery), disclosure to ≥1 family/community member by delivery was not 
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associated with VL, but disclosure to a male partner was associated with a reduced risk of 
elevated VL at delivery. By delivery, 57% and 66% of this group had disclosed to a male 
partner and to ≥1 family/community member, respectively. The impact of disclosure to a 
male partner on VL persisted after adjustment [adjusted risk ratio (aRR): 0.56; 95% CI: 0.31, 
1.01], and results were similar when restricted to women who had been on ART >16 weeks at 
delivery (aRR: 0.58; 95% CI: 0.26, 1.29). This impact appeared to be modified by 
relationship status: among women who were married and/or cohabiting, disclosure to a male 
partner was strongly associated with a reduced risk of elevated VL at delivery in adjusted 
models (aRR: 0.20; 95% CI: 0.08, 0.55), but no effect was observed among women who were 
neither married nor cohabiting (aRR: 0.80; 95% CI: 0.43, 1.49; p-value for 
interaction=0.006). 
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Table 7.2 Impact of disclosure on elevated viral load (VL, in copies/mL) at entry into antenatal care among women already on antiretroviral therapy (ART)  
Variable Total sample – n (%) VL <50 – n (%) VL ≥50 – n (%) OR [95% CI]1 P-value aOR [95% CI]2 P-value 
Number of women  559 439 120     
Male partner disclosure 
   Has not disclosed 
   Has disclosed 
83 (15) 
476 (85) 
63 (14) 
376 (86) 
20 (17) 
100 (83) 
Reference 
0.84 [0.48, 1.45] 0.528 
Reference 
0.84 [0.48, 1.49] 0.558 
Family/community disclosure 
   Disclosed to none 
   Disclosed to ≥1 person 
30 (5) 
529 (95) 
24 (5) 
415 (95) 
6 (5) 
114 (95) 
Reference 
1.10 [0.44, 2.75] 0.841 
Reference 
0.90 [0.35, 2.33] 0.827 
1 OR: odds ratio; 2 aOR: adjusted odds ratio; adjusted for age, poverty, relationship status, time since HIV diagnosis. 
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Table 7.3 Impact of disclosure on elevated viral load (VL, in copies/mL) at delivery among women initiating antiretroviral therapy (ART) during the pregnancy 
Variable Total sample – n (%) VL <50 – n (%) VL ≥50 – n (%) RR [95% CI]1 P-value aRR [95% CI]2 P-value 
Tested HIV-positive before pregnancy 
Number of women 215 172 43     
Male partner  
   Has not disclosed 
   Has disclosed 
59 (27) 
156 (73) 
50 (29) 
122 (71) 
9 (21) 
34 (79) 
Reference 
1.43 [0.73, 2.80] 0.298 
Reference 
1.46 [0.75, 2.82] 0.261 
Family/community 
   Disclosed to none 
   Disclosed to ≥1 person 
35 (16) 
180 (84) 
28 (16) 
144 (84) 
7 (16) 
36 (84) 
Reference 
1.00 [0.48, 2.07] 1.000 
Reference 
1.01 [0.48, 2.14] 0.973 
 
Tested HIV-positive during pregnancy 
Number of women 236 187 49     
Male partner  
   Has not disclosed 
   Has disclosed 
101 (43) 
135 (57) 
73 (39) 
114 (61) 
28 (57) 
21 (43) 
Reference 
0.56 [0.34, 0.93] 0.025 
Reference 
0.56 [0.31, 1.01] 0.055 
Family/community 
   Disclosed to none 
   Disclosed to ≥1 person 
80 (34) 
156 (66) 
64 (34) 
123 (66) 
16 (33) 
33 (67) 
Reference 
1.06 [0.62, 1.80] 0.837 
Reference 
0.82 [0.46, 1.47] 0.510 
1 RR: risk ratio; 2 aRR: adjusted risk ratio; adjusted for age, poverty, relationship status, pregnancy intention, log10 VL at entry into antenatal care, duration of ART use at delivery. 
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7.3.4 Women initiating ART: impact of disclosure on VL at 12m postpartum 
Of 471 women who were breastfeeding and enrolled into postpartum follow-up, 60 women 
were excluded from analysis: 59 women (13%) were lost from the study, and one woman did 
not have a VL measure at 12m postpartum. Compared to women retained and with VL 
measures available, those excluded were significantly younger, had entered antenatal care at a 
later gestation, and were more likely to report that this was their first pregnancy and to have 
been diagnosed during the pregnancy; no differences in disclosure by the time of delivery 
were observed between those excluded from analysis and those retained (Table S7.2).  
 
Among women diagnosed before the pregnancy and included in analyses (36% with elevated 
VL ≥50 copies/mL at 12m postpartum), no association between elevated VL and either 
disclosure to a male partner or disclosure to ≥1 family/community member was observed 
(Table 7.4). By 12m postpartum, disclosure to a male partner was reported by 74% of these 
women, and disclosure to ≥1 family/community member by 86%. Among women diagnosed 
during the pregnancy and included in analyses (32% with elevated VL ≥50 copies/mL at 12m 
postpartum), no association was observed between disclosure to a male partner and elevated 
VL, but disclosure to ≥1 family/community member appeared to reduce the risk of elevated 
VL at 12m postpartum in adjusted models (aRR: 0.69; 95% CI: 0.48, 0.97). By 12m 
postpartum, 60% of women in this group had disclosed to their male partner, and 73% had 
disclosed to ≥1 family/community member. 
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Table 7.4 Impact of disclosure on elevated viral load (VL, in copies/mL) at 12 months postpartum among women initiating antiretroviral therapy (ART) during the pregnancy 
Variable Total sample – n (%) VL <50 – n (%) VL ≥50 – n (%) RR [95% CI]1 P-value aRR [95% CI]2 P-value 
Tested HIV-positive before pregnancy 
Number of women 183 118 65     
Male partner  
   Has not disclosed 
   Has disclosed 
47 (26) 
136 (74) 
28 (24) 
90 (76) 
19 (29) 
46 (71) 
Reference 
0.84 [0.55, 1.27] 0.406 
Reference 
0.78 [0.52, 1.17] 0.233 
Family/community 
   Disclosed to none 
   Disclosed to ≥1 person 
25 (14) 
158 (86) 
17 (14) 
101 (86) 
8 (12) 
57 (88) 
Reference 
1.13 [0.61, 2.07] 0.700 
Reference 
1.18 [0.67, 2.09] 0.563 
 
Tested HIV-positive during pregnancy 
Number of women 228 154 74     
Male partner  
   Has not disclosed 
   Has disclosed 
91 (40) 
137 (60) 
61 (40) 
93 (60) 
30 (41) 
44 (59) 
Reference 
0.97 [0.67, 1.43] 0.893 
Reference 
0.79 [0.56, 1.14] 0.209 
Family/community 
   Disclosed to none 
   Disclosed to ≥1 person 
62 (27) 
166 (73) 
38 (25) 
116 (75) 
24 (32) 
50 (68) 
Reference 
0.78 [0.53, 1.15] 0.208 
Reference 
0.69 [0.48, 0.97] 0.035 
1 RR: risk ratio; 2 aRR: adjusted risk ratio; adjusted for age, poverty, relationship status, pregnancy intention, design effect, VL at delivery, duration of ART use at 12 months 
postpartum. 
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7.4 Discussion 
In this sample of pregnant and postpartum women in South Africa, high levels of HIV-status 
disclosure were reported, however the association between disclosure and VL was complex. 
Disclosure did not appear to have an impact on VL at any time point assessed among women 
who tested HIV-positive before the pregnancy, including women who were established on 
ART and those initiating ART during the pregnancy. Yet among women who were newly 
diagnosed HIV-positive during the pregnancy and initiated ART, disclosure to a male partner 
appeared to be associated with a reduced risk of elevated VL at delivery, although this 
association was only observed among women who were married and/or cohabiting. In this 
group of women who tested HIV-positive during the pregnancy, we also observed an 
association between disclosure to ≥1 family/community member and a reduced risk of 
elevated VL at 12m postpartum. Altogether, though we observed high levels of both 
disclosure and viraemia in this cohort, non-disclosure does not appear to be a primary driver 
of elevated VL.  
 
The few existing studies of the impact of disclosure to a male partner on viral suppression in 
the context of PMTCT suggest a beneficial effect [21-23]. Our findings suggest a more 
nuanced association: here, disclosure has a beneficial effect on viral suppression only among 
some women, and only in some circumstances. This is consistent with qualitative research 
suggesting that many women manage to maintain ART adherence regardless of non-
disclosure [30]. Studies of the impact of disclosure on VL in adults living with HIV in Africa 
have yielded mixed results, with some showing that disclosure reduces the odds of virologic 
failure [31], others finding no association between disclosure and VL [32, 33], and still others 
showing higher levels of treatment failure among individuals reporting having disclosed [34]. 
Through our use of longitudinal data and nuanced disclosure measures, as well as our 
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consideration of subgroups, our results may help put these mixed findings into context. We 
propose that the impact of disclosure on VL is modified by three factors: (i) the timing of 
HIV diagnosis (before versus during the pregnancy); (ii) relationship to the person(s) to 
whom women disclose; and (iii) in the case of disclosure to a male partner, relationship 
status. We explore each of these proposed modifying factors below.   
 
Significant associations between disclosure and adherence have been observed less frequently 
in longitudinal compared to cross-sectional research [19]. Here, we show that the impact of 
disclosure differs across the timing of HIV diagnosis, and across time points of assessment. 
Our results suggest that there is a critical window during which disclosure to a male partner 
helps newly-diagnosed women to establish optimal adherence behaviours. Women who are 
diagnosed HIV-positive during pregnancy face a triple burden: they must quickly adjust to 
the pregnancy, a new HIV diagnosis and the need to start lifelong ART [35], and barriers to 
ART adherence may be even more pronounced in this group [10]. Qualitative work in 
Uganda has suggested an evolution of coming to terms with an HIV diagnosis and developing 
coping strategies [36], and our results suggest that disclosure to a married or cohabiting male 
partner may be most beneficial during this critical window. Further, our results suggest that 
counselling should consider that the consequences of disclosure evolve over time [37]. 
 
The reasons for disclosing to different categories of people may differ [30, 38], and our 
results suggest that the impact of disclosing to different individuals may similarly differ. In 
previous research among pregnant women in South Africa, both disclosure to a male partner 
and disclosure to family members have been found to be associated with improved ART 
adherence [39], but different effects of disclosure to male partners and to family/community 
members on the use of PMTCT services have been demonstrated in Kenya [40]. Similarly, 
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disclosure to a partner has been shown to increase linkage to HIV care among males in 
Kenya, while disclosure to family members has increased linkage among females [41]. In the 
present study, disclosure to family/community members appeared to play a more important 
role in VL outcomes at 12m postpartum among newly-diagnosed women.  
 
We observed an association between disclosure to a male partner and VL at delivery only 
among women who were married and/or cohabiting, suggesting that an individual’s living 
situation may moderate both the patterns of disclosure and the consequences of disclosure 
[42]. Married and/or cohabiting relationship status is a well-documented predictor of 
disclosure to a male partner [43-46]; here, we demonstrate that relationship status 
additionally affects the impact of disclosure on VL. Disclosure to a male partner has been 
previously shown to only affect adherence to antiretrovirals for PMTCT under certain 
conditions [47] including, for example, delivering at home versus in a health facility [48]. For 
women who are neither married nor cohabiting with their partner, maintaining high levels of 
adherence may be easier due to the relative ease of secrecy around ART use. Alternatively, 
the mediating processes that happen as a result of disclosure, rather than the disclosure event 
alone, may be critical in affecting outcomes [49]; here, women in married and/or cohabiting 
relationships may be provided with greater support after disclosing, leading to improved 
outcomes, while non-disclosure may contribute to poorer ART outcomes.  
 
A strength of the present study is the inclusion of longitudinal analyses, and the inclusion of a 
robust biological and clinical endpoint. We included a large sample recruited from a primary 
care antenatal clinic, and our findings are likely to be generalisable to other communities of 
pregnant and postpartum women in the region, although further research is needed to 
extrapolate our findings outside of the context of pregnancy. A limitation of this analysis is 
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that disclosure was assessed using self-report and may be subject to recall and social 
desirability bias, but this is common to all disclosure research. Thus, we used nuanced 
disclosure measures and extend the literature by assessing both disclosure to a male partner 
and to family/community members in analysis. We did not assess women’s reports of 
individuals’ reactions to disclosure, which may determine whether disclosure is beneficial 
[49, 50]. Women who were lost to follow-up were excluded from analysis, although we used 
sensitivity analyses to explore the impact of these missing data. Finally, a fairly large 
proportion of women (25%) did not have a sufficient duration of ART use and were excluded 
from analyses of VL at delivery. Our results from these analyses are thus restricted to women 
who had initiated ART earlier in the pregnancy. 
 
Despite some limitations, these results are notable. Although disclosure may have other 
benefits, we argue that the widely-held belief that disclosure always has a beneficial impact 
on adherence needs to recognise that this relationship is more nuanced: disclosure may be 
beneficial for some women, at some time points, but these benefits are dependent on three 
critical factors: (i) the timing of HIV diagnosis (before versus during the pregnancy); (ii) 
relationship to the person(s) to whom women disclose; and (iii) in the case of disclosure to a 
male partner, relationship status. Further research is needed to explore the causality and 
mechanisms of these unique findings. We recommend that counselling about disclosure 
should ideally be tailored to individual women’s circumstances, particularly during 
pregnancy and the postpartum period. While individualised counselling may not be feasible 
in busy primary care settings, our results suggest that there are particular subgroups, such as 
newly-diagnosed women, for whom tailored counselling around disclosure may be most 
beneficial.   
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Table S7.1 Comparison between women included in analysis of viral load at delivery and women excluded due to insufficient duration on antiretroviral therapy 
Variable 
Total sample enrolled into 
follow-up – n (%)1 Included in analysis Excluded from analysis P-value 
Number of women 628 451 147  
Median [IQR] age 28.0 [24.6, 32.2] 28.4 [24.7, 32.1] 27.6 [24.5, 32.7] 0.885 
Educational attainment 
   Less than secondary 
   Completed secondary/any tertiary 
462 (74) 
166 (26) 
336 (75) 
115 (26) 
105 (71) 
42 (29) 0.462 
Currently employed 238 (38) 180 (40) 48 (33) 0.116 
Poverty categories 
   Most disadvantaged 
   Moderate disadvantage 
   Least disadvantaged 
227 (36) 
208 (33) 
193 (31) 
154 (34) 
158 (35) 
139 (31) 
56 (38) 
43 (29) 
48 (33) 0.424 
Married/cohabiting 259 (41) 192 (43) 55 (37) 0.270 
First pregnancy 111 (18) 82 (18) 20 (14) 0.200 
Pregnancy intentions 
   Unintended 
   Intended 
442 (70) 
186 (30) 
295 (65) 
156 (35) 
123 (84) 
24 (16) <0.001 
Median [IQR] gestation in weeks at entry into antenatal 
care 20 [16, 26] 19 [14, 22] 31 [27, 33] <0.001 
Median [IQR] CD4 cell count 345 [236, 517] 339 [235, 500] 387 [259, 583] 0.091 
Timing of diagnosis 
   Tested HIV-positive before pregnancy 
   Tested HIV-positive during pregnancy 
276 (44) 
352 (56) 
215 (48) 
236 (52) 
49 (33) 
98 (67) 0.002 
Disclosed to a male partner by delivery 385 (64) 291 (65) 94 (64) 0.899 
Disclosed to ≥1 family/community member by delivery 430 (72) 336 (75) 94 (64) 0.013 
1 Includes 30 women who were lost to follow-up before delivery 
 
  
207 
 
Table S7.2 Comparison between women included and excluded from analysis of viral load at 12 months postpartum 
Variable 
Total sample enrolled into 
postpartum follow-up – n (%) Included in analysis Excluded from analysis P-value 
Number of women 471 411 60  
Median [IQR] age 27.8 [24.5, 32.3] 28.0 [24.7, 32.6] 26.0 [23.0, 30.5] 0.009 
Educational attainment 
   Less than secondary 
   Completed secondary/any tertiary 
354 (75) 
117 (25) 
310 (75) 
101 (25) 
44 (73) 
16 (27) 0.726 
Currently employed 184 (39) 155 (38) 29 (48) 0.115 
Poverty categories 
   Most disadvantaged 
   Moderate disadvantage 
   Least disadvantaged 
164 (35) 
158 (34) 
149 (32) 
143 (35) 
137 (33) 
131 (32) 
21 (35) 
21 (35) 
18 (30) 0.950 
Married/cohabiting 193 (41) 169 (41) 24 (40) 0.869 
First pregnancy 82 (17) 61 (15) 21 (35) <0.001 
Pregnancy intentions 
   Unintended 
   Intended 
338 (72) 
133 (28) 
291 (71) 
120 (29) 
47 (78) 
13 (22) 0.226 
Median [IQR] gestation in weeks at entry into antenatal 
care 21 [16, 26] 21 [16, 26] 24 [19, 31] 0.016 
Median [IQR] CD4 cell count 354 [248, 517] 346 [248, 507] 415 [247, 539] 0.181 
Timing of diagnosis 
   Tested HIV-positive before pregnancy 
   Tested HIV-positive during pregnancy 
198 (42) 
273 (58) 
183 (45) 
228 (55) 
15 (25) 
45 (75) 0.004 
Disclosed to a male partner by delivery 292 (62) 258 (63) 34 (57) 0.363 
Disclosed to ≥1 family/community member by delivery 332 (70) 295 (72) 37 (62) 0.109 
Viral load at delivery 
   <50 copies/mL 
   ≥50 copies/mL 
355 (75) 
116 (25) 
312 (76) 
99 (24) 
43 (72) 
17 (28) 0.476 
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Chapter 8: Discussion and recommendations 
 
One in three pregnant women in South Africa are living with HIV [1], but pregnant and 
postpartum women represent a particularly vulnerable group for poor antiretroviral therapy 
(ART) outcomes. HIV-status disclosure has been widely promoted as beneficial to both 
population and individual health. At the population level, disclosure may decrease HIV 
transmission through the adoption of preventive behaviours; at the individual level, disclosure 
is thought to improve both psychological well-being and adherence to ART. Additional 
psychosocial factors which may have important implications for adherence include HIV-
related stigma and social support, each of which is closely interrelated with disclosure, as 
well as poor mental health and unintended pregnancy.  
 
This thesis sought to provide insights into the patterns, predictors and impact of HIV-status 
disclosure among pregnant and postpartum women in the context of lifelong ART in South 
Africa, including considerations of stigma, social support, depression and unintended 
pregnancy. This final chapter provides a synopsis of findings in relation to the objectives of 
this thesis, followed by a discussion of the limitations of this work and then a discussion of 
key findings. Finally, this chapter presents recommendations for research and practice, 
including policy guidelines, based on the combined results of this work. Recommendations 
pertaining to disclosure are aimed at disclosure as both a risk factor and an important 
outcome in its own right. Additional recommendations are made pertaining to two other 
major risk factors of interest in this work: HIV-related stigma and unintended pregnancy.   
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8.1 Synopsis 
In Chapter 3, a novel analytic technique was used to describe patterns of disclosure during 
pregnancy and postpartum. Based on the findings from this analysis, disclosure was assessed 
as two separate dimensions in subsequent chapters: disclosure to a male partner, and 
disclosure to family/community members. As well as describing patterns of disclosure, this 
chapter examined predictors of disclosure to male partners and to family/community 
members to address the first objective of this thesis. This chapter highlighted that social and 
economic circumstances are central determinants of disclosure. Chapter 4 addressed the 
second objective of this thesis by exploring associations among stigma, social support and 
depression during pregnancy. This chapter highlighted the profound negative impact of 
stigma: in this sample, stigma modified the association between social support and depressive 
symptoms such that higher levels of social support were not associated with lower levels of 
depression among women reporting high levels of stigma.  
 
Key assumptions related to disclosure which this thesis sought to test included: (i) that 
disclosure is universally beneficial with (ii) effects that are consistent over time, and (iii) that 
these benefits are consistent across the person(s) to whom individuals disclose. Chapter 5 
tested these assumptions as part of an exploration of the impact of disclosure on depressive 
symptoms during pregnancy and postpartum, as well as the role of pregnancy intention in this 
relationship. The findings presented in this chapter suggest that unintended pregnancy 
modifies the impact of disclosure to a male partner on depressive symptoms during 
pregnancy among women who had been newly diagnosed HIV-positive during their 
pregnancy. In this group of women, disclosure to a male partner was associated with lower 
levels of depression among women who reported that their current pregnancy was intended 
but was associated with higher levels of depression among women who reported that their 
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pregnancy was unintended. Chapter 5 additionally showed that the effects of disclosure on 
depression are neither consistent over time nor consistent across the person(s) to whom 
women disclose. Chapter 6 addressed the fourth objective of this thesis by exploring the 
impact of unintended pregnancy on viral load during the postpartum period. This chapter 
presented novel evidence that unintended pregnancy is a prevalent and persistent predictor of 
elevated viral load up to five years postpartum.  
 
Finally, Chapter 7 addressed the fifth objective of this thesis and, along with Chapter 5, tested 
the three assumptions that this thesis aimed to critique. This chapter provided strong evidence 
against these assumptions and suggested that the association between disclosure and viral 
load is complex. The findings presented in this chapter suggest that the association between 
disclosure and viral load is modified by three factors: (i) timing of HIV diagnosis (before 
versus during pregnancy); (ii) relationship to the person(s) to whom women disclose, and (iii) 
in the case of disclosure to a male partner, relationship status.  
 
8.2 Strengths and limitations 
Limitations pertaining to each analysis were included in each of the results chapters, but there 
are overarching limitations that must be considered prior to discussing the key findings of this 
body of work and making recommendations.  
 
First and foremost, these data arise from a single population: pregnant and postpartum 
women. Levels of disclosure to partner(s) are significantly lower among women compared to 
men [2-5], and disclosure to male partners may be particularly difficult among women tested 
in the context of antenatal care [6], as discussed in Chapter 2. Women test for HIV at much 
higher rates than men and face a disproportionately higher obligation to disclose [7, 8], but 
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unstable relationships and high levels of migrant work in countries such as South Africa may 
contribute to difficulties related to disclosing to male partners [7, 9, 10]. Coupled with this, 
women’s economic dependence on their partners may make them particularly vulnerable and 
may decrease the odds of disclosure [8, 11-16]. Among women initiating ART during 
pregnancy in the study from which these data arise, just over half of women were diagnosed 
HIV-positive during their current pregnancy; one-quarter had completed secondary 
education; and only two in five were employed (Chapter 4). The vulnerability of this 
particular sample may have profound implications for the patterns and predictors of 
disclosure observed here, and these findings should be extrapolated to other pregnant and 
postpartum populations with caution. As more women enter antenatal care already on ART, 
due to the adoption of Option B+ guidelines, the results observed here may change in 
important ways. Finally, it has been acknowledged throughout that the findings and 
discussion thereof should be extrapolated to non-pregnant populations with caution. 
 
A further issue related to generalisability is that these data arise from a single site, the 
Gugulethu Midwife Obstetric Unit (MOU) in Cape Town, South Africa. The impact that 
context may have on the findings presented in this thesis was discussed in Chapter 2, but key 
impacts are repeated here. All of the constructs explored in this thesis are situated within a 
broader social, cultural and political context [17]. Levels of stigma remain high in the country 
[18-20], despite increased ART availability and uptake. As represented in the conceptual 
frameworks presented in Chapter 2, stigma is a critical construct in relation to disclosure, 
adherence and mental health, and the findings from this thesis may be profoundly different in 
contexts with different levels of stigma. Again, the findings presented herein should be 
extrapolated to other settings with caution.  
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There are limitations to determining causality of the results arising from this research. As 
discussed in Chapter 2, disclosure may result directly in improved adherence and consequent 
viral suppression or may be a marker of factors such as more supportive relationships [21-
23]. The causality of observed associations between pregnancy intentions and improved 
outcomes is similarly difficult to determine, given that pregnancy intentions are influenced by 
interrelated factors at the individual, couple, family and community levels [24]. The data 
presented herein arise from an observational study, and the potential for residual and 
unmeasured confounding cannot be ignored. However, many of the exposures of interest in 
this thesis, for example disclosure, stigma and unintended pregnancy, are not amenable to 
randomisation. As such, no other study design could have provided stronger evidence for the 
associations observed. In all analyses, potential confounders were included in models of the 
exposure-outcome association. Given that the data included were constrained by what factors 
were measured in the study from which these data arise, and the schedule of measurements, 
an exploration of mechanisms was not possible. Issues related to causality and mechanisms 
are discussed further below as critical caveats to the findings from this work.  
 
As stated above, the data presented herein were constrained by the measurements undertaken 
in the study from which these arise. Disclosure was assessed using self-report, and only 
voluntary disclosure was assessed. It has been shown that self-reported disclosure is not 
necessarily concordant with confirmation of the disclosure act by the person(s) to whom 
individuals report having disclosed [25]. Only pregnant women were enrolled into this study 
and confirmation of disclosure was not assessed. Although this is a limitation of this work, 
confirming disclosure would be very resource intensive and, as such, may not be feasible in 
research and practice. Women were asked to report whether or not they had disclosed to each 
person in a list of persons. Allowing women to report to whom they had disclosed without the 
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use of a list of possible persons may have resulted in different responses. However, the use of 
a list may have prompted women to report having disclosed to particular individuals who 
they may not have reported if disclosure was assessed as an open-ended question.  
 
Three further important limitations related to the way in which disclosure was assessed and 
treated in analyses are: (i) only voluntary acts of disclosure were assessed, and involuntary 
disclosure may lead to negative responses and, consequently, poorer outcomes; (ii) responses 
to disclosure were not assessed and, as argued in various parts of this thesis, these responses 
may be critical determinants of whether or not disclosure is beneficial; and (iii) the response 
options ‘No’ and ‘Not applicable’ regarding disclosure to each possible person were 
combined in analyses. This third limitation meant that women who had decided not to 
disclose to a particular person and women who had not disclosed because this person is not 
present in their life were combined in one group in analyses, which may conflate disclosure 
events with the size of an individual’s social network. Given that the intention was to 
compare women who had disclosed to women who had not disclosed, regardless of reason, 
this approach was appropriate, but more nuanced analyses where these categories are 
separated may lead to different results.  
 
A further limitation related to measurement is the way in which stigma was assessed. In the 
broader study, a subset of items from the Social Impact Scale, which was developed in the 
United States, was used to measure stigma, and other scales may have been more valid in this 
population of South African pregnant women. Further, only enacted stigma (in the form of 
social rejection) and internalised stigma were assessed, thus these results do not speak to the 
potential impact of perceived and anticipated stigma. In addition, intersectional stigmas, for 
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example stigma related to socioeconomic status or unintended pregnancy, and structural 
stigma were not assessed [26].  
 
Differences in the measures included in analyses and analytic methods used arose over time 
as this work progressed, and some analyses used more robust measures than others. For 
example, some analyses used the single measure of unintended pregnancy while others used 
the more sophisticated London Measure of Unplanned Pregnancy (LMUP). As stated in 
Chapter 1, these two measures have been compared within this cohort with high levels of 
concordance [27], thus the conclusions are likely robust despite the different measures used. 
 
This thesis explored the impact of disclosure on two outcomes: depressive symptoms and 
HIV viral load. Disclosure may have other benefits, and the findings presented herein may 
not be generalisable to other outcomes. In addition, intimate partner violence may be 
critically related to disclosure to sexual partners, but an in-depth exploration of intimate 
partner violence was beyond the scope of this thesis. Finally, missing data is an important 
limitation of this work, both by design, as only breastfeeding women were followed during 
the postpartum period, and by missed study visits. However, sensitivity analyses were 
conducted as part of many of these analyses to explore the impact of missing data. 
 
Despite these limitations, this thesis notably extends the literature in several areas. These 
analyses are strengthened by the consideration of subgroups; inclusion of prospectively-
collected data; and use of nuanced disclosure measures which allowed an exploration of 
disclosure to different persons. Alongside the nuanced measures of disclosure, these analyses 
used a novel method to explore the patterns of disclosure that informed subsequent analyses. 
In addition, the analyses presented in Chapter 6 used a robust and well-validated measure of 
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unintended pregnancy: the LMUP. Viral load, a robust biological and clinical outcome, was 
included as an outcome in these analyses. Further extensions to the literature include the 
exploration of interrelationships between constructs of interest, including stigma, social 
support and depression; an investigation of the effects of disclosure on depression, for which 
the evidence is mixed; and a consideration of the long-term effects of unintended pregnancy, 
an understudied issue. Each of these contributions to the literature is expanded on in the 
discussion below.  
 
8.3 Discussion of key findings 
While keeping in mind the limitations described above, this section presents a discussion of 
key findings prior to making recommendations. This discussion focusses on three broad 
underlying themes: (i) the individual is central to disclosure; (ii) disclosure occurs within 
social relationships; and (iii) pregnancy is a critical window.  
 
8.3.1 The individual is central to disclosure 
Over a decade ago, Remien and Mellins [28] argued that we cannot forget the individual in 
our global response to the HIV pandemic. Public health approaches are centred on 
population-level interventions to improve health and well-being and are typically not tailored 
to the individual. However, the findings of this work strongly suggest that the individual is 
central to our understanding of disclosure. In particular, women’s social and economic 
circumstances appear to be central determinants of disclosure, as demonstrated in Chapter 3; 
and the beneficial effects of disclosure on depression and viral load appear to be contextual 
rather than universal, as demonstrated in Chapters 5 and 7. Taken together, these findings 
suggest that individual women’s characteristics may critically determine whether or not they 
disclose as well as whether or not disclosure is beneficial. Further, the findings reported in 
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Chapter 4 suggest that women’s experiences of stigma determine whether or not their 
perceived level of social support buffers against depression during pregnancy. It is 
worthwhile to revisit Figure 2.1 as a useful conceptual understanding of disclosure [29, 30] 
on which this thesis draws, and to frame the remainder of this section of the Discussion.  
 
 
Individuals have different antecedent goals related to disclosure, represented as approach and 
avoidance goals in the figure above. Indeed, Chapter 2 reported that women’s motivations for 
disclosing to, for example, family members differ from their motivations for disclosing to a 
male partner [31, 32]. Although most individuals disclose to at least one person [33], 
strategies for disclosure range from widespread to selective disclosure [34]. In addition, 
individuals disclose in different ways, and not always directly [32, 35, 36]. These differences 
are represented as part of the disclosure event in the figure above. Despite widespread 
acceptance that individuals have vastly different disclosure experiences, however, the 
Re-presentation of Figure 2.1. Disclosure Processes Model, adapted for this thesis [29, 30] 
 
Decision-Making Process Outcome Process 
Antecedent Goals
Approach goals
Pursue positive
outcomes
Avoidance goals
Prevent negative 
outcomes
Disclosure Event
Confidant
Strategy
Reaction of confidant
Mediating 
Processes
Reduced secrecy
Social support
HIV-related stigma
Individual 
outcomes
Mental health
HIV viral suppression
Feedback loop towards greater visibility 
or greater concealment
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predominant narrative in each of research, practice and policy is that disclosure is universally 
beneficial, i.e. that the benefits of disclosure do not differ across individuals.  
 
Indeed, disclosure is framed in each of research, policy and practice as an act that should be 
strongly, and universally, encouraged. Authors have stated, for example, that it is ‘commonly 
accepted’ that disclosure leads to higher levels of psychosocial support and ART adherence, 
ultimately improving treatment outcomes and reducing the risk of HIV transmission [37]; or 
that their findings that non-disclosure is associated with suboptimal adherence are 
‘predictable’ [38]. Disclosure has even been described as critical to HIV prevention, through 
increased support for preventive actions, easier access to HIV services and the prevention of 
sexual transmission [39], with others arguing that reductions in HIV incidence as well as in 
stigma and discrimination will not be achieved without disclosure [17]. Authors have even 
gone as far as to state that healthcare providers and policymakers need to convince people to 
disclose their HIV status in cases where they are reluctant to do so [40-42].  
 
Numerous quantitative studies have demonstrated associations between disclosure and 
improved adherence to ART among pregnant women [43], but few have considered the 
possibility that the benefits of disclosure may differ in different subgroups and that disclosure 
may not be universally beneficial. A notable exception is an early study that reported that 
disclosure to a male partner was only associated with adherence to single-dose nevirapine 
(NVP) among women who delivered at home [44]. It has been previously noted that context 
and individuals’ living environments moderate both the patterns of disclosure and its 
consequences [45]. The findings presented in this thesis are along these same lines, and 
notably extend the literature by providing strong evidence against the assumption that 
disclosure is a universally beneficial act. Indeed, the findings from Chapter 5 suggest that 
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disclosing to a male partner may lead to higher levels of depressive symptoms among newly-
diagnosed women who experience an unintended pregnancy. It has been argued that 
disclosure may not always be in the best interests of women [46], and this thesis demonstrates 
that disclosure may in fact be harmful in this group of women. Other authors have argued that 
disclosure is not a universally positive act [34] and that disclosure does not have one 
inevitable outcome [17]; this thesis provides strong support for these viewpoints.  
 
Although the data on which this thesis draws preclude an exploration of mechanisms and 
causality, as noted in the limitations section above, several hypotheses can be considered. 
First, and drawing on the conceptual framework above, the reaction of the person(s) to whom 
women disclose may be critical determinants of whether or not disclosure is beneficial [47]. 
Disclosure may lead to increased social support or increased stigma, and these outcomes may 
similarly be critical in terms of whether or not the disclosure act is beneficial [48]. This thesis 
demonstrated that when levels of stigma are high, social support does not buffer against 
depression; where levels of stigma are high, it is plausible that lower levels of disclosure are 
in fact protective [49]. A further hypothesis is that disclosure is a marker of a more 
supportive relationship. Indeed, individuals are more likely to disclose to individuals who 
they deem to be supportive [50], and non-disclosure may be a marker of an unhealthy 
relationship [46]. The findings presented in this thesis suggest that disclosure to a male 
partner is beneficial among women who are married and/or cohabiting. The importance of 
relationships is discussed further under Section 8.3.2, below, but it is plausible that whether 
or not disclosure is beneficial is determined by the responses of the individual(s) to whom 
women disclose, and the quality of their relationships with these individual(s). 
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A further hypothesis to consider is that there is a critical window during which disclosure is 
most beneficial. The findings presented herein suggest that the benefits of disclosure are not 
consistent over time but rather that disclosure is particularly beneficial during pregnancy 
among women who were newly diagnosed HIV-positive during the pregnancy. As disclosure 
did not appear to have beneficial effects on viral load among women who were diagnosed 
prior to the pregnancy, it is plausible that it is the timing of diagnosis that is critical, and that 
among newly-diagnosed women this critical window coincides with pregnancy. The 
importance of this window is discussed further under Section 8.3.3, below. Finally, this thesis 
highlighted that unintended pregnancy is both a moderator of the relationship between 
disclosure to a male partner and depression as well as a persistent predictor of poor ART 
outcomes. This is in line with the hypothesis that context moderates both the patterns of 
disclosure and its consequences [45]. Indeed, Chapter 3 demonstrated that the intendedness of 
the pregnancy is an important predictor of disclosure to a male partner.  
 
Taken together, this thesis presents compelling evidence that disclosure is not universally 
beneficial and that the individual is central to our understandings of disclosure, although it 
cannot definitively explain why disclosure appears to be beneficial in some women but not 
among others. 
 
8.3.2 Disclosure occurs within social relationships 
The findings presented in this thesis highlight the relational aspects of disclosure. Disclosure 
is inherently an act that occurs within social relationships [50]. Indeed, the socio-ecological 
framework [51], which is described in Chapter 2 and on which this thesis draws, situates 
disclosure within the level of family and peer influences on adherence. It has been suggested 
that whether or not an individual discloses to a particular person is an indicator of social 
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connectedness and the quality of the relationship [52]. As discussed in Chapter 2, the 
majority of disclosure research to date has operationalised disclosure as any versus no 
disclosure and has not provided a rationale for how disclosure was assessed and/or treated in 
analysis. Using a novel methodological approach, Chapter 3 describes how disclosure forms 
two separate dimensions in the sample of women from which these data arise. Further, this 
chapter demonstrates that the determinants of these two forms of disclosure differ; this 
finding would not have been observed if disclosure had been treated in analysis as a binary 
variable indicating any versus no disclosure. As alluded to above, motivations for disclosing 
to different individuals may differ; these quantitative data suggest that different individual 
characteristics may determine the likelihood of disclosure to different people.  
 
As discussed above, the quality of relationships may critically determine the outcomes, both 
positive and negative, of disclosure. However, there are few explicit considerations of 
whether disclosure to different individuals has different effects. As highlighted in Chapter 2, 
it is unclear whether researchers have explored outcomes across different dimensions of 
disclosure and have only reported significant associations, or whether they did not consider 
that effects may differ according to the person(s) to whom individuals disclose. A notable 
exception is a study from Kenya which suggested that self-reported adherence was associated 
with disclosure to (i) anyone, (ii) a male partner and (iii) an immediate family member, but 
not with disclosure to others, including friends, more distant relatives and members of the 
community [48]. The third assumption which this thesis aimed to test was that the benefits of 
disclosure are consistent across the person(s) to whom individuals disclose, such that the 
benefits of disclosing to, for example, a male partner are consistent with the benefits of 
disclosing to a sister or friend.  
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Chapter 5 demonstrated that disclosure to a male partner is associated with depressive 
symptoms during pregnancy, but that disclosure to family/community members was 
associated with depressive symptoms during the early postpartum period. In line with this, 
Chapter 7 demonstrated that disclosure to a male partner is associated with viral load at 
delivery among women who are newly-diagnosed HIV-positive and in a married and/or 
cohabiting relationship; and that disclosure to family/community members is associated with 
viral load at 12 months postpartum among newly-diagnosed women. Taken together, these 
findings suggest that the person(s) to whom women disclose is important, and that the 
potential benefits of disclosure for depressive symptoms and viral load outcomes are not 
consistent across these person(s). In addition, the finding that disclosure to a male partner is 
more likely among women who are married and/or cohabiting (Chapter 3) and is only 
associated with viral load at delivery among newly-diagnosed women who are in a married 
and/or cohabiting relationship (Chapter 7) lends further support to the argument that 
relationship quality critically determines both the likelihood and the benefits of disclosure.  
 
Along with disclosure occurring within social relationships, an HIV diagnosis and consequent 
decisions about whether or not to disclose occur in the context of pre-existing psychosocial 
and economic stressors [53]. As summarised in the review of the literature in Chapter 2 and 
alluded to above, disclosure to a male partner is particularly challenging in contexts where 
women are socially and economically dependent on their partner. Chapter 3 shows that higher 
levels of poverty are associated with a reduced likelihood of disclosure to a male partner 
among women who are neither married nor cohabiting, speaking to women’s economic 
vulnerability [54]. A further psychosocial stressor that plays a central role in several parts of 
this thesis is unintended pregnancy, with the findings suggesting that unintended pregnancy is 
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a critical stressor in the context of prevention of mother-to-child transmission (PMTCT). 
Findings related to pregnancy intention are discussed further in Section 8.3.3, below.  
 
A final construct related to social relationships that warrants discussion is that of HIV-related 
stigma. The socio-ecological framework presented in Chapter 2 situates stigma within the 
level of community determinants of adherence [51] but acts of stigma also occur within social 
relationships [26]. Drawing on the Disclosure Processes Model re-presented above [29, 30], 
the goal of avoiding stigma may reduce the likelihood of disclosing, but social rejection 
following disclosure may also lead to poorer outcomes; indeed, non-disclosure has been 
described as a manifestation of stigma [26]. Stigma has also been identified as a determinant 
of social support [55], mental health [56] and, ultimately, treatment outcomes [57]. In line 
with this, Chapter 4 extends the literature by highlighting the interrelationships among 
stigma, social support and depression among women initiating ART during pregnancy. In this 
sample of women, both social rejection and internalised shame were found to be strongly 
associated with depressive symptoms, although stronger effects were observed for 
internalised shame. Further, this chapter demonstrated that higher levels of social support do 
not buffer against the detrimental effects of stigma on depression in this sample. These 
findings speak to the profound negative effects of stigma in this population. Despite the hope 
that levels of stigma would decrease over time as more people initiated ART, stigma remains 
a pervasive and harmful issue [18-20]. 
  
As highlighted in this section, this thesis provides quantitative evidence that social 
relationships are key to understanding disclosure: the patterns and determinants of disclosure 
to different individuals differ; the quality and nature of women’s relationships with their 
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partners are profound determinants of disclosure and the benefits thereof; and stigma remains 
a pervasive and harmful factor at the social and community level.  
 
8.3.3 Pregnancy is a critical window  
A key assumption that this thesis sought to test was that the effects of disclosure are 
consistent over time. Despite being viewed as a sequential process that occurs over time [17, 
35], much of the existing literature has relied on cross-sectional data to investigate each of the 
patterns, determinants, and effects of disclosure. Chapter 2 provided an overview and critique 
of existing studies, including the finding that significant effects of disclosure on adherence 
are more frequently reported in cross-sectional compared to longitudinal studies [58]. This 
thesis notably extends the literature by including both cross-sectional and prospectively-
collected data. Chapter 5 provides evidence that disclosure to each of a male partner and to 
family/community members are associated with depressive symptoms at some time points 
but not at others. Similarly, the findings from Chapter 7 suggest that disclosure to a male 
partner is associated with a reduced risk of elevated viral load at delivery among women who 
tested HIV-positive during the pregnancy; and that disclosure to family/community members 
is associated with a reduced risk of elevated viral load at 12 months postpartum in this same 
group of women. In contrast, disclosure was not associated with viral load at entry into 
antenatal care among women who were diagnosed before the pregnancy and were established 
on ART, or at delivery or 12 months postpartum among women who were diagnosed before 
the pregnancy and were initiating ART.  
 
These results suggest that the effects of disclosure on each of depressive symptoms and viral 
load are not consistent over time. Rather, it appears as though there may be a critical window 
during which disclosure affects depressive symptoms and viral load among newly-diagnosed 
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women and, as stated above, this critical window coincides with pregnancy. Newly-
diagnosed women need time to come to terms with their diagnosis [6] and to establish 
adherence behaviours, and disclosure may be beneficial for some women during this period. 
Over time, however, disclosure does not appear to be a primary driver of depressive 
symptoms or viral load outcomes in this population. Pregnancy has previously been described 
as a ‘teachable moment’, defined as an event or experience which presents an opportunity for 
learning [59]. This window may be particularly amenable to interventions based on mothers’ 
desires for a healthy pregnancy and baby and their adoption of a new social role [59, 60]. In 
South Africa, is has been previously noted that women prioritise antenatal and HIV care for 
the health of their baby but are less motivated to seek care for their own health during the 
postpartum period [61]. The data presented in Chapter 6 suggest that viraemia increases with 
increasing time postpartum, suggesting that the motivation to maintain high levels of 
adherence may decrease over time. As stated in the limitations section above, these findings 
should be extrapolated to non-pregnant populations with caution, and it remains unclear 
whether disclosure in the period of time immediately post-diagnosis may similarly improve 
outcomes outside of the context of pregnancy.  
 
A further critical finding related to pregnancy is the importance of the intendedness of the 
pregnancy. As argued in various parts of this thesis, unintended pregnancy has long been 
acknowledged as a prevalent issue [62, 63] which heightens women’s vulnerability [54, 64, 
65]. However, there is limited quantitative evidence for the impact of unintended pregnancy 
on women’s health and well-being, particularly in the context of HIV. Chapter 3 
demonstrates that an unintended pregnancy reduces the likelihood of disclosure to a male 
partner among women diagnosed HIV-positive during the pregnancy, and Chapter 5 
describes unintended pregnancy as a modifier of the association between disclosure to a male 
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partner and depressive symptoms in this group. Chapter 6 then presents compelling evidence 
for the long-term negative impact of an unintended pregnancy, demonstrating associations 
with elevated viral load up to five years after delivery.  
 
As highlighted in this section, the findings from this thesis suggest that pregnancy is a critical 
window during which disclosure may improve ART outcomes, but that the intendedness of 
the pregnancy is critical in terms of affecting disclosure; heightening women’s vulnerability; 
and determining long-term HIV treatment outcomes. 
 
8.4 Recommendations for research 
The discussion above leads to several recommendations for research. Although alluded to in 
various parts of this thesis, they are summarised here in order to provide overarching 
recommendations. Following this, additional recommendations are made relating to 
methodological aspects of research. 
 
8.4.1 Disclosure research  
Disclosure has long been acknowledged as an important issue in the lives of HIV-infected 
individuals [28]. As such, there has been much research interest in the act of disclosure, and it 
is likely that this research focus will continue. However, if it can be accepted that disclosure 
may not be universally beneficial, then the focus of research should shift to a focus on when 
and why disclosure is likely to be beneficial [30]. This necessitates explorations of sub-
groups: context and individual’s social and economic circumstances must be taken into 
account when exploring the determinants and impacts of disclosure. Pertinent sub-groups 
arising from this research include women who are married and/or cohabiting versus those 
who are neither married nor cohabiting; women who are experiencing an unintended versus 
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intended pregnancy; and women who were newly-diagnosed during their current pregnancy 
versus those diagnosed before the pregnancy. Other sub-groups may be more relevant among 
non-pregnant adult populations, and these should be explored in future research.  
 
A second recommendation for future research is that longitudinal data are critical in 
exploring patterns and the impacts of disclosure. This thesis showed that the effects of 
disclosure on depressive symptoms and viral load are not consistent over time; these results 
would not have been observed using only cross-sectional data. Further, the findings from this 
thesis suggest that the benefits of disclosure are not consistent across the person(s) to whom 
women disclose. It is recommended that researchers first explore the dimensionality of 
disclosure in their samples before operationalising disclosure, as has been argued previously 
[66, 67]. Without this exploration, both the differing determinants of disclosure and the 
differing impacts of disclosure to different person(s) may be lost in analysis. Although not 
measured in the study from which these data arise, individuals’ responses to disclosure 
should be explored in future research as important determinants of the impact of disclosure, 
in line with the Disclosure Processes Model. 
 
8.4.2 Stigma research  
As discussed in Chapter 2, the negative effects of HIV-related stigma on mental health and on 
treatment outcomes have been definitively established, but there are nuances that have been 
less frequently explored that should be addressed in future research. In particular, there have 
been few considerations of the impacts of different types of HIV-related stigma on health and 
HIV treatment outcomes [26]; future research should explore these as well as the impacts of 
structural and intersectional stigmas. As structural stigma by definition will differ across 
contexts, and intersectional stigma and forms of HIV-related stigma may similarly differ 
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across context, research which includes multiple communities would be beneficial in order to 
explore findings across settings. A critical research need in the field of HIV-related stigma is 
an exploration of mediators and moderators. Methodological considerations are discussed 
under Section 8.4.4, below, but it should be noted here that investigations of the mechanisms 
that lead to poor mental health and treatment outcomes, as well as factors that may protect 
against these outcomes, are needed in order to inform intervention efforts.  
 
8.4.3 Unintended pregnancy research  
This thesis provides novel evidence for the long-term impacts of an unintended pregnancy on 
elevated viral load during the postpartum period. As argued in Chapter 6, unintended 
pregnancy should be escalated as a global public health concern. Alongside this 
recommendation, the findings from this thesis suggest that unintended pregnancy warrants 
further attention in quantitative research. Much qualitative work has highlighted the 
heightened vulnerability that women face in the context of an unintended pregnancy, as 
discussed in various parts of this thesis, but additional research is needed to (i) explore the 
long-term impacts of an unintended pregnancy on maternal and child health and (ii) examine 
the role of unintended pregnancy as a potential effect modifier in other associations regarding 
psychosocial well-being during pregnancy. Finally, the methodological limitations of 
assessing unintended pregnancy were discussed in Chapter 6, and future research should 
focus on how best to measure this construct as well as changes in pregnancy intentions and 
desirability from the pre-conception period through delivery; this latter recommendation will 
require longitudinal data. 
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8.4.4 Methodological considerations  
Methodological recommendations are made throughout this work and in the sections above 
but are summarised and expanded on here. First, the three assumptions which this thesis 
sought to test lead to three critical recommendations: (i) sub-groups must be considered when 
exploring the patterns and impacts of disclosure, given the findings related to effect 
modification presented in this thesis; (ii) longitudinal data are needed to parse out changes in 
the effects of disclosure over time; and (iii) disclosure must be operationalised with 
considerations of the different person(s) to whom individuals disclose. Effect modification 
was evident in most chapters of this thesis. Chapter 3 showed that the determinants of 
disclosure to a male partner differ across relationship status; Chapters 5 and 7 showed that the 
impacts of disclosure differ across pregnancy intentions and across timing of diagnosis and 
relationship status, respectively. In line with this, Chapter 4 showed that the impact of social 
support on depressive symptoms is modified by stigma. Taken together, these findings 
suggest that sub-groups are central to our understandings of these constructs and should be 
considered in all future research. Second, longitudinal data are necessary to explore patterns 
and outcomes of disclosure over time, given that disclosure is a process, and to explore 
dynamic relationships between psychosocial constructs as well as the long-term impacts of 
these constructs over time. The importance of exploring the dimensionality of data is argued 
above, and researchers should use comprehensive measures of disclosure to allow for this 
exploration of dimensionality. The importance of future studies focussing on the 
measurement of unintended pregnancy is noted above.  
 
The findings presented in this thesis and the limitations thereof lead to several 
recommendations relating to analytic methods and causal thinking. Clearly, recommendations 
made above regarding sub-groups, longitudinal data and the operationalisation of disclosure 
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have analytic implications. In addition, both the design and analysis of future research should 
be strongly informed by causal considerations. The constructs of interest in this thesis are 
critically interrelated, as is evident from the preceding chapters, and arise within complex 
social contexts and relationships. As such, causality is difficult to determine. Future research 
must consider potential confounders and should be driven by and empirically test existing 
causal frameworks pertaining to these constructs. In particular, it was noted in various parts 
of this thesis that these data did not allow for an exploration of the mechanisms of the 
associations observed. Causal frameworks are critical to future explorations of these 
mechanisms, and the importance of elucidating these is discussed under Section 8.5.7, below. 
Finally, it is critical to re-emphasise that all of these findings arise from a cohort of pregnant 
women in South Africa. The implications of context were discussed in Chapter 2, but it must 
be reiterated that these findings should be extrapolated to non-pregnant populations and other 
settings with caution. Future research should investigate the similarities and differences of 
these findings when similar research is conducted in other populations and settings.  
 
8.5 Recommendations for practice 
In addition to recommendations for research, several recommendations for practice and 
policy arise from this work. At the outset, it is important to note that social context strongly 
shapes patterns of disclosure [67]. Disclosure patterns may be expected to differ widely in 
contexts where, for example, non-disclosure is criminalised, women are heavily dependent on 
their male partners, or levels of HIV-related stigma are high. The data on which this thesis are 
based arise from a single community in South Africa. The influence that context might have 
on the findings presented here was discussed in Chapter 2, but it is important to note that 
recommendations given here are tailored to the context of pregnancy in South Africa and 
should be generalised to other settings with caution. Recommendations are made regarding 
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existing practices, for example better implementation of existing guidelines, as well as 
regarding the potential for interventions to improve outcomes. The potential interventions 
discussed here are specifically targeted toward HIV-infected pregnant and postpartum women 
and may not be appropriate or effective in populations of non-pregnant adults.  
 
8.5.1 Individualised counselling  
This discussion of key findings began by noting that public health approaches are centred on 
population-level interventions and are typically not tailored to the individual. However, this 
thesis presents strong evidence that the individual is central. Disclosure is ultimately a 
personal matter [28], and the individual cannot be ignored in counselling. Indeed, an early 
article argued that blanket disclosure in all circumstances should not be advised [22], and 
others have argued that it is not possible to develop a generic template for disclosure 
counselling that would be helpful for all HIV-infected people [34]. This thesis provides 
strong support for these arguments, with Chapter 3 concluding by stating that counselling 
messaging should ideally be tailored to the broader social and economic circumstances of 
individual women’s lives. Chapter 7 notes that individualised counselling may not be feasible 
in busy primary care settings, but this section recommends that individualised counselling at 
least be provided for particular sub-groups.  
 
A particularly vulnerable sub-group who may benefit most from individualised counselling is 
women who are newly diagnosed HIV-positive in the context of an unintended pregnancy. 
Pregnancy is a socially vulnerable period [36], but there is ample qualitative evidence, 
summarised in the literature review presented in Chapter 2, that an unintended pregnancy 
confers additional vulnerability, with this thesis providing quantitative evidence that this 
vulnerability continues into the postpartum period. It has been argued that it is reasonable to 
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delay counselling messaging that emphasises immediate disclosure among women 
experiencing a new HIV diagnosis in the context of an unintended pregnancy, in order to 
support women to come to terms with their diagnosis before they are able to disclose [54]. 
Based on the findings presented in this thesis, counselling messaging among this group of 
women should focus not only on disclosure, but also on the potential adverse impacts of the 
unintended pregnancy.  
 
Given that women repeatedly visit antenatal clinics during pregnancy, the antenatal period 
represents a window of opportunity during which well-trained healthcare providers and lay 
counsellors could support women who are most vulnerable. Ongoing supportive counselling 
should be offered during this period, not limited to the time of diagnosis [6]. Postpartum 
women in South Africa report that responses to disclosure range from supportive to angry and 
disappointed [32], and some women experience negative outcomes such as abandonment and 
violence [6, 15]. Counselling services need to be made available for women who experience 
negative outcomes after disclosing.  
 
8.5.2 Non-disclosure as an appropriate response  
In line with the argument about negative reactions above, it is recommended that non-
disclosure be recognised as an appropriate response in certain situations. From a public health 
perspective, the encouragement of all HIV-infected individuals to disclose their HIV status to 
their sexual partner(s) has been described as ‘sound in its intention’ [53]; this thesis makes 
the argument that disclosure may not always be beneficial and may in fact be harmful in 
some situations. An example is contexts in which levels of stigma remain high: in these 
settings, non-disclosure may be an appropriate alternative to revealing one’s HIV-positive 
status given the potential for experiencing enacted stigma. Among HIV-infected women in 
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India, for example, concealing one’s HIV status has been described as essential in order to 
avoid stigma and maintain a normal life [49]. Disclosure is universally promoted in policy 
and in counselling services, but the environment in which HIV-infected individuals live may 
not always encourage or be conducive to disclosure.  
 
Non-disclosure should also be viewed as appropriate in situations in which abuse is a possible 
response to disclosure [68]; in these situations, non-disclosure may be a reasoned response to 
a dangerous situation [69]. Notably, intimate partner violence is prevalent in South Africa 
[70] but considerations of violence are absent from recommendations promoting blanket 
disclosure in all circumstances. Further, the evidence base for interventions to facilitate safer 
disclosure among women who fear or are experiencing violence is limited [71]. Support for 
disclosure must protect women’s rights, autonomy and safety [48], drawing on the principle 
of doing no harm [46], and counsellors should be made aware that there will always be 
women for whom disclosure is not a safe or recommended behaviour [72].  
  
Healthcare providers and lay counsellors should ideally be trained not only to recognise that 
disclosure may not always be in a woman’s best interests, but also to discuss partner 
dynamics [69]. Currently, counselling about disclosure does not include discussions of 
strategies to address the very relationship characteristics that may make women reluctant to 
disclose [73]; indeed, counselling about disclosure should ignore neither the individual nor 
the couple. It has been previously argued that counselling to enhance trust and a supportive 
relationship may facilitate disclosure within couples [74]. However, counselling messaging 
must take into account that in settings such as South Africa, stable relationships characterised 
by trust and support may not be the norm, as highlighted in the review of the literature 
presented in Chapter 2.  
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Early guidelines for the management of HIV in pregnant women stated that all women should 
be encouraged to disclose to their partner [75]. Over time, it has been recognised that not all 
women are able to or want to disclose. For healthcare workers and counsellors, this creates an 
ethical dilemma of balancing the desire to prevent HIV transmission with that of providing 
support to HIV-infected women and respecting their privacy [76]. A discussion of the ethics 
of disclosure is beyond the scope of this thesis. Drawing on the findings of this thesis, 
however, the recommendations for practice and policy presented here centre on promoting 
disclosure as an act that may be beneficial for some women and in some circumstances, 
rather than as a universally beneficial act. It is recommended that counselling messaging 
allows for the possibility that women’s individual characteristics and the quality of their 
relationships critically shape disclosure and its benefits. As disclosure occurs as a process of 
revealing one’s status to an increasing number of individuals over time, disclosure decisions 
have to be made repeatedly [33], and evidence suggests that disclosure does not become 
easier over time [77]. As such, ongoing supportive counselling may be needed.  
 
8.5.4 Facilitating disclosure 
While recognising that non-disclosure may be an appropriate response in some situations, 
disclosure may benefit some individuals and lead to population-level benefits and should be 
supported where appropriate. In low- and middle-income countries (LMICs), interventions to 
increase disclosure have included cognitive-behavioural support groups; using peers or 
community health workers to provide individual support for disclosure; or using partner 
notification by healthcare providers, with mixed results [78]. Similarly, a recent systematic 
review including five intervention studies which sought to increase disclosure to sexual 
partners in the United States reported mixed success [72].  
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In South Africa and many other settings, women face a disproportionately high burden of 
disclosure, as discussed earlier in this thesis. Recognising this, it has been suggested that 
facilitated disclosure, where a healthcare worker acts as an intermediary, may benefit 
pregnant women [79, 80]. However, it has also been argued that using women as a go-
between to increase male partner testing may add an unnecessary burden on women [81], and 
no single method of facilitated disclosure will be appropriate for every pregnant woman [80]. 
Ultimately, shifting the burden of disclosure away from women is critical. A further 
suggestion to increase disclosure is to promote couples counselling and testing [79, 80], 
although the uptake of this approach remains extremely low [82]. Finally, home-based testing 
may improve the yield of testing and mutual disclosure [81]. 
 
In addition, the purpose of an intervention to increase disclosure should be carefully 
considered. For example, partner notification to warn of possible exposure and encourage the 
adoption of preventive behaviours and disclosure to increase support for the HIV-infected 
individual are two different goals. It has been noted that contextual factors are critical in 
thinking about adherence interventions, as the effectiveness of interventions may differ across 
settings [83]. If facilitating disclosure is thought of as an intervention to improve adherence, 
then context must be considered; indeed, the importance of context has been alluded to 
throughout this thesis. In contexts where levels of stigma are particularly high, for example, 
interventions to increase disclosure may be less effective. In addition, timing must be 
considered: facilitating disclosure may be most helpful during pregnancy among newly-
diagnosed women, which may reduce the risk of mother-to-child transmission (MTCT), but 
disclosure interventions at other timepoints may be less beneficial. In line with the discussion 
of individualised counselling, above, interventions targeted at those who may benefit most 
from disclosure should be considered. However, given that disclosure may not always benefit 
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HIV-infected individuals and may lead to harm in certain situations, the purpose of 
interventions as well as other possible ways to achieve these goals should be considered. In 
particular, other interventions may be needed for women who do not disclose or who do not 
receive support after disclosing. Interventions focussed on maintaining high levels of 
adherence in the absence of disclosure or support are needed for these women.  
 
8.5.5 Stigma 
As stigma occurs at the community level, and can also stem from structural and intersectional 
stigmas, reducing stigma will entail changing attitudes and beliefs at the community level. As 
stigma exists in multiple forms, it is recommended that interventions target specific 
dimensions [26], but gaps and challenges remain in developing effective interventions [84]. 
Ultimately, reducing stigma at the community level may lead to an environment that is more 
conducive of disclosure. As community-level stigma is beyond the scope of this thesis, the 
recommendations made here focus on the individual and service level.  
 
As stated in Chapter 1, the Western Cape HIV treatment guidelines recommend that patients 
experiencing issues with non-disclosure or stigma should receive on-going counselling [85]. 
It is unclear how routinely and effectively this recommendation is implemented. A promising 
example of an individual-level intervention is peer support programmes to enhance 
individuals’ ability to cope [86, 87]. As these programmes can be facilitated by lay health 
workers, they may be particularly feasible in LMIC settings. Given that stigma may have 
negative effects on HIV treatment outcomes through secrecy around HIV care engagement, 
strategies which limit the opportunities for inadvertent disclosure are needed. For example, 
differentiated models of care such as adherence clubs may enable women to avoid 
stigmatising situations by situating care outside of healthcare centres [88]. Considering the 
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fact that there will always be a proportion of women who do not disclose their HIV status, 
counselling messaging for these women should include concrete strategies for remaining 
engaged in care and maintaining high levels of adherence in the absence of disclosure.  
 
8.5.6 Unintended pregnancy  
As argued in Chapter 6 and earlier in this discussion, unintended pregnancy needs to be 
escalated as a global public health concern. Despite the prevention of unintended pregnancy 
constituting an important aspect of the World Health Organization’s approach to prevent 
MTCT, most of the focus of global HIV prevention efforts have been on preventing MTCT to 
infants (prong 3) and, to a lesser extent, providing care and support to HIV-infected women 
and their children and families (prong 4) [89]. Indeed, the PMTCT cascade is conceptualised 
as beginning at HIV testing [90], and a much greater focus on preventing unintended 
pregnancies is warranted. Recommendations made here focus on (i) preventing unintended 
pregnancies and promoting safer pregnancies; and (ii) counselling in the context of an 
unintended pregnancy.  
 
The health and social benefits of family planning are widely accepted [62]. Despite this, HIV 
care, maternal and child health services, and reproductive healthcare have historically existed 
as separate silos [91]. The argument for integrating family planning into HIV services has 
been repeatedly made [90, 92, 93]. Despite HIV treatment guidelines in the Western Cape 
recommending discussions of family planning with all patients on ART at every opportunity 
[85], healthcare providers do not routinely assess fertility goals in the country [94], and 
qualitative research suggests that the onus is on patients to initiate conversations about 
pregnancy intentions and contraception [95]. In the broader study from which these thesis 
data arose, one-quarter of women who were established on ART when entering antenatal care 
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reported not using contraceptives during the past 12 months [27]. Among women initiating 
ART during pregnancy in this cohort, high levels of contraceptive discontinuation alongside 
low desires for a future period were observed during the postpartum period [96]. Together, 
these data suggest a major gap for women who are engaged in routine HIV care and speak to 
the urgent need for an increased focus on family planning within health services. 
 
Integrating family planning into HIV care services has been shown to be feasible [24] and 
effective [97]. Tools need to be developed and implemented to routinely screen for fertility 
intentions and contraceptive use [95]. Fertility intentions change over time [24] and should be 
assessed continuously, and implementation research will be critical to monitor 
implementation and understand how these recommendations can be achieved at scale [90]. 
Finally, integration must also include pre-conception care for individuals who intend to 
become pregnant [92]; indeed, reproductive health counselling must be tailored to 
reproductive goals [91]. In particular, the importance of viral suppression must be 
emphasised as part of pre-conception counselling [98, 99].  
 
For women who are experiencing an unintended pregnancy, counselling messaging must 
acknowledge the heightened vulnerability that this confers. In addition, an unintended 
pregnancy occurs within complex social relationships and circumstances, as argued in various 
parts of this thesis, and counselling must take these broader issues into account. In particular, 
enhanced counselling should target women who are newly diagnosed HIV-positive in the 
context of an unintended pregnancy: in this context, women have little time to adjust to this 
two-fold impact on their lives [54]. Recommendations regarding counselling around 
disclosure for this group of women were made above. In addition, counselling messaging 
should target the effects of an unintended pregnancy on women’s psychological well-being 
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and, as suggested by this thesis, long-term treatment outcomes. Indeed, women who did not 
intend to become pregnant may require ongoing support during the pregnancy and 
postpartum, alongside an enhanced focus on postpartum family planning in order to help 
prevent a repeat unintended pregnancy.  
 
8.5.7 Understanding mechanisms  
Finally, there is a need to investigate the mechanisms of the associations reported in this 
thesis and in the broader literature, as discussed above. Understanding causal mechanisms is 
critical to the design of interventions. This argument is best illustrated by considering HIV-
related stigma: levels of stigma remain high globally, but an understanding of mechanisms 
could lead to interventions that block the pathway from stigma to the mediating variable, or 
from the mediator to the adverse outcome [26]. In this way, outcomes may improve even 
without reducing stigma at the community level. Similarly, levels of unintended pregnancy 
remain high globally, but no causal mechanism has been elucidated to date to explain 
observed associations between an unintended pregnancy and poor maternal and child 
outcomes [65]; an exploration of mediators could allow for targeted interventions. In the 
same line, a better understanding of potential effect modifiers is needed. Given that 
interventions to reduce each of stigma and unintended pregnancy appear to have had limited 
impact to date, understanding the factors that may buffer against negative outcomes is a 
critical next step in order to inform practice.  
 
8.6 Conclusion 
This thesis sought to provide insights into the patterns, predictors and impact of HIV-status 
disclosure among pregnant and postpartum women in the context of lifelong ART in South 
Africa, including considerations of stigma, social support, depression and unintended 
239 
 
pregnancy. Importantly, these analyses suggest that disclosure occurs as two separate 
processes in this sample of women: disclosure to a male partner, and disclosure to 
family/community members. The findings presented in this thesis provide strong evidence 
that women’s social and economic circumstances are central to understandings of disclosure, 
mental health and HIV viral load. Indeed, both the prevalence of disclosure and its impact on 
depression and viral load were modified by women’s circumstances. In this setting, 
disclosure does not appear to have universally beneficial effects on either depression or viral 
load; the effects do not appear to be consistent over time; and the effects differ according to 
women’s relationships with the person(s) to whom they disclose. In these analyses, stigma 
emerged as a critical factor that adversely affects mental health, regardless of levels of social 
support. In addition, unintended pregnancy emerged as a critical factor that heightens 
women’s vulnerability, both during the pregnancy and up to five years postpartum.  
 
Massive progress has been made in preventing MTCT in South Africa and globally. Much of 
this progress has been due to population-wide public health approaches: routine HIV testing 
for all women as part of antenatal care; antiretroviral prophylaxis and now lifelong ART for 
all pregnant and breastfeeding women; and massive roll-outs of ART services within primary 
care settings throughout the country. Guidelines related to disclosure have similarly taken a 
blanket approach, with disclosure encouraged for its potential individual- and population-
level benefits. This thesis provides compelling evidence that the individual cannot be ignored 
in research, policy or practice. Disclosure is a complex phenomenon that occurs within 
complicated social relationships, and there is a need for nuance in the promotion of 
disclosure; indeed, the individual must be made central in our approach to HIV prevention 
and care.   
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Appendix 1: Schedule of study measurements in the MCH-ART study 
 
 
Phase 1 
(all HIV+ pregnant 
women) 
Phase 2  
(HIV+ pregnant women eligible for ART) 
Phase 3  
(HIV+ postpartum women on ART and breastfeeding) 
Item for completion 
1st antenatal visit  
(study visit 1) 
2nd antenatal visit  
(study visit 2) 
Late 3rd trimester 
 (study visit 3) 
< 7 days pp (up 
to 28 days) 
(study visit 4) 
6 weeks pp 
(study visit 5) 
3 months pp 
(study visit 6) 
6 months pp 
(study visit 7) 
9 months pp 
(study visit 8) 
12 months pp 
 (study visit 9) 
Procedural forms          
Eligibility Checklist X X  X      
Informed Consent  #1 #2  #3      
Locator Information 1 X X X X X X X X  
Randomization Log    X      
Questionnaires          
Demographics & medical history  X X3 X3 X3 X3 X3 X3 X3 X3 
HIV Knowledge Inventory X2 X   X   X  
Treatment Knowledge Inventory X2 X   X   X  
ART Medication Beliefs X2 X   X   X  
Adherence self-efficacy X2 X X    X  X 
K-10 & EPDS 4  X   X    X 
Alcohol/substance use screen 5  X X    X  X 
Trauma/abuse assessment  X  X     X 
Social impact scale  X   X    X 
Availability of social support scale  X X    X  X 
Infant feeding intentions/practices   X X X X X X X 
Family planning use/intentions X   X X  X X X 
Pregnancy intentions X   X X  X X X 
Patient-Provider relationship scale   X X X  X X X 
Unplanned Pregnancy assessment X         
Maternal adherence 6 X2 X X X X X X X X 
Infant adherence6    X X     
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Phase 1 
(all HIV+ pregnant 
women) 
Phase 2  
(HIV+ pregnant women eligible for ART) 
Phase 3  
(HIV+ postpartum women on ART and breastfeeding) 
Item for completion 
1st antenatal visit  
(study visit 1) 
2nd antenatal visit  
(study visit 2) 
Late 3rd trimester 
 (study visit 3) 
< 7 days pp (up 
to 28 days) 
(study visit 4) 
6 weeks pp 
(study visit 5) 
3 months pp 
(study visit 6) 
6 months pp 
(study visit 7) 
9 months pp 
(study visit 8) 
12 months pp 
 (study visit 9) 
Child Grants     X  X  X 
Anthropometry          
Maternal anthropometry 7     X X X X X 
Infant growth parameters     X X X X X 
Study laboratory measures          
HIV viral load X X X X X X X X X 
Maternal stored serum X X X X X  X X X 
Infant HIV PCR testing         X 
Infant rapid antibody test         X 
Clinical data abstraction 8          
ART initiation & follow-up   X X X X X X  X 
Antenatal & obstetric information X X X X      
Pharmacy ART dispensing records  X X X X X X X X 
Maternal laboratory test results 9 X X     X  X 
Infant growth and well-being    X X X X X X 
Infant HIV PCR result 9     X  X   
 
1. Participants’ locator information will be updated at each study visit, if it has changed since the last visit. 
2. These assessments will be administered to participants who are already on ART at the time of enrolment into Phase 1. 
3. A subset of demographic questions will be asked at all antenatal and postnatal study visits. 
4. Kessler-10 (screening questionnaire for non-specific psychological distress) and Edinburgh Postnatal Depression Survey. 
5. Alcohol use disorders identification test (AUDIT) and drug use disorders identification test (DUDIT). 
6. Adherence assessments will include maternal ART adherence and, postpartum, questions related to infant adherence nevirapine prophylaxis and co-trimoxazole. 
7. Note that maternal weight & mid-upper arm circumference will be measured at each Phase 3 study visit; maternal height will only be measured at the 6 week 
postpartum visit 
8. Abstraction of routine clinical data and laboratory data will take place at the end of the study. 
9. Results of routine laboratory testing on mothers (including pre-ART and on-ART CD4 cell count, pre-ART serum creatinine, alanine aminotransferase and full blood 
count) and infants (HIV PCR at 6 weeks and 2 weeks after cessation of breastfeeding; here marked for the 6 month visit) will come from record review.  
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Appendix 2: Study measures at the 36-60 month 
postpartum study visit 
 
36-60 month visit 
Procedural forms Study laboratory measures 
Informed Consent for LACE study visit HIV viral load 
Informed consent for genetic testing HIV resistance testing 
Locator Information  Genotyping 
Questionnaires Drug resistance testing (TDF/EFV) 
Demographics & medical history  Maternal stored plasma 
Movement  
K-10 & EPDS  Clinical data abstraction  
Alcohol/substance use screen  
Antenatal and PMTCT information for 
subsequent pregnancies 
Trauma/abuse assessment ART initiation and follow-up data 
Social impact scale Pediatric information 
Availability of social support scale Anthropometry 
Child questionnaire Maternal anthropometry  
Family planning use & Pregnancy 
Intentions 
Child anthropometry 
Patient-Provider relationship scale  
Maternal ART adherence & side effects Child development 
Child Grants Ages & Stages ASQ-3 
 Ages & Stages ASQ:SE-2 
Food security  
Life events  
Adverse childhood experiences  
Partner questionnaire  
 
 
 
 
 
 
 
